"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CA,A,CA 705166 A,118-143-786-592-287,1965-03-09,1965,CA 705166D A,,CA 705166T A,,REINFORCED CLOSURE AND RETAINER PANELS,,WALNUT IND,BLATT DAVID H,,https://lens.org/118-143-786-592-287,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
2,CA,A,CA 719476 A,120-247-762-565-741,1965-10-12,1965,CA 719476D A,,CA 719476T A,,TAPE REINFORCED PANELLING SYSTEM,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/120-247-762-565-741,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
3,US,A,US 2801784 A,197-076-495-808-242,1957-08-06,1957,US 57552556 A,1956-04-02,US 57552556 A,1956-04-02,Shipping container,,OWENS ILLINOIS GLASS CO,BLATT DAVID H,,https://lens.org/197-076-495-808-242,Granted Patent,no,2,6,1,1,0,B65D5/2033;;B65D85/04;;B65D5/2033;;B65D85/04,B65D5/20;;B65D85/04,,0,0,,,,EXPIRED
4,CA,A,CA 719475 A,028-780-828-745-085,1965-10-12,1965,CA 719475D A,,CA 719475T A,,REINFORCED CLOSURE AND RETAINER PANELS,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/028-780-828-745-085,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
5,US,A,US 3256837 A,073-647-044-440-434,1966-06-21,1966,US 40858964 A,1964-11-03,US 40858964 A;;BE 679704 A;;NL 6604650 A,1964-11-03,Bulkheading material,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/073-647-044-440-434,Granted Patent,no,3,7,2,3,0,B60P7/135;;B60P7/135;;B61D19/002;;B61D19/002;;B61D45/006;;B61D45/006,B60P7/135;;B61D19/00;;B61D45/00,,0,0,,,,EXPIRED
6,CH,A,CH 413894 A,029-627-121-359-653,1966-05-31,1966,CH 696764 A,1964-05-28,US 13383561 A;;US 16050061 A;;US 17757362 A;;US 19281962 A;;US 33483563 A,1961-08-25,Porte en carton,,WALNUT IND INC,DAVID HERBERT BLATT,,https://lens.org/029-627-121-359-653,Granted Patent,no,0,0,10,17,0,B60J5/0497;;B60J5/0497;;B60P1/003;;B60P1/003;;B60P1/28;;B60P1/28;;B60P7/14;;B60P7/14;;B61D19/00;;B61D19/00;;B61D19/002;;B61D19/002;;B61D45/006;;B61D45/006;;B62D29/00;;B62D29/00;;B62D29/04;;B62D29/04;;B65D5/441;;B65D5/441;;B65D5/443;;B65D5/443;;B65D65/38;;B65D65/38;;B65D65/403;;B65D65/403;;B65D75/68;;B65D75/68;;E04B2/74;;E04B2/74;;E04C2/3405;;E04C2/3405;;E04C2/40;;E04C2/40;;E04C2002/3466;;E04C2002/3466,B60J5/04;;B60P1/00;;B60P1/28;;B60P7/14;;B60P9/00;;B61D19/00;;B61D45/00;;B62D29/00;;B62D29/04;;B65D5/44;;B65D65/38;;B65D65/40;;B65D75/68;;E04B2/74;;E04C2/34;;E04C2/40,"37D,5/00",0,0,,,,EXPIRED
7,DE,B,DE 1239559 B,102-915-349-929-036,1967-04-27,1967,DE W0032794 A,1962-08-17,US 14688661 A,1961-10-23,Stauplatte,,WALNUT IND INC,BLATT DAVID HERBERT,,https://lens.org/102-915-349-929-036,Patent Application,no,2,0,6,9,0,B60P7/14;;B60P7/16;;B61D19/002;;B61D45/006;;B62D29/00;;E04B2/74;;Y10T428/24298;;Y10T428/24331;;Y10T428/24298;;Y10T428/24331;;B60P7/14;;B61D19/002;;B60P7/16;;E04B2/74;;B61D45/006;;B62D29/00,B60P7/14;;B60P7/16;;B61D19/00;;B61D45/00;;B62D29/00;;E04B2/74,,0,0,,,,DISCONTINUED
8,CH,A,CH 390785 A,121-532-597-042-689,1965-04-15,1965,CH 1007662 A,1962-08-24,US 13383561 A;;US 16050061 A;;US 17757362 A;;US 19281962 A;;US 33483563 A,1961-08-25,Panneau,,WALNUT IND INC,DAVID HERBERT BLATT,,https://lens.org/121-532-597-042-689,Granted Patent,no,0,2,10,17,0,B60J5/0497;;B60J5/0497;;B60P1/003;;B60P1/003;;B60P1/28;;B60P1/28;;B60P7/14;;B60P7/14;;B61D19/00;;B61D19/00;;B61D19/002;;B61D19/002;;B61D45/006;;B61D45/006;;B62D29/00;;B62D29/00;;B62D29/04;;B62D29/04;;B65D5/441;;B65D5/441;;B65D5/443;;B65D5/443;;B65D65/38;;B65D65/38;;B65D65/403;;B65D65/403;;B65D75/68;;B65D75/68;;E04B2/74;;E04B2/74;;E04C2/3405;;E04C2/3405;;E04C2/40;;E04C2/40;;E04C2002/3466;;E04C2002/3466,B60J5/04;;B60P1/00;;B60P1/28;;B60P7/14;;B60P9/00;;B61D19/00;;B61D45/00;;B62D29/00;;B62D29/04;;B65D5/44;;B65D65/38;;B65D65/40;;B65D75/68;;E04B2/74;;E04C2/34;;E04C2/40,"37B,2/02",0,0,,,,EXPIRED
9,CA,A,CA 522994 A,037-055-455-629-819,1956-03-20,1956,CA 522994D A,,CA 522994T A,,METHOD OF AND MACHINE FOR MAKING A TRANSPARENT CORRUGATED BOARD,,ASSOCIATED PACKAGING COMPANY,BLATT DAVID H,,https://lens.org/037-055-455-629-819,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
10,US,A,US 2719566 A,158-344-981-463-861,1955-10-04,1955,US 26117151 A,1951-12-12,US 26117151 A,1951-12-12,Method of and machine for making a transparent corrugated board,,ASSOCIATED PACKAGING COMPANY,BLATT DAVID H,,https://lens.org/158-344-981-463-861,Granted Patent,no,7,9,1,1,0,B65D65/40;;B65D65/40;;Y10T156/1016;;Y10T156/1016,B65D65/40,B5S S17Y          KA          -;;B5S S170          KA          -;;B5S S19X          KA          -;;B5S S220          KA          -;;B5S S25Y          KA          -;;B5S S252          KA          -;;B5S S315          KA          -;;B5S S583          KA          -;;B5S S621          KA          -;;B5S S641          KA          -;;B5S S66Y          KA          -;;B5S S662          KA          -;;B5S S669          KA          -;;B5S S670          KA          -;;B5S S674          KA          -;;B5S S675          KA          -;;B5S S679          KA          -;;B5S S68X          KA          -;;B5S S68Y          KA          -;;B5S S682          KA          -;;B5S S684          KA          -;;B5S S69Y          KA          -;;B5S S690          KA          -;;B5S S698          KA          -;;B5S S70X          KA          -;;B5S S70Y          KA          -;;B5S S706          KA          -;;B5S S708          KA          -;;B5S S71X          KA          -;;B5S S710          KA          -;;B5S S784          KA          -;;B5S S796          KA          -,0,0,,,,EXPIRED
11,FR,E,FR 85674 E,169-295-796-149-900,1965-09-24,1965,FR 973064 A,1964-04-30,FR 973064 A;;US 13383561 A;;US 16050061 A;;US 17757362 A;;US 19281962 A;;US 33483563 A,1961-08-25,Panneaux en papier notamment cartonné renforcés par des bandes flexibles utilisables comme moyen de fermeture et de retenue,,WALNUT IND,BLATT DAVID HERBERT,,https://lens.org/169-295-796-149-900,Amended Patent,no,0,0,1,17,0,B60J5/0497;;B60P1/003;;B60P1/28;;B60P7/14;;B61D19/00;;B61D19/002;;B61D45/006;;B62D29/00;;B62D29/04;;B65D5/441;;B65D5/443;;B65D65/38;;B65D65/403;;B65D75/68;;E04B2/74;;E04C2/3405;;E04C2/40;;E04C2002/3466,B60J5/04;;B60P1/00;;B60P1/28;;B60P7/14;;B60P9/00;;B61D19/00;;B61D45/00;;B62D29/00;;B62D29/04;;B65D5/44;;B65D65/38;;B65D65/40;;B65D75/68;;E04B2/74;;E04C2/34;;E04C2/40,,0,0,,,,DISCONTINUED
12,DE,B,DE 1273972 B,115-888-794-068-626,1968-07-25,1968,DE W0032776 A,1962-08-11,US 1273972X A,1961-08-25,Wellpappe,,WALNUT IND INC,BLATT DAVID HERBERT,,https://lens.org/115-888-794-068-626,Patent Application,no,4,0,1,1,0,B65D65/403,B65D65/40,,0,0,,,,DISCONTINUED
13,US,A,US 3156604 A,137-078-885-978-581,1964-11-10,1964,US 14688661 A,1961-10-23,US 14688661 A,1961-10-23,Reinforced closure and retainer panels,,WALNUT IND INC,BLATT DAVID H,,https://lens.org/137-078-885-978-581,Granted Patent,no,8,3,6,9,0,B60P7/14;;B60P7/16;;B61D19/002;;B61D45/006;;B62D29/00;;E04B2/74;;Y10T428/24298;;Y10T428/24331;;Y10T428/24298;;Y10T428/24331;;B60P7/14;;B61D19/002;;B60P7/16;;E04B2/74;;B61D45/006;;B62D29/00,B60P7/14;;B60P7/16;;B61D19/00;;B61D45/00;;B62D29/00;;E04B2/74,,0,0,,,,EXPIRED
14,US,A,US 4401217 A,117-059-069-848-341,1983-08-30,1983,US 24031881 A,1981-03-04,US 24031881 A,1981-03-04,Roll retainer,"A container for shipping and storing large hollow cylindrical rolls of either solid material or wound sheet material. A skid or pallet is combined with a pair of special corrugated paperboard end pads, one for each end of the roll, a pair of spaced apart anti-roll retainers extending longitudinally of and secured to the top of the pallet and between which the roll is placed, a pair of top braces extending between and interfitted with the end pads, a pair of banding straps which transversely encircle and secure together the retained roll and the anti-roll retainers, and a pair of banding straps which longitudinally encircle and secure together the pallet and end pads and top braces. The end pads and anti-roll retainers secure the retained roll from endwise shifting and sidewise rolling motion, and are constructed so that a standard sized end section is utilizable with rolls of widely varying diameters.",FRANKLIN CONTAINER CORP,BLATT DAVID H,FRANKLIN CONTAINER CORPORATION (1981-02-27),https://lens.org/117-059-069-848-341,Granted Patent,yes,9,21,1,1,0,B65D85/66;;B65D85/66,B65D85/66,206/408;;206/386,0,0,,,,EXPIRED
15,US,A,US 4122949 A,031-790-444-455-297,1978-10-31,1978,US 83003477 A,1977-09-02,US 83003477 A,1977-09-02,Roll holding carton,"A combination shipping and storage containers for rolls of sheet material having hollow centers, the container having an interiorly disposed spindle like post extending vertically between opposite ends thereof upon which the rolls are held against radial shifting movement. The container is provided at each of its opposite ends with closure panels which are inwardly foldable from an open position thereof into flatwise superimposed closed positions to embrace therebetween out-turned flaps provided at each end of the post to hold the same in fixedly secured position within the closed container. The container is especially designed for use with rolls of low friction sheet material, such as mylar, to prevent telescoping of the rolled up convolutions relatively to one another and to this end each of the rolls ""spindled"" on the post is individually provided with an underlying centrally apertured flat support member so that said member and the roll supported thereon as a unit may be placed on and removed from the internal post of the container.",FRANKLIN CONTAINER CORP,BLATT DAVID H,,https://lens.org/031-790-444-455-297,Granted Patent,yes,7,36,1,1,0,B65D5/5035;;B65D5/5097;;B65D5/5035;;B65D5/5097,B65D5/50,206/303,0,0,,,,EXPIRED
16,FR,A,FR 1338482 A,138-436-786-067-997,1963-09-27,1963,FR 906574 A,1962-08-09,FR 906574 A;;US 13383561 A;;US 16050061 A;;US 17757362 A;;US 19281962 A;;US 33483563 A,1961-08-25,Panneaux en papier notamment cartonné renforcés par des bandes flexibles utilisables comme moyens de fermeture et de retenue,,WALNUT IND,BLATT DAVID HERBERT,,https://lens.org/138-436-786-067-997,Granted Patent,no,0,1,1,17,0,B60J5/0497;;B60P1/003;;B60P1/28;;B60P7/14;;B61D19/00;;B61D19/002;;B61D45/006;;B62D29/00;;B62D29/04;;B65D5/441;;B65D5/443;;B65D65/38;;B65D65/403;;B65D75/68;;E04B2/74;;E04C2/3405;;E04C2/40;;E04C2002/3466,B60J5/04;;B60P1/00;;B60P1/28;;B60P7/14;;B60P9/00;;B61D19/00;;B61D45/00;;B62D29/00;;B62D29/04;;B65D5/44;;B65D65/38;;B65D65/40;;B65D75/68;;E04B2/74;;E04C2/34;;E04C2/40,,0,0,,,,EXPIRED
17,CA,A,CA 759720 A,053-087-835-669-296,1967-05-30,1967,CA 759720D A,,CA 759720T A,,FLEXIBLE BARRIER AND METHOD OF INSTALLING THE SAME,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/053-087-835-669-296,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
18,CA,A,CA 721533 A,000-538-413-925-162,1965-11-16,1965,CA 721533D A,,CA 721533T A,,TAPE REINFORCED GRAIN DOOR PANEL,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/000-538-413-925-162,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
19,US,A,US 3873017 A,061-066-474-798-881,1975-03-25,1975,US 34866073 A,1973-04-06,US 34866073 A,1973-04-06,Corrugated polygonal container,"A polygonal shipping container, preferably hexagonal, formed of die cut blanks of corrugated paper board superposed and glued one upon another to provide a tubular type container having a side wall of triple ply thickness, the several plies of corrugated board being so respectively transversely scored and assembled as to permit the container to be knocked down into a flattened condition from which it may be easily erected into its expanded form for receiving and shipping goods. The outer ply of the container is provided at its opposite ends with end closure flaps which are designed to be infolded from each of the side wall panels of the container to provide a plurality of layered coplanar pairs of said flaps having their meeting edges disposed in abutting relation. Diametrically opposed corners of the container are fluted to permit stress-free folding of the container into flattened condition and provide hand hold ribs for rolling the container about its central axis and for otherwise conveniently handling the container. The corrugations of the inner plies extend orthogonally with respect to those of the outer ply of the container to strengthen and rigidify its side walls, the latter being internally shouldered at opposite ends thereof to receive removable end pads which each underlie the multi-layered end closure flaps. The container is provided with a tear tape for partially or completely detaching one end closure from its main body portion.",FRANKLIN CONTAINER CORP,BLATT DAVID H,,https://lens.org/061-066-474-798-881,Granted Patent,no,7,44,1,1,0,B65D5/0281;;B65D5/0281;;Y10S229/93;;Y10S229/93;;Y10S229/939;;Y10S229/939,B65D5/02,229 41C,0,0,,,,EXPIRED
20,US,A,US 3291195 A,033-883-667-991-13X,1966-12-13,1966,US 33483563 A,1963-12-31,US 33483563 A;;US 13383561 A;;US 16050061 A;;US 17757362 A;;US 19281962 A,1961-08-25,Tape reinforced grain door panel,,WALNUT IND COMPANY,BLATT DAVID H,,https://lens.org/033-883-667-991-13X,Granted Patent,no,11,2,10,17,0,B60J5/0497;;B60J5/0497;;B60P1/003;;B60P1/003;;B60P1/28;;B60P1/28;;B60P7/14;;B60P7/14;;B61D19/00;;B61D19/00;;B61D19/002;;B61D19/002;;B61D45/006;;B61D45/006;;B62D29/00;;B62D29/00;;B62D29/04;;B62D29/04;;B65D5/441;;B65D5/441;;B65D5/443;;B65D5/443;;B65D65/38;;B65D65/38;;B65D65/403;;B65D65/403;;B65D75/68;;B65D75/68;;E04B2/74;;E04B2/74;;E04C2/3405;;E04C2/3405;;E04C2/40;;E04C2/40;;E04C2002/3466;;E04C2002/3466,B60J5/04;;B60P1/00;;B60P1/28;;B60P7/14;;B60P9/00;;B61D19/00;;B61D45/00;;B62D29/00;;B62D29/04;;B65D5/44;;B65D65/38;;B65D65/40;;B65D75/68;;E04B2/74;;E04C2/34;;E04C2/40,,0,0,,,,EXPIRED
21,US,A,US 4151914 A,103-883-492-200-144,1979-05-01,1979,US 92747178 A,1978-07-24,US 92747178 A,1978-07-24,Shipping and storage container for rolls,"A combination shipping and storage container for hollow rolls of sheet material having an open-topped box structure and a top closure therefor, both said box structure and said top closure being each formed of two open-ended sections which are telescopically interfitted to provide the same with a capability of being lengthwise adjusted in correspondence with the length of the roll stored in the container and wherein the box structure sections are each provided in the closed end thereof with means affording access for insertion of a lifting bar axially through the hollow interior of the roll supported in the box for transferring roll into and out of its container.",FRANKLIN CONTAINER CORP,BLATT DAVID H,,https://lens.org/103-883-492-200-144,Granted Patent,yes,2,68,1,1,0,B65D85/66;;B65D85/66,B65D85/66,206/386,0,0,,,,EXPIRED
22,US,A,US 3626860 A,139-985-483-759-855,1971-12-14,1971,US 3626860D A,1970-06-01,US 4180970 A,1970-06-01,FOLDABLE EXPENDABLE FOUR-WAY ENTRY PALLET,,WALNUT IND CO,BLATT DAVID H,,https://lens.org/139-985-483-759-855,Granted Patent,no,7,47,1,1,0,B65D19/0026;;B65D19/0026;;B65D2519/00019;;B65D2519/00019;;B65D2519/00054;;B65D2519/00054;;B65D2519/00273;;B65D2519/00273;;B65D2519/00293;;B65D2519/00293;;B65D2519/00323;;B65D2519/00323;;B65D2519/00333;;B65D2519/00333;;B65D2519/00432;;B65D2519/00432;;B65D2519/00442;;B65D2519/00442;;B65D2519/00557;;B65D2519/00557;;B65D2519/00562;;B65D2519/00562,B65D19/00,108/58,0,0,,,,EXPIRED
23,CH,A,CH 393904 A,155-396-329-215-926,1965-06-15,1965,CH 981562 A,1962-08-16,US 15413761 A;;US 14688661 A,1961-10-23,Panneau de papier renforcé par au moins une bande flexible,,WALNUT IND INC,DAVID HERBERT BLATT,,https://lens.org/155-396-329-215-926,Granted Patent,no,0,0,3,9,0,E04C2/18,E04C2/18,"37B,2/01",0,0,,,,EXPIRED
24,CA,A,CA 692417 A,022-817-546-106-101,1964-08-11,1964,CA 692417D A,,CA 692417T A,,CLOSURE AND RETAINING PANELS,,WALNUT IND,BLATT DAVID H,,https://lens.org/022-817-546-106-101,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
25,FR,A,FR 1330664 A,113-635-221-073-147,1963-06-21,1963,FR 906452 A,1962-08-08,FR 906452 A,1962-08-08,Panneaux de papier renforcés destinés à être utilisés notamment comme moyens de fermeture et de retenue,,WALNUT IND,BLATT DAVID H,,https://lens.org/113-635-221-073-147,Granted Patent,no,0,0,1,1,0,B61D19/002;;B65D75/68,B61D19/00;;B65D75/68,,0,0,,,,EXPIRED
26,US,A,US 4264251 A,052-010-379-669-441,1981-04-28,1981,US 91245878 A,1978-06-05,US 91245878 A,1978-06-05,Bulkheading construction,"A load-retaining barrier construction formed exclusively of high tensile strength plastic sheet material having a limited stretch capability precut to length sufficient to provide the same with portions which are fixedly secured in position at opposite sides of a load confining space and with freely extending end portions which are adhesively secured together in overlapped relation, said overlapped part of the barrier being wrapped or turned upon itself about an axis extending across the width of the barrier material in the region of said overlap through a number of turns sufficient to tension the barrier to the degree desired. This tensioning is effected by a turning tool applied to the overlapped part of the barrier along said axis. Upon tensioning the barrier to its desired degree, a covering strip or blanket formed of the barrier sheet material is then adhesively secured in overlying relation to the exposed surfaces of said turned part as well as to portions of the barrier contiguous to opposite sides of said part for holding said tensioned contiguous portions secure against shear forces tending to pull the same apart.",WALNUT IND INC,BLATT DAVID H,,https://lens.org/052-010-379-669-441,Granted Patent,yes,4,92,1,1,0,B60P7/0823;;B60P7/0823;;B60P7/083;;B60P7/083,B60P7/08,410/100,0,0,,,,EXPIRED
27,EP,A4,EP 0406276 A4,069-773-062-115-97X,1991-08-28,1991,EP 89903670 A,1989-03-20,AU PI735188 A;;AU 1911/089001 W,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCHYARDS,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.","BLATT, DAVID WILLIAM ELI","BLATT, DAVID WILLIAM ELI",,https://lens.org/069-773-062-115-97X,Search Report,no,3,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,2,1,065-162-943-000-074,10.1049/ip-b.1983.0054,"IEE PROCEEDINGS SECTIONS A a I, vol. 130, no. 5, part B, September 1983, pages 360-363, Old Woking, Surrey, GB; J.A.J. PETTINGA et al.: ""A polyphase 500KA current measuring system with Rogowski coils"";;SIEMENS POWER ENGINEERING & AUTOMATION, vol. 7, no. 3, May/June 1985, pages 164-168, Erlangen, DE; E. BUURMAN et al.: ""Microprocessor-based control and protection system for switchgear, designed with an eye to the future""",EXPIRED
28,DE,D1,DE 68927168 D1,167-903-211-873-092,1996-10-17,1996,DE 68927168 T,1989-03-20,AU PI735188 A;;AU 1911/089001 W,1988-03-21,KONTROLLE UND SCHUTZ VOR FEHLERN VON HOCHSPANNUNGSSCHALTVORRICHTUNGEN,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/167-903-211-873-092,Granted Patent,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
29,AU,A,AU 1989/034355 A,108-930-808-998-780,1989-10-16,1989,AU 1989/034355 A,1989-03-20,AU PI735188 A,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCHYARDS,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/108-930-808-998-780,Patent Application,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
30,CA,C,CA 1331883 C,090-531-403-164-809,1994-09-06,1994,CA 594042 A,1989-03-17,AU PI735188 A,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCH YARDS,"MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCH YARDS The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID W E,BLATT DAVID W E,,https://lens.org/090-531-403-164-809,Granted Patent,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,D43240029    M,0,0,,,,EXPIRED
31,DE,T2,DE 68927168 T2,142-144-975-588-388,1997-04-03,1997,DE 68927168 T,1989-03-20,AU PI735188 A;;AU 1911/089001 W,1988-03-21,KONTROLLE UND SCHUTZ VOR FEHLERN VON HOCHSPANNUNGSSCHALTVORRICHTUNGEN,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/142-144-975-588-388,Granted Patent,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
32,EP,A1,EP 0406276 A1,167-558-585-726-404,1991-01-09,1991,EP 89903670 A,1989-03-20,AU PI735188 A;;AU 1911/089001 W,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCHYARDS.,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/167-558-585-726-404,Patent Application,yes,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
33,CN,A,CN 1040684 A,014-493-476-062-191,1990-03-21,1990,CN 89103124 A,1989-03-21,AU PI735188 A,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCH YARDS,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/014-493-476-062-191,Patent Application,no,0,1,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,DISCONTINUED
34,WO,A1,WO 1989/009411 A1,072-920-344-690-943,1989-10-05,1989,AU 1911/089001 W,1989-03-20,AU PI735188 A,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCHYARDS,"The currents flowing through high voltage conductors in a network or switchyard (14) are monitored by magnetic field sensors (31) in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network. Analog to digital conversion of the sampled values near each sensor location (30) prior to current loop signalling to the central processor (21) may also be used.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/072-920-344-690-943,Patent Application,yes,7,8,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,4,0,,,"PATENT ABSTRACTS OF JAPAN, E498, page 135, & JP,A, 61 264834 (Toshiba) 22 November 1986 (22.11.86);;PATENT ABSTRACTS OF JAPAN, E671, page 114, & JP,A, 63 136793 (Toshiba) 8 June 1988 (08.06.88);;PATENT ABSTRACTS OF JAPAN, P577, page 102, & JP,A, 61 289404 (Sato Tekko) 19 December 1986 (19.12.86);;PATENT ABSTRACTS OF JAPAN, P316, page 27, & JP,A, 59 126961 (Fujitsu) 21 July 1984 (21.07.84)",PATENTED
35,IN,B,IN 174635 B,185-917-237-349-723,1995-01-28,1995,IN 254DE1989 A,1989-03-17,AU PI735188 A,1988-03-21,An apparatus for monitoring electric current flowing through one or more conductors,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/185-917-237-349-723,Granted Patent,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
36,AU,B2,AU 632045 B2,059-626-725-535-084,1992-12-17,1992,AU 1989/034355 A,1989-03-20,AU PI735188 A,1988-03-21,MONITORING CONDUCTOR CURRENTS IN HIGH VOLTAGE SWITCHYARDS,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",DAVID WILLIAM ELI BLATT,DAVID WILLIAM ELI BLATT,,https://lens.org/059-626-725-535-084,Granted Patent,no,3,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,EXPIRED
37,US,A,US 5408176 A,079-277-432-135-426,1995-04-18,1995,US 58510190 A,1990-11-13,AU PI735188 A;;AU 1911/089001 W,1988-03-21,Monitoring and fault protection of high voltage switch yards,"The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT; DAVID W. E.,BLATT DAVID W E,,https://lens.org/079-277-432-135-426,Granted Patent,yes,16,19,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,324/107;;324/127;;324/512;;364/483,5,1,065-162-943-000-074,10.1049/ip-b.1983.0054,"Control and Protection Systems for Switchgear, Siemens Power Engineering & Automation VII No. 3 (1985).;;Pettinga, J. A. J. and Siersma, J., A Polyphase 500kA Current Measuring System with Rogowski Coils, IEEE Proc. 130B:360 363 (1983).;;PCT International Search Report, Ser. No.: PCT/AU 89/00111, Jul. 7, 1989.;;PCT International Preliminary Examination Reports, first and second opinions, Dec. 14, 1989 and Feb. 13, 1990.;;European Patent Office Supplementary Search Report, Ser. No.: AU8900111, Jul. 15, 1991.",EXPIRED
38,AT,T1,AT E142792 T1,069-196-800-706-468,1996-09-15,1996,AT 89903670 T,1989-03-20,AU PI735188 A,1988-03-21,KONTROLLE UND SCHUTZ VOR FEHLERN VON HOCHSPANNUNGSSCHALTVORRICHTUNGEN,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/069-196-800-706-468,Granted Patent,no,0,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,0,0,,,,DISCONTINUED
39,EP,B1,EP 0406276 B1,183-928-200-920-43X,1996-09-11,1996,EP 89903670 A,1989-03-20,AU PI735188 A;;AU 1911/089001 W,1988-03-21,MONITORING AND FAULT PROTECTION OF HIGH VOLTAGE SWITCHYARDS,"PCT No. PCT/AU89/00111 Sec. 371 Date Nov. 13, 1990 Sec. 102(e) Date Nov. 13, 1990 PCT Filed Mar. 20, 1989.The currents flowing through high voltage conductors in a network or switchyard are monitored by magnetic field sensors in the form of air-cored epoxy-filled coils which are electrostatically shielded by discontinuous shields. The magnetic field sensors are located a safe working distance away from the conductors being monitored to remain substantially at earth potential and are orientated to maximize the magnetic field influence from the conductors being monitored. The value of the magnetic field detected by the sensors are sampled instantaneously and the sampled value is processed, having regard to calibration and cross linking effects of the network being monitored to calculate the instantaneous current flowing through the network.",BLATT DAVID WILLIAM ELI,BLATT DAVID WILLIAM ELI,,https://lens.org/183-928-200-920-43X,Granted Patent,yes,10,0,14,14,0,G01R15/18;;H02H1/0007;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004;;Y02E60/00;;Y04S10/00;;Y04S40/124;;Y04S40/12;;H02J13/00006;;G01R15/18;;G01R33/02;;H02H1/0007;;H02J13/00028;;H02H1/0007;;G01R15/18;;Y02E60/00;;Y04S10/00;;H02J13/00017;;H02J13/00028;;H02J13/00034;;H02J13/0004,G01R15/18;;H02H1/00;;H02J13/00,,6,0,,,"IEE PROCEEDINGS SECTIONS A a I, vol. 130, no. 5, part B, September 1983, pages 360-363, Old Woking, Surrey, GB; J.A.J. PETTINGA et al.: ""A polyphase 500KA current measuring system with Rogowski coils"";;SIEMENS POWER ENGINEERING & AUTOMATION, vol. 7, no. 3, May/June 1985, pages 164-168, Erlangen, DE; E. BUURMAN et al.: ""Microprocessor-based controland protection system for switchgear, designed with an eye to the future"";;PATENT ABSTRACTS OF JAPAN, E498, page 135, JP,A, 61-264834 (Toshiba) 22 November 1986 (22.11.86);;PATENT ABSTRACTS OF JAPAN, E671, page 114, JP,A, 63-136793 (Toshiba) 8 June 1988 (08.06.88);;PATENT ABSTRACTS OF JAPAN, P577, page 102, JP,A, 61-289404 (Sato Tekko) 19 December 1986 (19.12.86);;PATENT ABSTRACTS OF JAPAN, P316, page 27, JP,A, 59-126961 (Fujitsu) 21 July 1984 (21.07.84)",EXPIRED
40,US,A,US 5051055 A,163-111-784-579-658,1991-09-24,1991,US 44615789 A,1989-12-05,US 44615789 A,1989-12-05,Article lifting device,"An article lifting device includes vertically elongate hollow tubular frame members, one telescopically received within the other for guided vertical movement. The outer member includes a bracket for fixedly mounting the outer member upon a support, which may be a horizontally movable shuttle carriage, and carries a reversible drive motor coupled to a drive gear mounted for rotation about a horizontal axis near the lower end of the outer member. A flexible belt having teeth at one side is fixed at opposite ends to the upper and lower ends of the inner member and a bight portion of the belt is meshed with the drive gear, the bight portion projecting from the inner member between two idler rolls mounted on the outer member and passing around the drive gear. The idler rolls hold those portions of the belt other than the idler rolls in face-to-face engagement with the inner member. This arrangement leaves the entire interior of the inner member available for the reception of a counterbalance cylinder and sliding electrical and pneumatic connections between the inner and outer member used to supply electric power and air under pressure to article holder devices carried at the lower end of the inner member.",BLATT JOHN A,BLATT JOHN A;;CROREY DAVID,BLATT JOHN A (1989-10-31);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/163-111-784-579-658,Granted Patent,yes,12,14,1,1,0,B25J18/02;;B25J18/02,B25J18/02,414/626;;414/627;;901/21,0,0,,,,EXPIRED
41,BE,A,BE 619062 A,040-458-769-372-555,1962-10-15,1962,BE 619062 A,1962-06-18,US 11843861 A,1961-06-20,Système de panneau de fermeture pour porte de wagon de marchandises ou analogues,,AMERICAN VISCOSE CORP,TALBOT JAMES E;;BLATT DAVID H,,https://lens.org/040-458-769-372-555,Granted Patent,no,0,0,5,6,0,B61D19/002;;B61D19/002,B61D19/00,,0,0,,,,EXPIRED
42,US,A,US 4518187 A,046-357-212-676-178,1985-05-21,1985,US 50152683 A,1983-06-06,US 50152683 A,1983-06-06,Parallel movement gripper head,A workpiece gripper head comprises a body including side plates interiorly slotted on a longitudinal axis adapted to slidably support a selectively reciprocal rod end. A pair of opposed jaw assemblies are guidably mounted within the body and connected thereto for alternate inward and outward movements in a path at right angles to the axis. Each jaw assembly includes a pair of jaw plates having an angular cam slot and a pair of aligned guide slots at right angles to the longitudinal axis. A series of cam rollers upon the rod end are nested within the cam slots and additional rollers are mounted upon the side walls and nested within the guide slots whereby movement in the rod end in one direction moves the jaws towards each other and movement in the opposite direction moves the jaws away from each other.,BLATT LELAND F,BLATT LELAND F;;CROREY DAVID J,BLATT LELAND D. TRUSTEE OF THE L.F. BLATT TRUST U/TA APRIL 12 1977 (1988-09-01);;BLATT ELAINE E. TRUSTEE OF THE L.F. BLATT TRUST U/TA APRIL 12 1977 (1988-09-01);;ISI MANUFACTURING INC. A MI CORP (1988-09-01);;BLATT LELAND F (1983-04-30),https://lens.org/046-357-212-676-178,Granted Patent,yes,2,41,1,1,0,B65G47/90;;B65G47/90;;B23Q7/043;;B23Q7/043;;B25J15/028;;B25J15/028,B23Q7/04;;B25J15/02;;B65G47/90,294/88,0,0,,,,EXPIRED
43,US,S,US D0334701 S,130-118-992-615-267,1993-04-13,1993,US 64527591 F,1991-01-24,US 64527591 F,1991-01-24,Gripper assembly,,BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1990-12-20);;NORGREN AUTOMOTIVE INC (2001-05-30),https://lens.org/130-118-992-615-267,Design Right,yes,35,2,1,1,0,,,D 8 72,0,0,,,,EXPIRED
44,CN,A,CN 107210611 A,059-288-461-283-485,2017-09-26,2017,CN 201580072706 A,2015-01-06,US 2015/0010379 W,2015-01-06,Electronic device with charging module,"An example of a system includes a electronic device having a rechargeable battery, a charging module to charge the rechargeable battery and moveable between a retracted position and an extended position to provide a stand during charging of the rechargeable battery, and a communication module to wirelessly transfer and receive data during charging of the rechargeable battery. The example system also includes a charging mat to charge the rechargeable battery when the charging module is in the extended position and coupled to the charging mat and a docking module to wirelessly transfer data to and wirelessly receive data from the communication module of the electronic device.",HEWLETT PACKARD DEVELOPMENT CO,JABORI MONJI;;NGUYEN BACH;;BLATT DAVID,,https://lens.org/059-288-461-283-485,Patent Application,no,2,1,5,5,0,H02J50/80;;H02J50/10;;H02J7/0044;;H02J2310/22;;H02J7/0042;;H02J50/80;;H02J50/10;;H02J7/00034;;H02J7/0013;;H02J2310/22;;H02J7/0042;;H02J7/0044,H02J7/00,,0,0,,,,INACTIVE
45,US,A,US 3099314 A,052-606-573-876-935,1963-07-30,1963,US 11843861 A,1961-06-20,US 11843861 A,1961-06-20,Closure for car doors and the like,,AMERICAN VISCOSE CORP,TALBOT JAMES E;;BLATT DAVID H,,https://lens.org/052-606-573-876-935,Granted Patent,no,4,1,5,6,0,B61D19/002;;B61D19/002,B61D19/00,,0,0,,,,EXPIRED
46,US,A,US 5492443 A,182-131-583-301-200,1996-02-20,1996,US 13658693 A,1993-10-14,US 13658693 A,1993-10-14,Apparatus for handling a workpiece between work stations,"An apparatus for automatically handling a workpiece between automated workstations wherein the workpiece is lifted from an unloading workstation, moved along a predetermined linear reciprocal path between work stations while simultaneously inverting the workpiece, and lowering the workpiece into a loading workstation. The apparatus provides a vertical lift portion and an articulating portion for manipulating the workpiece. The vertical lift portion utilizes a compact design to minimize space requirements and moving parts by providing both vertical movement and rotational movement within a common structure. The articulating portion is attached to the bottom of the vertical lift portion and provides a pivot arm that is pivotally attached to a workpiece holder. The vertical lift portion provides a rotational input to a harmonic drive unit which has its output coupled to the pivot arm. When the pivot arm rotates, a continuous timing belt provides for counter-rotational movement of the workpiece holder. The workpiece is detachably secured by the workpiece holder, and when the pivot arm and the workpiece holder are equivalent in length, the workpiece will travel in a linear path while also inverting the orientation of the workpiece upon completing the linear path. The range of movement of the workpiece may also be extended by mounting the apparatus on an overhead gantry which moves the entire apparatus, along with the workpiece, further along the linear path. A linear drive unit may also by utilized as a workpiece holder to provide an extended reach to the workpiece along the linear path.",BLATT LELAND D,CROREY DAVID J;;BLATT LELAND D,LELAND D. BLATT (1993-11-30);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/182-131-583-301-200,Granted Patent,yes,10,14,1,1,0,B65G47/914;;B65G47/914,B65G47/91,414/744.5;;212/224;;212/319;;901/15;;901/21,0,0,,,,EXPIRED
47,US,A,US 5632588 A,078-967-432-102-095,1997-05-27,1997,US 36842895 A,1995-01-04,US 36842895 A;;US 3456593 A;;US 75649291 A;;US 97813492 A;;US 66502991 A,1991-03-06,Automatic tool changer,"A production line which includes a shuttle conveyor extending between two work stations. A first transfer device for transferring a workpiece from one of the work stations to the conveyor and a second transfer device for transferring the workpiece to the second work station are equipped with workpiece gripping or supporting devices which may be rapidly changed when the line is shifted from the production of one form of workpiece to the production of another workpiece having a different configuration. Replacement workpiece gripping devices are supported adjacent the shuttle conveyor upon holding pedestals. Upon line changeover, the transfer devices locate their workpiece gripping devices upon empty holding pedestals and actuating devices on the pedestal release the gripping devices from their transfer devices. The empty transfer devices are then shifted and coupled to new workpiece gripping devices supported on other holding pedestals. The transfer device includes the ability for adjustment of the article engaging devices in three directions.",BLATT LELAND D,CROREY DAVID J;;BLATT LELAND D,NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/078-967-432-102-095,Granted Patent,yes,60,32,2,4,0,B23Q7/04;;B23Q7/04;;B21D43/05;;B21D43/05;;B21D43/057;;B21D43/057;;B21D43/105;;B21D43/105;;B23Q1/58;;B23Q1/58,B21D43/05;;B21D43/10;;B23Q1/58;;B23Q7/04,414/225;;901/30;;901/41,0,0,,,,EXPIRED
48,US,A1,US 2018/0219414 A1,010-506-155-483-053,2018-08-02,2018,US 201615748380 A,2016-01-29,US 2016/0015611 W,2016-01-29,ELECTRONIC DEVICES FOR WIRELESS CHARGING,"Examples disclosed herein provide an electronic device to allow wireless charging of the electronic device when it is operated in various operation modes. The electronic device can include a base member comprising a top surface and a bottom surface opposite the top surface and a display member rotatably connected to the base member. The electronic device can include a rechargeable battery and a receiver to wirelessly charge the rechargeable battery when the bottom surface of the base member is to be placed atop a transmitter. As an example, the bottom surface of the base member is to remain atop the transmitter while the electronic device is in different operation modes.",HEWLETT PACKARD DEVELOPMENT CO,JABORI MONJI G;;BLATT DAVID ISAAC,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-01-29),https://lens.org/010-506-155-483-053,Patent Application,yes,2,0,3,3,0,H04B1/3883;;G06F1/162;;G06F1/26;;H02J7/0042;;H02J50/00;;H04B1/3883;;H02J50/00;;H02J50/05;;H02J50/10;;G06F1/162;;G06F1/26;;H02J7/0042,H02J50/05;;G06F1/16;;G06F1/26;;H02J7/00;;H02J7/02;;H02J50/10;;H04B1/3883,,0,0,,,,ACTIVE
49,CA,C,CA 2088685 C,022-647-877-143-362,1998-12-29,1998,CA 2088685 A,1991-08-01,US 56325390 A;;US 9105492 W,1990-08-06,WORK HOLDER SUPPORT APPARATUS,"A work holder support apparatus includes an elongate support member (10) having an undercut longitudinal slot (12). A base plate (18) at one side of the support member carries a spherical ball (16) and a clamp bolt (28) seated in a recessed bore (24) in the ball which passes through the base plate and slot to be threadably receiv ed in a first clamp plate (32) at the opposite side of the support member. An elongate work holder mounting member (64) and a second cl amp plate (70a) cooperatively define a ball receiving socket at one end of the mounting member enabling the mounting member to be clamped at any of a wide range of rotative adjustments relative to the ball. An opening (72a, 68a) into the socket affords access to the recessed clamping bolt head.",BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,,https://lens.org/022-647-877-143-362,Granted Patent,no,0,0,5,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/14;;F16M11/2078;;F16M2200/022;;B65G47/91;;F16M11/10;;B25B5/006;;F16M11/14;;F16M2200/022;;F16M11/2078,B25B5/00;;B65G47/91;;F16M11/14,,0,0,,,,EXPIRED
50,US,A,US 5261715 A,107-117-975-651-233,1993-11-16,1993,US 80377891 A,1991-12-05,US 80377891 A;;US 27117888 A;;US 56325390 A,1988-11-14,Work holder support apparatus,A work holder support apparatus includes an elongate support member having an undercut longitudinal slot. A base plate at one side of the support member carries a spherical ball and a clamp bolt seated in a recessed bore in the ball passes through the base plate and slot to be threadably received in a first clamp plate at the opposite side of the support member. An elongate work holder mounting member and a second clamp plate cooperatively define a ball receiving socket at one end of the mounting member enabling the mounting member to be clamped at any of a wide range of rotative adjustments relative to the ball. An opening into the socket affords access to the recessed clamping bolt head.,BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/107-117-975-651-233,Granted Patent,yes,33,47,1,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/2078;;F16M2200/022;;B25B5/006;;F16M11/10;;F16M11/2078;;F16M2200/022;;B65G47/91,B25B5/00;;B65G47/91;;F16M11/14,294/88;;294/86.41,0,0,,,,EXPIRED
51,US,A,US 5152566 A,199-550-966-905-785,1992-10-06,1992,US 64014091 A,1991-01-11,US 64014091 A;;US 63983191 A,1991-01-09,Spreader arm mounting device,"Various forms of mounting devices for mounting workpiece gripper carrying spreader bars upon a boom of a transfer device are disclosed. The boom is formed within an undercut T slot which extends the length of the boom and slidably receives a retainer member. A base spans the slot and is clamped to the side of the boom by clamping screws threadably received in the retainer member so that the base and retainer can be fixedly clamped to the boom at any selected location longitudinally of the boom. A recessed clamp member cooperatively defines within a recess in the base the socket of a ball and socket joint. In one form of the device, the same clamping screws which clamp the base to the boom simultaneously clamp a spherical coupling member fixed to a spreader bar and received in the socket in a selected fixed angularly adjusted position between the clamp member and base. In another form of device one set of clamping screws clamps the base and retainer to the boom and a second set of clamping screws are engaged between the clamp member and base. The coupling member may take the form of an annular split ring resiliently clamped to the spreader bar or may take the form of a spherical enlargement formed on the spreader bar.",BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1990-01-15);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/199-550-966-905-785,Granted Patent,yes,8,22,1,2,0,B21D43/057;;B23Q1/0018;;B23Q1/015;;B23Q1/5462;;B65G47/918;;B21D43/057;;B65G47/918;;B23Q1/015;;B23Q1/0018;;B23Q1/5462,B23Q1/00;;B23Q1/01;;B23Q1/54;;B65G47/91,294/81.2;;294/65,2,0,,,cpi Engineered End Arm Tooling Systems for stamping and assembly operations (brochure).;;cpi Automation Komponenten (drawing).,EXPIRED
52,US,A,US 5452981 A,085-306-417-151-660,1995-09-26,1995,US 3456593 A,1993-03-19,US 3456593 A;;US 75649291 A;;US 97813492 A;;US 66502991 A,1991-03-06,Automatic tool changer,"A production line which includes a shuttle conveyor extending between two work stations. A first transfer device for transferring a workpiece from one of the work stations to the conveyor and a second transfer device for transferring the workpiece to the second work station all equipped with workpiece gripping or supporting devices which may be rapidly changed when the line is shifted from the production of one form of workpiece to the production of another workpiece having a different configuration. Replacement workpiece gripping devices are supported adjacent the shuttle conveyor upon holding pedestals. Upon line changeover, the transfer devices locate their workpiece gripping devices upon empty holding pedestals and actuating devices on the pedestal release the gripping devices from their transfer devices. The empty transfer devices are then shifted and coupled to new workpiece gripping devices supported on other holding pedestals. The transfer device includes the ability for adjustment of the article engaging devices in three directions.",LELAND BLATT D,CROREY DAVID J;;BLATT LELAND D,LELAND D. BLATT (1993-11-30);;ISI NORGREN INC (1996-12-12),https://lens.org/085-306-417-151-660,Granted Patent,yes,39,63,2,4,0,B23Q7/04;;B23Q7/04;;B21D43/05;;B21D43/05;;B21D43/057;;B21D43/057;;B21D43/105;;B21D43/105;;B23Q1/58;;B23Q1/58,B21D43/05;;B21D43/10;;B23Q1/58;;B23Q7/04,414/225;;414/737;;414/744.8;;414/751;;198/468.6;;100/207,0,0,,,,EXPIRED
53,WO,A1,WO 1992/002339 A1,174-340-282-483-507,1992-02-20,1992,US 9105492 W,1991-08-01,US 56325390 A,1990-08-06,WORK HOLDER SUPPORT APPARATUS,"A work holder support apparatus includes an elongate support member (10) having an undercut longitudinal slot (12). A base plate (18) at one side of the support member carries a spherical ball (16) and a clamp bolt (28) seated in a recessed bore (24) in the ball which passes through the base plate and slot to be threadably received in a first clamp plate (32) at the opposite side of the support member. An elongate work holder mounting member (64) and a second clamp plate (70a) cooperatively define a ball receiving socket at one end of the mounting member enabling the mounting member to be clamped at any of a wide range of rotative adjustments relative to the ball. An opening (72a, 68a) into the socket affords access to the recessed clamping bolt head.",BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,,https://lens.org/174-340-282-483-507,Patent Application,yes,8,0,5,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/14;;F16M11/2078;;F16M2200/022;;B65G47/91;;F16M11/10;;B25B5/006;;F16M11/14;;F16M2200/022;;F16M11/2078,B25B5/00;;B65G47/91;;F16M11/14,,0,0,,,,PENDING
54,WO,A1,WO 2016/111682 A1,199-705-375-321-204,2016-07-14,2016,US 2015/0010379 W,2015-01-06,US 2015/0010379 W,2015-01-06,ELECTRONIC DEVICE WITH CHARGING MODULE,"An example of a system includes a electronic device having a rechargeable battery, a charging module to charge the rechargeable battery and moveable between a retracted position and an extended position to provide a stand during charging of the rechargeable battery, and a communication module to wirelessly transfer and receive data during charging of the rechargeable battery. The example system also includes a charging mat to charge the rechargeable battery when the charging module is in the extended position and coupled to the charging mat and a docking module to wirelessly transfer data to and wirelessly receive data from the communication module of the electronic device.",HEWLETT PACKARD DEVELOPMENT CO,JABORI MONJI;;NGUYEN BACH;;BLATT DAVID,,https://lens.org/199-705-375-321-204,Patent Application,yes,5,0,5,5,0,H02J50/80;;H02J50/10;;H02J7/0044;;H02J2310/22;;H02J7/0042;;H02J50/80;;H02J50/10;;H02J7/00034;;H02J7/0013;;H02J2310/22;;H02J7/0042;;H02J7/0044,H02J7/00,,0,0,,,,PENDING
55,CA,A1,CA 2088685 A1,014-190-699-599-350,1992-02-07,1992,CA 2088685 A,1991-08-01,US 56325390 A;;US 9105492 W,1990-08-06,WORK HOLDER SUPPORT APPARATUS,,BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,,https://lens.org/014-190-699-599-350,Patent Application,no,0,1,5,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/14;;F16M11/2078;;F16M2200/022;;B65G47/91;;F16M11/10;;B25B5/006;;F16M11/14;;F16M2200/022;;F16M11/2078,B25B5/00;;B65G47/91;;F16M11/14,,0,0,,,,EXPIRED
56,US,B2,US 10355524 B2,134-435-721-248-447,2019-07-16,2019,US 201615748380 A,2016-01-29,US 2016/0015611 W,2016-01-29,Electronic devices for wireless charging,"Examples disclosed herein provide an electronic device to allow wireless charging of the electronic device when it is operated in various operation modes. The electronic device can include a base member comprising a top surface and a bottom surface opposite the top surface and a display member rotatably connected to the base member. The electronic device can include a rechargeable battery and a receiver to wirelessly charge the rechargeable battery when the bottom surface of the base member is to be placed atop a transmitter. As an example, the bottom surface of the base member is to remain atop the transmitter while the electronic device is in different operation modes.",HEWLETT PACKARD DEVELOPMENT CO;;HEWIETT PACKARD DEV COMPANY L P,JABORI MONJI G;;BLATT DAVID ISAAC,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-01-29),https://lens.org/134-435-721-248-447,Granted Patent,yes,13,1,3,3,0,H04B1/3883;;G06F1/162;;G06F1/26;;H02J7/0042;;H02J50/00;;H04B1/3883;;H02J50/00;;H02J50/05;;H02J50/10;;G06F1/162;;G06F1/26;;H02J7/0042,H02J50/05;;G06F1/16;;G06F1/26;;H02J7/00;;H02J7/02;;H02J50/00;;H02J50/10;;H04B1/3883,,1,0,,,"Edwards, L., “Dell's Latitude Z Introduces Wireless Charging”, Sep. 30, 2009.",ACTIVE
57,US,A,US 5222854 A,176-387-432-913-535,1993-06-29,1993,US 75649291 A,1991-09-09,US 75649291 A,1991-09-09,Automatic tool changer,"A production line which includes a shuttle conveyor extending between two work stations. A first transfer device for transferring a workpiece from one of the work stations to the conveyor and a second transfer device for transferring the workpiece to the second work station all equipped with workpiece gripping or supporting devices which may be rapidly changed when the line is shifted from the production of one form of workpiece to the production of another workpiece having a different configuration. Replacement workpiece gripping devices are supported adjacent the shuttle conveyor upon holding pedestals. Upon line changeover, the transfer devices locate their workpiece gripping devices upon empty holding pedestals and actuating devices on the pedestal release the gripping devices from their transfer devices. The empty transfer devices are then shifted and coupled to new workpiece gripping devices supported on other holding pedestals.",BLATT LELAND D,BLATT LELAND D;;CROREY DAVID J,ISI NORGREN INC (1996-12-12);;BLATT LELAND D (1992-01-27),https://lens.org/176-387-432-913-535,Granted Patent,yes,15,66,1,4,0,B23Q1/58;;B23Q1/58;;B21D43/057;;B21D43/057;;B23Q7/04;;B23Q7/04;;Y10S414/13;;Y10S414/13,B21D43/05;;B23Q1/58;;B23Q7/04,414/225;;414/917;;414/737;;414/749;;901/30,0,0,,,,EXPIRED
58,US,A,US 5299847 A,103-413-829-881-584,1994-04-05,1994,US 64514091 A,1991-01-24,US 64514091 A;;US 56325390 A,1990-08-06,Gripper assembly,A gripper assembly for gripping a workpiece having removable and replaceable mountings. A gripper assembly is substantially square-shaped and has a corresponding square-shaped mounting spacer. The mounting spacer may be positioned about any side of the gripper assembly. This allows an operator to locate the assembly in any orientation to a workpiece assembly unit. The mounting is also removable and replaceable with other mounting configurations as desired. Several mounting couplings may be provided on the gripper to restrict or enlarge movement of the gripper about a workpiece holder assembly.,BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1990-12-20);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/103-413-829-881-584,Granted Patent,yes,28,27,5,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/14;;F16M11/2078;;F16M2200/022;;B65G47/91;;F16M11/10;;B25B5/006;;F16M11/14;;F16M2200/022;;F16M11/2078,B25B5/00;;B65G47/91;;F16M11/14,294/88;;294/86.41,0,0,,,,EXPIRED
59,US,A,US 5271651 A,012-889-337-224-726,1993-12-21,1993,US 56325390 A,1990-08-06,US 56325390 A;;US 27117888 A,1988-11-14,Work holder support apparatus,A work holder support apparatus includes an elongate support member having an undercut longitudinal slot. A base plate at one side of the support member carries a spherical ball and a clamp bolt seated in a recessed bore in the ball passes through the base plate and slot to be threadably received in a first clamp plate at the opposite side of the support member. An elongate work holder mounting member and a second clamp plate cooperatively define a ball receiving socket at one end of the mounting member enabling the mounting member to be clamped at any of a wide range of rotative adjustments relative to the ball. An opening into the socket affords access to the recessed clamping bolt head.,BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1990-08-01);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/012-889-337-224-726,Granted Patent,yes,28,56,5,13,0,B25B5/006;;B65G47/91;;F16M11/10;;F16M11/14;;F16M11/2078;;F16M2200/022;;B65G47/91;;F16M11/10;;B25B5/006;;F16M11/14;;F16M2200/022;;F16M11/2078,B25B5/00;;B65G47/91;;F16M11/14,294/88;;294/86.4;;248/288.3;;248/288.5,0,0,,,,EXPIRED
60,US,A,US 5125632 A,015-482-164-075-156,1992-06-30,1992,US 64745291 A,1991-01-29,US 64745291 A,1991-01-29,Rotary actuated workpiece holder,"A workpiece holder includes first and second workpiece engaging members, one of which is rotatable with respect to the other. A rotary actuator drives the rotatable workpiece engaging member between two positions relative to the other workpiece engaging member. The rotatable actuator includes opposed, radially extending vanes mounted on a rotatable shaft extending through a hollow, closed body. The rotatable workpiece engaging member is fixedly connected to and rotatable with the rotatable shaft. The vanes are disposed in the hollow body and respectively create a pair of chambers between themselves and circumferentially spaced legs formed in the body and extending radially inward into the interior cavity of the body toward the rotatable shaft. Pressurized fluid is alternately supplied to and exhausted from each pair of chambers to exert force on and rotate the vanes, the rotatable shaft and the rotatable workpiece engaging member between the two positions. A mounting plate or arm is connected to the body for mounting the workpiece holder to a support surface.",BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1991-01-15);;ISI NORGREN INC (1996-12-12),https://lens.org/015-482-164-075-156,Granted Patent,yes,51,33,1,1,0,B25B5/061;;B25B5/061;;B23K37/0408;;B23K37/0408;;B25B5/006;;B25B5/006;;B25B5/04;;B25B5/04;;B25B5/163;;B25B5/163;;F15B15/12;;F15B15/12,B23K37/04;;B25B5/00;;B25B5/04;;B25B5/06;;B25B5/16;;F15B15/12,269/32,0,0,,,,EXPIRED
61,US,A,US 2634042 A,010-738-337-577-627,1953-04-07,1953,US 8689449 A,1949-04-12,US 8689449 A,1949-04-12,Cellular container for article shipping and storage,,BLATT DAVID H;;MANN FREDRIC R,BLATT DAVID H;;MANN FREDRIC R,,https://lens.org/010-738-337-577-627,Granted Patent,no,4,3,1,1,0,B65D5/48008;;B65D5/48008;;Y10S229/939;;Y10S229/939,B65D5/4805,,0,0,,,,EXPIRED
62,US,A,US 5135276 A,125-589-762-022-175,1992-08-04,1992,US 63983191 A,1991-01-09,US 63983191 A,1991-01-09,Transfer boom,"A transfer boom adapted for suspension from a reciprocal shuttle carriage comprises a boom arm having a plurality of interior passages extending the length of the boom arm. These passages define air passages, thereby eliminating the need for exterior hoses. A T-shaped cavity is provided within the exterior walls of the boom arm. A boom mount, having Venturi cups or grippers is detachably mounted to the boom arm within the T-shaped cavity by a T-bolt. This enables the boom mount to be mounted anywhere along the length of the boom arm. The T-bolt provides for easy removability of the boom mount from the boom arm.",BLATT JOHN A,BLATT JOHN A;;TOMLIN DAVID C,BLATT JOHN A (1991-06-06);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/125-589-762-022-175,Granted Patent,yes,11,19,1,2,0,B23Q1/0018;;B23Q1/015;;B23Q1/5462;;B65G47/918;;B25J15/0061;;B23Q1/0018;;B23Q1/015;;B65G47/918;;B23Q1/5462;;B25J15/0061,B23Q1/00;;B23Q1/01;;B23Q1/54;;B65G47/91,294/65;;138/111;;138/115;;212/221;;414/752,0,0,,,,EXPIRED
63,US,A,US 5174709 A,087-287-501-705-138,1992-12-29,1992,US 66502991 A,1991-03-06,US 66502991 A,1991-03-06,Workpiece transfer device,"A workpiece transfer device includes a mounting frame assembly having an upper fixed frame and an inner subframe slidably mounted to the fixed frame. The inner subframe supports a gear rack on its upper surface and a separate conveying system within its frame. A drive unit is mounted on top of the fixed frame and includes idler rollers and a drive gear. The drive gear engages the gear rack thereby moving the whole inner subframe assembly, including the conveyor system in a horizontal path between two presses. As the inner subframe moves along a horizontal plane, a locking plate assembly prevents the conveyor belt from traveling with the inner subframe. The end gears in the conveyor rotate along the stationary belt forcing a workpiece carrier to move from one end of the conveyor system to the opposite end in the same direction as the inner subframe. Therefore, as the inner subframe moves in a horizontal path, the carrier is simultaneously moved along the same path.",BLATT LELAND D,BLATT JOHN A;;CROREY DAVID J,BLATT LELAND D (1992-01-27);;NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/087-287-501-705-138,Granted Patent,yes,16,21,1,4,0,B21D43/05;;B21D43/105;;B23Q1/58;;B23Q7/04;;B23Q7/04;;B23Q1/58;;B21D43/05;;B21D43/105,B21D43/05;;B21D43/10;;B23Q1/58;;B23Q7/04,414/567;;414/591;;414/744.2;;414/751;;198/468.2,0,0,,,,EXPIRED
64,CA,A,CA 719474 A,113-801-158-440-215,1965-10-12,1965,CA 719474D A,,CA 719474T A,,CLOSURE FOR CAR DOORS AND THE LIKE,,FMC CORP,TALBOT JAMES E;;BLATT DAVID H,,https://lens.org/113-801-158-440-215,Granted Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
65,US,A,US 5509777 A,011-534-044-316-476,1996-04-23,1996,US 33950494 A,1994-11-14,US 33950494 A;;US 3709393 A,1993-03-25,Mechanical side shift and tip apparatus,An article transfer apparatus includes a power driven shuttle carriage mounted for movement along a first linear path between opposite end limits. An article holder assembly includes a base mounted on the carriage for movement relative to the carriage along a second linear path normal to the first linear path between opposite end limits. The holder base mounts a sleeve slidable along an elongate guide rod whose opposite ends may be independently positioned transversely of the first linear path. The guide rod may thus be located to extend parallel to or be inclined relative to the first path to accordingly enable the sleeve to position the holder on the second linear path or to move the holder base transversely of the carriage driving movement of the carriage along the first linear path or may be inclined relative to the first path to accordingly enable the article holder to be adjusted about one axis relative to the base and driven in rotative adjustment relative to the base about the axis relative to the guide rod inclination.,BLATT LELAND D,CROREY DAVID J;;BLATT LELAND D,NORGREN AUTOMOTIVE INC (1996-12-12),https://lens.org/011-534-044-316-476,Granted Patent,yes,7,4,1,1,0,B23Q7/1447;;B23Q7/1447,B23Q7/14,414/749;;198/468.6,0,0,,,,EXPIRED
66,WO,A1,WO 2017/131734 A1,144-955-991-394-833,2017-08-03,2017,US 2016/0015611 W,2016-01-29,US 2016/0015611 W,2016-01-29,ELECTRONIC DEVICES FOR WIRELESS CHARGING,"Examples disclosed herein provide an electronic device to allow wireless charging of the electronic device when it is operated in various operation modes. The electronic device can include a base member comprising a top surface and a bottom surface opposite the top surface and a display member rotatably connected to the base member. The electronic device can include a rechargeable battery and a receiver to wirelessly charge the rechargeable battery when the bottom surface of the base member is to be placed atop a transmitter. As an example, the bottom surface of the base member is to remain atop the transmitter while the electronic device is in different operation modes.",HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI G;;BLATT DAVID ISAAC,,https://lens.org/144-955-991-394-833,Patent Application,yes,5,6,3,3,0,H04B1/3883;;G06F1/162;;G06F1/26;;H02J7/0042;;H02J50/00;;H04B1/3883;;H02J50/00;;H02J50/05;;H02J50/10;;G06F1/162;;G06F1/26;;H02J7/0042,H02J13/00;;H02J7/02;;H02J50/00;;H04B1/3883,,0,0,,,,PENDING
67,WO,A1,WO 2018/004604 A1,191-492-645-074-673,2018-01-04,2018,US 2016/0040424 W,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,"In an example, a light blocker may comprise a bellow to extend from an outer edge of a key to an inner edge of a key window to span a key gap in between the key and the key window. The bellow may extend along a periphery of the key, and the bellow may block light originating from under the key from passing through the key gap.",HEWLETT PACKARD DEVELOPMENT CO LP,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,,https://lens.org/191-492-645-074-673,Patent Application,yes,5,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H13/705;;H01H9/02;;H01H13/7065,,0,0,,,,PENDING
68,US,A1,US 2019/0164704 A1,125-796-045-575-449,2019-05-30,2019,US 201616092920 A,2016-08-03,US 2016/0045327 W,2016-08-03,MODULAR KEYBOARD,"Example implementations relate to modular keyboards. In an example, a modular keyboard can include a keyboard module including keys, where the keyboard module includes a plurality of locking mechanisms, and a lattice removably coupled by the plurality of locking mechanisms to the keyboard module, where the lattice comprises a keyboard overlay.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID ISAAC;;HUNG JACK;;HUNG JERRY,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-07-26),https://lens.org/125-796-045-575-449,Patent Application,yes,3,1,3,3,0,H01H13/04;;G06F3/0202;;H01H2223/014;;H01H2223/012;;H01H2223/028;;H01H13/04;;H01H9/20;;H01H9/02;;G06F3/0202;;H01H2223/014;;H01H13/86;;H01H2223/012;;H01H2223/022;;H01H2223/028;;H01H2223/034,H01H13/86,,0,0,,,,ACTIVE
69,EP,B1,EP 3437114 B1,068-391-321-913-002,2022-02-23,2022,EP 16907561 A,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,,HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/068-391-321-913-002,Granted Patent,yes,9,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H9/02;;H01H13/06;;H01H13/705;;H01H13/7065;;H01H13/83,,0,0,,,,ACTIVE
70,US,B2,US 10903026 B2,197-961-366-121-278,2021-01-26,2021,US 201616092920 A,2016-08-03,US 2016/0045327 W,2016-08-03,Modular keyboard,"Example implementations relate to modular keyboards. In an example, a modular keyboard can include a keyboard module including keys, where the keyboard module includes a plurality of locking mechanisms, and a lattice removably coupled by the plurality of locking mechanisms to the keyboard module, where the lattice comprises a keyboard overlay.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID ISAAC;;HUNG JACK;;HUNG JERRY,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-07-26),https://lens.org/197-961-366-121-278,Granted Patent,yes,14,3,3,3,0,H01H13/04;;G06F3/0202;;H01H2223/014;;H01H2223/012;;H01H2223/028;;H01H13/04;;H01H9/20;;H01H9/02;;G06F3/0202;;H01H2223/014;;H01H13/86;;H01H2223/012;;H01H2223/022;;H01H2223/028;;H01H2223/034,H01H13/705;;G06F3/02;;H01H9/02;;H01H9/20;;H01H13/04;;H01H13/86,,0,0,,,,ACTIVE
71,TW,A,TW 201802848 A,003-875-835-851-77X,2018-01-16,2018,TW 106107584 A,2017-03-08,US 2016/0040424 W,2016-06-30,Light blockers,"In an example, a light blocker may comprise a bellow to extend from an outer edge of a key to an inner edge of a key window to span a key gap in between the key and the key window. The bellow may extend along a periphery of the key, and the bellow may block light originating from under the key from passing through the key gap.",HEWLETT PACKARD DEVELOPMENT CO LP,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,,https://lens.org/003-875-835-851-77X,Patent of Addition,no,0,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H13/02,,0,0,,,,INACTIVE
72,WO,A1,WO 2018/026361 A1,158-963-810-739-133,2018-02-08,2018,US 2016/0045327 W,2016-08-03,US 2016/0045327 W,2016-08-03,MODULAR KEYBOARD,"Example implementations relate to modular keyboards. In an example, a modular keyboard can include a keyboard module including keys, where the keyboard module includes a plurality of locking mechanisms, and a lattice removably coupled by the plurality of locking mechanisms to the keyboard module, where the lattice comprises a keyboard overlay.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID ISAAC;;HUNG JACK;;HUNG JERRY,,https://lens.org/158-963-810-739-133,Patent Application,yes,4,0,3,3,0,H01H13/04;;G06F3/0202;;H01H2223/014;;H01H2223/012;;H01H2223/028;;H01H13/04;;H01H9/20;;H01H9/02;;G06F3/0202;;H01H2223/014;;H01H13/86;;H01H2223/012;;H01H2223/022;;H01H2223/028;;H01H2223/034,G06F3/02;;H01H9/02;;H01H9/20;;H01H13/04,,0,0,,,,PENDING
73,US,A1,US 2019/0066946 A1,015-353-679-531-877,2019-02-28,2019,US 201616091020 A,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,"In an example, a light blocker may comprise a bellow to extend from an outer edge of a key to an inner edge of a key window to span a key gap in between the key and the key window. The bellow may extend along a periphery of the key, and the bellow may block light originating from under the key from passing through the key gap.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-06-29),https://lens.org/015-353-679-531-877,Patent Application,yes,1,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H13/83;;G06F1/16,,0,0,,,,ACTIVE
74,TW,B,TW I622072 B,057-103-343-556-343,2018-04-21,2018,TW 106107584 A,2017-03-08,US 2016/0040424 W,2016-06-30,Light blockers,,HEWLETT PACKARD DEVELOPMENT CO LP,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,,https://lens.org/057-103-343-556-343,Granted Patent,no,2,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,,,0,0,,,,INACTIVE
75,EP,A4,EP 3437114 A4,082-331-429-486-826,2019-10-23,2019,EP 16907561 A,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,,HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/082-331-429-486-826,Search Report,no,4,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H9/02;;H01H13/06;;H01H13/705;;H01H13/7065;;H01H13/83,,1,0,,,See also references of WO 2018004604A1,ACTIVE
76,EP,A1,EP 3437114 A1,177-989-353-527-593,2019-02-06,2019,EP 16907561 A,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,,HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/177-989-353-527-593,Patent Application,yes,0,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H9/02;;H01H13/705;;H01H13/7065,,0,0,,,,ACTIVE
77,US,B2,US 10373778 B2,033-363-229-220-432,2019-08-06,2019,US 201616091020 A,2016-06-30,US 2016/0040424 W,2016-06-30,Key light blockers with bellows,"In an example, a light blocker may comprise a bellow to extend from an outer edge of a key to an inner edge of a key window to span a key gap in between the key and the key window. The bellow may extend along a periphery of the key, and the bellow may block light originating from under the key from passing through the key gap.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-06-29),https://lens.org/033-363-229-220-432,Granted Patent,yes,18,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H13/83;;G06F1/16;;H01H13/7065,,1,0,,,"The 10 Best Keyboards, Sep. 27, 2015, <http://www.xiontech.net/the-10-best-keyboards/>.",ACTIVE
78,CN,A,CN 109074975 A,111-207-052-307-075,2018-12-21,2018,CN 201680085231 A,2016-06-30,US 2016/0040424 W,2016-06-30,LIGHT BLOCKERS,"In an example, a light blocker may comprise a bellow to extend from an outer edge of a key to an inner edge of a key window to span a key gap in between the key and the key window. The bellow may extend along a periphery of the key, and the bellow may block light originating from under the key from passing through the key gap.",HEWLETT PACKARD DEVELOPMENT CO,BLATT DAVID I;;PETERSON ALAN D;;VINSON DAVID C,,https://lens.org/111-207-052-307-075,Patent Application,no,5,0,10,10,0,H01H2219/054;;H01H2219/064;;H01H13/83;;H01H13/063;;H01H2219/054;;H01H2219/064;;H01H13/063;;H01H13/83;;G06F1/1662;;H01H13/7065,H01H9/02;;H01H13/705;;H01H13/7065,,0,0,,,,ACTIVE
79,GB,A,GB 2359022 A,124-388-546-225-130,2001-08-15,2001,GB 0110612 A,1999-10-05,IL 9900527 W;;US 39275498 A,1998-10-07,Controlled-release garlic formulations,"There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations reguired for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37{C. A process for preparing the formulations of the invention is also disclosed.",BIO DAR LTD,BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED,,https://lens.org/124-388-546-225-130,Patent Application,no,4,0,7,7,0,A61K9/5073;;A61K9/5073;;A61K9/2081;;A61K9/2081;;A61K9/5042;;A61K9/5042;;A61K9/5047;;A61K9/5047;;A61K36/8962;;A61K36/8962,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K36/8962,A5B BJB           BJB2;;A5B B180          BJB2;;A5B B30X          BJB2;;A5B B30Y          BJB2;;A5B B828          BJB2;;A5B B829          BJB2;;A5B B835          BJB2;;U1S S1278;;U1S S1330,1,0,,,"DATABASE WPI Section Ch, Week 198923 Derwent Publication Ltd.London, GB; Class B04, AN 1989-167839 XP002134264 & HU 47 858 A2 (KERBOLT K) abstract",DISCONTINUED
80,US,B1,US 6340478 B1,038-543-549-700-240,2002-01-22,2002,US 32775299 A,1999-06-07,US 32775299 A,1999-06-07,Microencapsulated and controlled-release herbal formulations,"
    There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37 C. A process for the preparation of such formulation is also provided. 
",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,BIO DAR LTD (1999-05-15),https://lens.org/038-543-549-700-240,Granted Patent,yes,5,14,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/20;;A61K9/50;;A61K36/38,424/489;;424/490;;424/451;;424/464;;424/195.1,0,0,,,,EXPIRED
81,DE,D1,DE 60031307 D1,067-019-824-541-362,2006-11-23,2006,DE 60031307 T,2000-06-07,US 32775299 A;;IL 0000334 W,1999-06-07,MIKROVERKAPSELTE UND MIT GESTEURTER FREIGABE KRÄUTER FORMULIERUNGEN,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/067-019-824-541-362,Granted Patent,no,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/50;;A61K9/20;;A61K36/38,,0,0,,,,EXPIRED
82,TW,B,TW I640143 B,168-757-698-656-076,2018-11-01,2018,TW 106107778 A,2017-03-09,US 2016/0024437 W,2016-03-28,Wireless charging device and method,,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI;;LAGNADO ISAAC;;BLATT DAVID;;MERKEL HAROLD,,https://lens.org/168-757-698-656-076,Granted Patent,no,3,0,3,3,0,H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00034;;H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00,,,0,0,,,,INACTIVE
83,US,A1,US 2022/0090598 A1,199-836-284-393-157,2022-03-24,2022,US 202117410656 A,2021-08-24,DE 102020124392 A,2020-09-18,CLEARANCE ADJUSTMENT FOR TWIN-SCREW PUMPS,"Technologies are generally described for clearance adjustments in twin-screw pump assemblies. A twin-screw pump assembly may include a conically shaped portion of a drive shaft enveloped by a bushing. For clearance adjustment, both clamping nuts of the drive shaft, which provide pretention to the bushing and secure an axial position of a threaded screw to the drive shaft, may be removed on the flow side of the pump assembly and the bushing loosened to adjust the angularity between bushing and drive shaft. The bushing may then be pushed over the conically shaped portion and both clamping nuts re-assembled. In some examples, a clamping nut of the driven shaft may be designed and used as removal/loosening tool for the drive shaft bushing.",ITT BORNEMANN GMBH,LISSEL MANUELA;;KORTE EIKE STEFFEN;;BLATT DAVID JOHANNES,ITT BORNEMANN GMBH (2020-09-11),https://lens.org/199-836-284-393-157,Patent Application,yes,8,0,3,3,0,F04C2/16;;F04C15/0057;;F01C17/02;;F04C2240/605;;F04C29/0078;;F04C29/0071;;F04C2/16;;F04C15/0061;;F04C2230/601;;F04C2240/805;;F04C2240/30;;F04C2240/60;;F04C2230/602,F04C2/16;;F04C15/00,,0,0,,,,ACTIVE
84,SG,A,SG 10201901010P A,016-664-516-051-03X,2019-03-28,2019,SG 10201901010P A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection. [Figure 1]",ALIOS BIOPHARMA INC,BLATT LAWRENCE;;BEIGELMAN LEONID;;SMITH DAVID;;WANG GUANGYI,,https://lens.org/016-664-516-051-03X,Unknown,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,,,0,0,,,,PENDING
85,WO,A1,WO 2000/074656 A1,033-822-734-681-934,2000-12-14,2000,IL 0000334 W,2000-06-07,US 32775299 A,1999-06-07,MICROENCAPSULATED AND CONTROLLED-RELEASE HERBAL FORMULATIONS,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75 % of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1 % w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37 °C. A process for the preparation of such formulation is also provided.",BIO DAR LTD;;BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/033-822-734-681-934,Patent Application,yes,5,7,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/20;;A61K9/50;;A61K36/38,,0,0,,,,PATENTED
86,DE,T2,DE 60031307 T2,117-276-936-793-82X,2007-05-24,2007,DE 60031307 T,2000-06-07,US 32775299 A;;IL 0000334 W,1999-06-07,MIKROVERKAPSELTE KRÄUTER FORMULIERUNGEN MIT GESTEUERTER FREIGABE,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/117-276-936-793-82X,Granted Patent,no,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/50;;A61K9/20;;A61K36/38,,0,0,,,,EXPIRED
87,EP,A1,EP 1278514 A1,012-277-036-217-605,2003-01-29,2003,EP 00935455 A,2000-06-07,IL 0000334 W;;US 32775299 A,1999-06-07,MICROENCAPSULATED AND CONTROLLED-RELEASE HERBAL FORMULATIONS,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/012-277-036-217-605,Patent Application,yes,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/20;;A61K9/50;;A61K36/38,,0,0,,,,EXPIRED
88,US,A1,US 2007/0293281 A1,163-368-294-265-30X,2007-12-20,2007,US 42446506 A,2006-06-15,US 42446506 A,2006-06-15,SEAL FOR PORTABLE ELECTRONIC DEVICE HOUSING WITH FLEX CIRCUIT,"The invention is directed to a portable electronic device and includes a portable electronic device housing ( 110 ) where the housing has at least one orifice ( 120 ) to an internal portion ( 130 ) of the housing. The electronic device also includes a flex circuit ( 140 ) projecting from the orifice, a seal ( 150 ) located at the orifice to prevent liquid from entering the internal portion of the housing, where the seal has a first portion ( 150 a ) and a second portion ( 150 b ). The first portion and the second portion of the seal sandwich the flex circuit and the seal is snug fit in the orifice. A method ( 300 ) of installing a seal for a portable electronic device housing having an orifice through which a flex circuit protrudes is also provided.",MOTOROLA INC,NOGUEIRAS EDUARDO;;BLATT DAVID I;;NGUYEN BACH L,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2006-06-15),https://lens.org/163-368-294-265-30X,Patent Application,yes,9,4,2,2,0,H04M1/026;;H04M1/026;;H04M1/0216;;H04M1/0216;;H04M1/18;;H04M1/18,H04M1/00,455/575.1,0,0,,,,INACTIVE
89,EP,B1,EP 1278514 B1,033-049-043-969-482,2006-10-11,2006,EP 00935455 A,2000-06-07,IL 0000334 W;;US 32775299 A,1999-06-07,MICROENCAPSULATED AND CONTROLLED-RELEASE HERBAL FORMULATIONS,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/033-049-043-969-482,Granted Patent,yes,5,2,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/50;;A61K9/20;;A61K36/38,,0,0,,,,EXPIRED
90,AU,A,AU 2000/050994 A,097-321-445-215-773,2000-12-28,2000,AU 2000/050994 A,2000-06-07,IL 0000334 W;;US 32775299 A,1999-06-07,Microencapsulated and controlled-release herbal formulations,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/097-321-445-215-773,Patent Application,no,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/20;;A61K9/50;;A61K36/38,,0,0,,,,DISCONTINUED
91,US,B2,US 7590434 B2,149-849-838-503-59X,2009-09-15,2009,US 42446506 A,2006-06-15,US 42446506 A,2006-06-15,Seal for portable electronic device housing with flex circuit,"A portable electronic device includes a portable electronic device housing ( 110 ) where the housing has at least one orifice ( 120 ) to an internal portion ( 130 ) of the housing. The electronic device also includes a flex circuit ( 140 ) projecting from the orifice, a seal ( 150 ) located at the orifice to prevent liquid from entering the internal portion of the housing, where the seal has a first portion ( 150 a ) and a second portion ( 150 b ). The first portion and the second portion of the seal sandwich the flex circuit and the seal is snug fit in the orifice. A method ( 300 ) of installing a seal for a portable electronic device housing having an orifice through which a flex circuit protrudes is also provided.",MOTOROLA INC,NOGUEIRAS EDUARDO;;BLATT DAVID I;;NGUYEN BACH L,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2006-06-15),https://lens.org/149-849-838-503-59X,Granted Patent,yes,11,4,2,2,0,H04M1/026;;H04M1/026;;H04M1/0216;;H04M1/0216;;H04M1/18;;H04M1/18,H04M1/00;;H01R12/00;;H05K1/00,455/575.1;;439/65,0,0,,,,INACTIVE
92,ES,T3,ES 2273697 T3,043-192-393-612-285,2007-05-16,2007,ES 00935455 T,2000-06-07,US 32775299 A,1999-06-07,FORMULACIONES MICROENCAPSULADAS Y DE LIBERACION CONTROLADA DE HIEREBAS.,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/043-192-393-612-285,Granted Patent,no,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/50;;A61K9/20;;A61K36/38,,0,0,,,,EXPIRED
93,US,B2,US 11598333 B2,148-951-385-145-64X,2023-03-07,2023,US 202117410656 A,2021-08-24,DE 102020124392 A,2020-09-18,Clearance adjustment for twin-screw pumps,"Technologies are generally described for clearance adjustments in twin-screw pump assemblies. A twin-screw pump assembly may include a conically shaped portion of a drive shaft enveloped by a bushing. For clearance adjustment, both clamping nuts of the drive shaft, which provide pretention to the bushing and secure an axial position of a threaded screw to the drive shaft, may be removed on the flow side of the pump assembly and the bushing loosened to adjust the angularity between bushing and drive shaft. The bushing may then be pushed over the conically shaped portion and both clamping nuts re-assembled. In some examples, a clamping nut of the driven shaft may be designed and used as removal/loosening tool for the drive shaft bushing.",ITT BORNEMANN GMBH,LISSEL MANUELA;;KORTE EIKE STEFFEN;;BLATT DAVID JOHANNES,ITT BORNEMANN GMBH (2020-09-11),https://lens.org/148-951-385-145-64X,Granted Patent,yes,8,0,3,3,0,F04C2/16;;F04C15/0057;;F01C17/02;;F04C2240/605;;F04C29/0078;;F04C29/0071;;F04C2/16;;F04C15/0061;;F04C2230/601;;F04C2240/805;;F04C2240/30;;F04C2240/60;;F04C2230/602,F01C1/16;;F03C2/00;;F03C4/00;;F04C2/16;;F04C15/00;;F04C18/00,,0,0,,,,ACTIVE
94,DE,A1,DE 102020124392 A1,079-506-225-071-251,2022-03-24,2022,DE 102020124392 A,2020-09-18,DE 102020124392 A,2020-09-18,ABSTANDSEINSTELLUNG FÜR DOPPELSCHNECKENPUMPEN,"Im Allgemeinen werden Technologien für Abstandseinstellungen in Doppelschneckenpumpenbaugruppen beschrieben. Eine Doppelschneckenpumpenbaugruppe kann einen konisch geformten Abschnitt einer Antriebswelle beinhalten, der von einer Buchse umschlossen ist. Zur Abstandseinstellung können beide Spannmuttern der Antriebswelle, die eine Vorspannung der Buchse bereitstellen und eine axiale Position einer Gewindeschnecke in Bezug auf die Antriebswelle sichern, an der Strömungsseite der Pumpenbaugruppe entfernt werden und die Buchse kann zur Einstellung der Winkelstellung zwischen Buchse und Antriebswelle gelockert werden. Die Buchse kann dann über den konisch geformten Abschnitt geschoben werden und beide Spannmuttern können wieder zusammengesetzt werden. In einigen Beispielen kann eine Spannmutter der Abtriebswelle als Entfernungs-/Lockerungswerkzeug für die Antriebswellenbuchse ausgestaltet und verwendet werden.",ITT BORNEMANN GMBH,LISSEL MANUELA;;KORTE EIKE STEFFEN;;BLATT DAVID JOHANNES,,https://lens.org/079-506-225-071-251,Patent Application,no,0,1,3,3,0,F04C2/16;;F04C15/0057;;F01C17/02;;F04C2240/605;;F04C29/0078;;F04C29/0071;;F04C2/16;;F04C15/0061;;F04C2230/601;;F04C2240/805;;F04C2240/30;;F04C2240/60;;F04C2230/602,F04C2/16,,0,0,,,,PENDING
95,AT,T1,AT E342049 T1,127-907-851-521-658,2006-11-15,2006,AT 00935455 T,2000-06-07,US 32775299 A,1999-06-07,MIKROVERKAPSELTE UND MIT GESTEURTER FREIGABE KRÄUTER FORMULIERUNGEN,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.",BIO DAR LTD,BLATT YOAV;;KIMMELMAN EUGENE;;COHEN DAVID;;ROTMAN AVNER,,https://lens.org/127-907-851-521-658,Granted Patent,no,0,0,9,9,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5047;;A61K9/5047;;A61K9/2027;;A61K9/2081;;A61K9/2054,A61K9/20;;A61K9/50;;A61K36/38,,0,0,,,,EXPIRED
96,US,A1,US 2019/0214835 A1,172-050-965-502-924,2019-07-11,2019,US 201515539779 A,2015-01-06,US 2015/0010379 W,2015-01-06,ELECTRONIC DEVICE WITH CHARGING MODULE,"An example of a system includes a electronic device having a rechargeable battery, a charging module to charge the rechargeable battery and moveable between a retracted position and an extended position to provide a stand during charging of the rechargeable battery, and a communication module to wirelessly transfer and receive data during charging of the rechargeable battery. The example system also includes a charging mat to charge the rechargeable battery when the charging module is in the extended position and coupled to the charging mat and a docking module to wirelessly transfer data to and wirelessly receive data from the communication module of the electronic device",HEWLETT PACKARD DEVELOPMENT CO,JABORI MONJI;;NGUYEN BACH LIEN;;BLATT DAVID ISAAC,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-12-28),https://lens.org/172-050-965-502-924,Patent Application,yes,4,4,5,5,0,H02J50/80;;H02J50/10;;H02J7/0044;;H02J2310/22;;H02J7/0042;;H02J50/80;;H02J50/10;;H02J7/00034;;H02J7/0013;;H02J2310/22;;H02J7/0042;;H02J7/0044,H02J7/00;;H02J7/02;;H02J50/80,,0,0,,,,ACTIVE
97,TW,A,TW 201737593 A,033-350-451-642-115,2017-10-16,2017,TW 106107778 A,2017-03-09,US 2016/0024437 W,2016-03-28,Wireless charging device,Examples include a wireless charging device. Examples comprise a wireless power supply to generate an electromagnetic field. Examples further comprise at least one non-contact sensor. Examples include a controller to control the at least one non-contact sensor to detect proximity of a particular object to the wireless charging device. Examples determine at least one material characteristic associated with the particular object based at least in part on sensor data received from the non-contact sensor. Examples control the wireless power supply to selectively generate the electromagnetic field based at least in part on he at least one material characteristic of the particular object.,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI;;LAGNADO ISAAC;;BLATT DAVID;;MERKEL HAROLD,,https://lens.org/033-350-451-642-115,Patent of Addition,no,0,2,3,3,0,H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00034;;H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00,H02J50/80,,0,0,,,,INACTIVE
98,WO,A1,WO 2018/144020 A1,138-304-512-570-961,2018-08-09,2018,US 2017/0016556 W,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,"In some examples, a thermal control device includes a vapor chamber comprising a fluid to transport heat from a first portion of the vapor chamber to a second portion of the vapor chamber, and an isolation chamber adjacent the vapor chamber and fluidically isolated from the vapor chamber, the isolation chamber evacuated to a pressure less than atmospheric pressure to thermally isolate at least a portion of the vapor chamber.",HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/138-304-512-570-961,Patent Application,yes,8,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20;;G12B15/02,,0,0,,,,PENDING
99,TW,B,TW I650060 B,015-463-511-928-253,2019-02-01,2019,TW 107103641 A,2018-02-01,US 2017/0016556 W,2017-02-03,Thermal control with vapor and isolation chambers,,HEWLETT PACKARD DEVELOPMENT CO LP,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/015-463-511-928-253,Granted Patent,no,4,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,,,0,0,,,,INACTIVE
100,WO,A1,WO 2017/171702 A1,038-681-863-436-324,2017-10-05,2017,US 2016/0024437 W,2016-03-28,US 2016/0024437 W,2016-03-28,WIRELESS CHARGING DEVICE,Examples include a wireless charging device. Examples comprise a wireless power supply to generate an electromagnetic field. Examples further comprise at least one non-contact sensor. Examples include a controller to control the at least one non-contact sensor to detect proximity of a particular object to the wireless charging device. Examples determine at least one material characteristic associated with the particular object based at least in part on sensor data received from the non-contact sensor. Examples control the wireless power supply to selectively generate the electromagnetic field based at least in part on he at least one material characteristic of the particular object.,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI G;;LAGNADO ISAAC;;BLATT DAVID;;MERKEL HAROLD,,https://lens.org/038-681-863-436-324,Patent Application,yes,5,1,3,3,0,H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00034;;H02J50/90;;H02J50/12;;H02J50/60;;H02J7/00,H02J7/00;;H02J50/10;;H02J50/90,,0,0,,,,PENDING
101,US,A1,US 2004/0054156 A1,084-254-606-488-395,2004-03-18,2004,US 34290203 A,2003-01-15,US 34290203 A;;US 87747801 A;;US 69634700 A;;US 63638500 A;;US 53102500 A;;US 43643099 A;;US 19362794 A;;US 88271292 A,1992-05-14,Method and reagent for inhibiting hepatitis B viral replication,"
   The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed. 
",DRAPER KENNETH;;BLATT LAWRENCE;;MCSWIGGEN JAMES A.;;MORRISSEY DAVID,DRAPER KENNETH;;BLATT LAWRENCE;;MCSWIGGEN JAMES A;;MORRISSEY DAVID,,https://lens.org/084-254-606-488-395,Patent Application,yes,17,74,1,1181,6592,A61K38/21;;A61K38/21;;C12P19/305;;C12P19/305;;C07H19/10;;C07H19/10;;C07H19/20;;C07H19/20;;C07H21/00;;C07H21/00;;C07K14/005;;C07K14/005;;C12N15/111;;C12N15/111;;C12N15/113;;C12N15/113;;C12N15/1131;;C12N15/1131;;C12N15/1137;;C12N15/1137;;C12N15/1138;;C12N15/1138;;C12N15/85;;C12N15/85;;C12N15/86;;C12N15/86;;C12N2310/11;;C12N2310/11;;C12N2310/12;;C12N2310/12;;C12N2310/121;;C12N2310/121;;C12N2310/122;;C12N2310/122;;C12N2310/13;;C12N2310/13;;C12N2310/16;;C12N2310/16;;C12N2310/18;;C12N2310/18;;C12N2310/315;;C12N2310/315;;C12N2310/317;;C12N2310/317;;C12N2310/318;;C12N2310/318;;C12N2310/319;;C12N2310/319;;C12N2310/321;;C12N2310/321;;C12N2310/322;;C12N2310/322;;C12N2310/332;;C12N2310/332;;C12N2310/346;;C12N2310/346;;C12N2310/3519;;C12N2310/3519;;C12N2310/3521;;C12N2310/3521;;C12N2310/3531;;C12N2310/3531;;C12N2310/3533;;C12N2310/3533;;C12N2310/3535;;C12N2310/3535;;C12N2320/31;;C12N2320/31;;C12N2320/51;;C12N2320/51;;C12N2730/10122;;C12N2730/10122;;C12P19/30;;C12P19/30;;C12Q1/706;;C12Q1/706;;C12Y207/07049;;C12Y207/07049;;C12Y301/03048;;C12Y301/03048,A61K38/00;;A61K38/21;;C07H19/10;;C07H19/20;;C07H21/00;;C07K14/08;;C12N15/11;;C12N15/113;;C12N15/85;;C12N15/86;;C12P19/30;;C12Q1/68;;C12Q1/70,536/23.1;;435/366;;424/93.21,0,0,,,,DISCONTINUED
102,US,A1,US 2015/0007389 A1,142-434-969-903-949,2015-01-08,2015,US 201414491600 A,2014-09-19,US 201414491600 A;;US 201414289238 A;;US 201361829733 P,2013-05-31,BEDDING APPARATUS,"Various embodiments of the present disclosure provide a bedding apparatus. In one embodiment, the bedding apparatus is configured to slip over a mattress such that the bedding apparatus substantially encloses the mattress except the front or head of the mattress. The bedding apparatus is configured such that, once installed over the mattress, there is sufficient space between the top of the mattress and the top panel of the bedding apparatus to enable a user to lay atop the mattress and under the top panel of the bedding apparatus. Additionally, once installed, the bottom panel of the bedding apparatus is positioned under the mattress such that the bedding apparatus is held in place by a combination of the weight of the mattress and the weight of the user (when the user is laying on the mattress).",ZZZ SOCK LLC,BLETHEN JEFFREY RONALD;;BLATT KYLE PARKER;;WINANS FREDERICK DAVID,ZZZ SOCK LLC (2015-02-19),https://lens.org/142-434-969-903-949,Patent Application,yes,0,8,2,4,0,A47G9/0238;;A47G9/0238;;A47G9/02;;A47G9/0246;;A47G9/04;;A47G9/04,A47G9/02;;A47G9/04,5/494,0,0,,,,ACTIVE
103,US,A1,US 2006/0007047 A1,000-335-814-503-948,2006-01-12,2006,US 88519304 A,2004-07-06,US 88519304 A,2004-07-06,Alignment cam for non-circular retractable antenna,"A retractable antenna ( 100 ) is provided that includes a body ( 106 ) having an orifice ( 204 ), a whip ( 104 ) retractably coupled to the body ( 106 ), at least one follower ( 200 ) disposed about the whip ( 104 ), and a cam ( 202 ) disposed about the orifice ( 204 ). The cam ( 202 ) is shaped such that the at least one follower ( 200 ) interacts with the cam ( 202 ) during retraction of the whip ( 104 ) so as to rotate the whip as necessary to align the whip in a rotational position that allows full retraction of the antenna. Also provided are an electronic communication device ( 102 ) that includes at least one such non-circular retractable antenna ( 100 ), and an alignment system for rotationally aligning an extendable portion of a non-circular retractable antenna (100 ) during retraction.",DAWSON MICHAEL P;;BLATT DAVID I;;FEIN BRIAN T,DAWSON MICHAEL P;;BLATT DAVID I;;FEIN BRIAN T,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2004-07-06),https://lens.org/000-335-814-503-948,Patent Application,yes,9,3,2,2,0,H01Q1/244;;H01Q1/244,H01Q1/24;;H01Q1/10,343/702;;343/901,0,0,,,,ACTIVE
104,CN,A,CN 110024500 A,008-845-863-897-139,2019-07-16,2019,CN 201780068121 A,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,"In some examples, a thermal control device includes a vapor chamber comprising a fluid to transport heat from a first portion of the vapor chamber to a second portion of the vapor chamber, and an isolation chamber adjacent the vapor chamber and fluidically isolated from the vapor chamber, the isolation chamber being evacuated to a pressure less than atmospheric pressure to thermally isolate at least a portion of the vapor chamber.",HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/008-845-863-897-139,Patent Application,no,9,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20;;G12B15/02,,0,0,,,,INACTIVE
105,US,A1,US 2003/0068301 A1,161-249-646-762-752,2003-04-10,2003,US 87747801 A,2001-06-08,US 87747801 A;;US 69634700 A;;US 63638500 A;;US 53102500 A;;US 43643099 A;;US 19362794 A;;US 88271292 A,1992-05-14,Method and reagent for inhibiting hepatitis B virus replication,"
   Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed. 
",DRAPER KENNETH;;BLATT LAWRENCE;;MCSWIGGEN JAMES A.;;MORRISSEY DAVID,DRAPER KENNETH;;BLATT LAWRENCE;;MCSWIGGEN JAMES A;;MORRISSEY DAVID,RIBOZYME PHARMACEUTICALS INC (2001-06-11),https://lens.org/161-249-646-762-752,Patent Application,yes,0,56,1,1181,0,A61K38/21;;C07H19/10;;C07H19/20;;C07H21/00;;C07K14/005;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N15/85;;C12N15/86;;C12N2310/11;;C12N2310/12;;C12N2310/121;;C12N2310/122;;C12N2310/13;;C12N2310/16;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/332;;C12N2310/346;;C12N2310/3519;;C12N2310/3521;;C12N2310/3531;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/51;;C12N2730/10122;;C12P19/30;;C12P19/305;;C12Q1/706;;C12Y207/07049;;C12Y301/03048;;C12N15/1131;;C07H19/20;;C12N2310/332;;C12N2310/3533;;C12N2310/11;;C12N2310/18;;C07H21/00;;C12N15/85;;C12N2310/321;;C07K14/005;;C12N2310/3535;;C12P19/30;;C07H19/10;;C12N2310/121;;C12N2310/16;;C12Y207/07049;;C12N2310/3531;;C12N2310/13;;C12N2310/346;;C12N2310/322;;C12N2310/3521;;C12N2310/315;;A61K38/21;;C12N15/86;;C12N2320/51;;C12N2310/318;;C12N2310/3519;;C12N2730/10122;;C12N2310/12;;C12P19/305;;C12N15/1138;;C12N2310/319;;C12N15/1137;;C12N2320/31;;C12Q1/706;;C12N2310/122;;C12N2310/317;;C12Y301/03048,A61K38/00;;A61K38/21;;C07H19/10;;C07H19/20;;C07H21/00;;C07K14/08;;C12N15/113;;C12N15/85;;C12N15/86;;C12P19/30;;C12Q1/68;;C12Q1/70,424/85.6;;514/44;;424/85.7;;536/23.1,0,0,,,,DISCONTINUED
106,US,B2,US 9247835 B2,085-613-604-654-941,2016-02-02,2016,US 201414491600 A,2014-09-19,US 201414491600 A;;US 201414289238 A;;US 201361829733 P,2013-05-31,Bedding apparatus,"Various embodiments of the present disclosure provide a bedding apparatus. In one embodiment, the bedding apparatus is configured to slip over a mattress such that the bedding apparatus substantially encloses the mattress except the front or head of the mattress. The bedding apparatus is configured such that, once installed over the mattress, there is sufficient space between the top of the mattress and the top panel of the bedding apparatus to enable a user to lay atop the mattress and under the top panel of the bedding apparatus. Additionally, once installed, the bottom panel of the bedding apparatus is positioned under the mattress such that the bedding apparatus is held in place by a combination of the weight of the mattress and the weight of the user (when the user is laying on the mattress).",ZZZ SOCK LLC,BLETHEN JEFFREY RONALD;;BLATT KYLE PARKER;;WINANS FREDERICK DAVID,ZZZ SOCK LLC (2015-02-19),https://lens.org/085-613-604-654-941,Granted Patent,yes,51,6,2,4,0,A47G9/0238;;A47G9/0238;;A47G9/02;;A47G9/0246;;A47G9/04;;A47G9/04,A47G9/02;;A47G9/04,,5,0,,,"Therm-a-Rest Ventra Down Comforter Sleeping Pad Accessory; available at www.backcountryedge.com; printed prior to May 31, 2013. (1 page).;;Disney Princesses EZ Bed; available at http://www.walmart.com/ip/Disney-Princesses-EZ-Bed/8812037; printed prior to May 31, 2013. (1 page).;;Disney Cars EZ Bed; available at http://www.walmart.com/ip/Disney-Cars-EZ-Bed/8812034; printed prior to May 31, 2013 . (1 page).;;Sleeping Bag Sofa; available at http://www.dudeiwantthat.com/household/furniture/sleeping-bag-sofa.asp; printed prior to May 31, 2013. (2 pages).;;Zipit Bedding, website, zipitbedding.com/Home.html, screenshot as of Apr. 26, 2013 (2 pages).",ACTIVE
107,TW,A,TW 201832639 A,183-109-825-536-842,2018-09-01,2018,TW 107103641 A,2018-02-01,US 2017/0016556 W,2017-02-03,Thermal control with vapor and isolation chambers,"In some examples, a thermal control device includes a vapor chamber comprising a fluid to transport heat from a first portion of the vapor chamber to a second portion of the vapor chamber, and an isolation chamber adjacent the vapor chamber and fluidically isolated from the vapor chamber, the isolation chamber evacuated to a pressure less than atmospheric pressure to thermally isolate at least a portion of the vapor chamber.",HEWLETT PACKARD DEVELOPMENT CO LP,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/183-109-825-536-842,Patent of Addition,no,0,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20,,0,0,,,,INACTIVE
108,US,A,US 5241695 A,028-762-610-934-589,1993-08-31,1993,US 79946691 A,1991-11-26,US 79946691 A,1991-11-26,Molded shield with integral key switch circuitry,The molded key switch shield assembly (100) includes a molded member (104) and a key switch overlay (102). The molded member (104) includes a shield metallization pattern (136) which substantially covers major portions of both the first (138) and second major surfaces (140) of the molded member (104). The molded member also includes a metallization pattern (124) having a plurality of key switch locations (118) which can be shorted by conductive locations (112) on key switch overlay (102).,MOTOROLA INC,ROSHITSH TODD W;;BLATT DAVID I;;MAGINNESS JAMES W,MOTOROLA INC (1991-11-19),https://lens.org/028-762-610-934-589,Granted Patent,yes,14,18,1,1,0,H04B1/3827;;H04B1/3827;;H04B1/086;;H04B1/086,H04B1/08;;H04B1/38,455/128;;455/344;;455/349;;455/350;;361/814;;361/816,2,0,,,"Connection Technology Update: Three Dimensional Molded Interconnec by Sharon MacCorquodale, pp. 23 25, Jun. 1990.;;EMC Technology Coated Plastics Offer Shielding and Savings by Richard Brander, Peter Kuzyk and Richard Bellemare of Ethon OME, Inc., pp. 37 40, Jul./Aug., 1990.",EXPIRED
109,EP,A4,EP 3510849 A4,175-634-464-984-185,2020-04-15,2020,EP 17894894 A,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,,HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/175-634-464-984-185,Search Report,no,4,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20;;G12B15/02,,0,0,,,,ACTIVE
110,US,B2,US 7190311 B2,001-011-008-353-581,2007-03-13,2007,US 88519304 A,2004-07-06,US 88519304 A,2004-07-06,Alignment cam for non-circular retractable antenna,"A retractable antenna ( 100 ) is provided that includes a body ( 106 ) having an orifice ( 204 ), a whip ( 104 ) retractably coupled to the body ( 106 ), at least one follower ( 200 ) disposed about the whip ( 104 ), and a cam ( 202 ) disposed about the orifice ( 204 ). The cam ( 202 ) is shaped such that the at least one follower ( 200 ) interacts with the cam ( 202 ) during retraction of the whip ( 104 ) so as to rotate the whip as necessary to align the whip in a rotational position that allows full retraction of the antenna. Also provided are an electronic communication device ( 102 ) that includes at least one such non-circular retractable antenna ( 100 ), and an alignment system for rotationally aligning an extendable portion of a non-circular retractable antenna (100 ) during retraction.",MOTOROLA INC,DAWSON MICHAEL P;;BLATT DAVID I;;FEIN BRIAN T,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2004-07-06),https://lens.org/001-011-008-353-581,Granted Patent,yes,10,5,2,2,0,H01Q1/244;;H01Q1/244,H01Q1/24;;H01Q1/12;;H01Q9/30,343/702;;343/878;;343/900,0,0,,,,ACTIVE
111,US,B2,US 10637265 B2,051-183-527-939-941,2020-04-28,2020,US 201515539779 A,2015-01-06,US 2015/0010379 W,2015-01-06,Electronic device with charging module,"An example of a system includes a electronic device having a rechargeable battery, a charging module to charge the rechargeable battery and moveable between a retracted position and an extended position to provide a stand during charging of the rechargeable battery, and a communication module to wirelessly transfer and receive data during charging of the rechargeable battery. The example system also includes a charging mat to charge the rechargeable battery when the charging module is in the extended position and coupled to the charging mat and a docking module to wirelessly transfer data to and wirelessly receive data from the communication module of the electronic device.",HEWLETT PACKARD DEVELOPMENT CO,JABORI MONJI G;;NGUYEN BACH LIEN;;BLATT DAVID ISAAC,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-12-28),https://lens.org/051-183-527-939-941,Granted Patent,yes,10,0,5,5,0,H02J50/80;;H02J50/10;;H02J7/0044;;H02J2310/22;;H02J7/0042;;H02J50/80;;H02J50/10;;H02J7/00034;;H02J7/0013;;H02J2310/22;;H02J7/0042;;H02J7/0044,H02J7/00;;H02J7/02;;H02J50/10;;H02J50/80,,0,0,,,,ACTIVE
112,US,A,US 3452267 A,057-212-271-669-236,1969-06-24,1969,US 3452267D A,1968-01-31,US 44104865 A;;US 70210968 A,1965-03-19,HIGH VOLTAGE RECTIFIER,,UNITRODE CORP,SCHULER CHESTER L;;MARGOLIEN DAVID H;;BLATT FRED M,,https://lens.org/057-212-271-669-236,Granted Patent,no,6,3,2,2,0,H01L25/07;;H01L25/07;;H01L23/041;;H01L23/041;;H01L25/11;;H01L25/11;;H01L25/117;;H01L25/117;;H01L2924/0002;;H01L2924/0002;;H02M7/106;;H02M7/106,H01L23/04;;H01L25/07;;H01L25/11;;H02M7/10,321/27,0,0,,,,EXPIRED
113,US,S,US D0792124 S,146-778-802-047-014,2017-07-18,2017,US 201429502865 F,2014-09-19,US 201429502865 F;;US 201329456554 F,2013-05-31,Mattress cover,,ZZZ SOCK LLC,BLATT KYLE PARKER;;BLETHEN JEFFREY RONALD;;WINANS FREDERICK DAVID,ZZZ SOCK LLC (2015-02-19),https://lens.org/146-778-802-047-014,Design Right,no,0,14,1,2,0,,,0609;;D 6596,0,0,,,,ACTIVE
114,EP,B1,EP 3510849 B1,063-846-320-228-026,2023-08-30,2023,EP 17894894 A,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,,HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/063-846-320-228-026,Granted Patent,yes,2,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,G06F1/20;;H05K7/20,,0,0,,,,ACTIVE
115,EP,A1,EP 3510849 A1,123-515-513-495-954,2019-07-17,2019,EP 17894894 A,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,,HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,,https://lens.org/123-515-513-495-954,Patent Application,yes,0,0,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20;;G12B15/02,,0,0,,,,ACTIVE
116,US,A1,US 2019/0357387 A1,038-874-072-851-24X,2019-11-21,2019,US 201716463292 A,2017-02-03,US 2017/0016556 W,2017-02-03,THERMAL CONTROL WITH VAPOR AND ISOLATION CHAMBERS,"In some examples, a thermal control device includes a vapor chamber comprising a fluid to transport heat from a first portion of the vapor chamber to a second portion of the vapor chamber, and an isolation chamber adjacent the vapor chamber and fluidically isolated from the vapor chamber, the isolation chamber evacuated to a pressure less than atmospheric pressure to thermally isolate at least a portion of the vapor chamber.",HEWLETT PACKARD DEVELOPMENT CO,PETERSON ALAN D;;BLATT DAVID ISAAC;;PESCETTO MICHAEL JAMES,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2017-02-01),https://lens.org/038-874-072-851-24X,Patent Application,yes,10,5,9,9,0,H05K7/20336;;G06F1/203;;G06F2200/201;;G06F1/203;;H05K7/20327,H05K7/20;;G06F1/20,,0,0,,,,DISCONTINUED
117,CN,A,CN 106999509 A,069-892-631-101-431,2017-08-01,2017,CN 201580054124 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,Combination therapy for treating a paramyxovirus,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/069-892-631-101-431,Patent Application,no,1,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,DISCONTINUED
118,CL,A1,CL 2017000285 A1,162-860-334-346-63X,2017-10-06,2017,CL 2017000285 A,2017-02-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,Terapia combinada para el tratamiento de un paramixovirus,<p>MÉTODO PARA ALIVIAR O TRATAR UNA INFECCION POR PARAMIXOVIRUS QUE COMPRENDE EL USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE CITOSINA Y UN ANTICUERPO.</p>,ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/162-860-334-346-63X,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/4184;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/675;;A61K31/7068;;A61K38/21;;A61K39/155;;A61P31/14,,0,0,,,,PENDING
119,EP,A4,EP 3177299 A4,090-192-311-661-679,2018-04-04,2018,EP 15829092 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,"JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/090-192-311-661-679,Search Report,no,3,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4436;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K31/7056;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,4,3,101-595-923-888-798;;068-478-798-729-386;;110-297-893-673-518,21831008;;10.1517/14712598.2011.608062;;14742189;;10.1128/aac.48.2.413-422.2004;;pmc321540;;10.1093/infdis/jir622;;21998474,"KRISTIN A SHADMAN ET AL: ""A review of palivizumab and emerging therapies for respiratory syncytial virus"", EXPERT OPINION ON BIOLOGICAL THE, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, vol. 11, no. 11, 1 November 2011 (2011-11-01), pages 1455 - 1467, XP008164923, ISSN: 1471-2598, DOI: 10.1517/14712598.2011.608062;;C. CIANCI ET AL: ""Orally Active Fusion Inhibitor of Respiratory Syncytial Virus"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 48, no. 2, 23 January 2004 (2004-01-23), pages 413 - 422, XP055245278, ISSN: 0066-4804, DOI: 10.1128/AAC.48.2.413-422.2004;;B. SCHEPENS ET AL: ""Nanobodies(R) Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion"", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 204, no. 11, 12 October 2011 (2011-10-12), CHICAGO, IL., pages 1692 - 1701, XP055218541, ISSN: 0022-1899, DOI: 10.1093/infdis/jir622;;See also references of WO 2016022464A1",DISCONTINUED
120,US,B1,US 6270803 B1,172-271-871-524-769,2001-08-07,2001,US 39275498 A,1998-10-07,US 39275498 A,1998-10-07,Controlled-release garlic formulations,"There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations required for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours, as determined by U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37.degree. C. A process for preparing the formulations of the invention is also disclosed.",BIO DAR LTD,BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,BIO DAR LTD (1998-11-05),https://lens.org/172-271-871-524-769,Granted Patent,yes,7,14,7,7,0,A61K9/5073;;A61K9/5073;;A61K9/2081;;A61K9/2081;;A61K9/5042;;A61K9/5042;;A61K9/5047;;A61K9/5047;;A61K36/8962;;A61K36/8962,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K36/8962,424/489;;424/476;;424/468;;424/494,1,0,,,"HU 47 858 A2, Kerbolt K., Apr. 28, 1989 (abstract).",EXPIRED
121,US,A1,US 2003/0110020 A1,014-764-920-789-744,2003-06-12,2003,US 1023901 A,2001-12-07,US 1023901 A,2001-12-07,Power modeling methodology for a pipelined processor,"
   A method for modeling the power behavior of a pipelined processor has been developed. The method uses a power model integrated into a cycle accurate simulator. To create the power model, design blocks of the processor are divided into sub-blocks. Power modeling equations for each sub-block are developed by collaboration between the sub-block circuit designer and the simulator developer, using activity information relevant to the sub-block that is available in the simulator model. Each equation is calculated multiple times with different sets of power parameters to represent varying power conditions. Every simulation cycle, sub-block power is summed to generate full-chip power for multiple power conditions. 
",BLATT MIRIAM G.;;KONGETIRA POONACHA;;GREENHILL DAVID J.;;GANESAN VIDYASAGAR,BLATT MIRIAM G;;KONGETIRA POONACHA;;GREENHILL DAVID J;;GANESAN VIDYASAGAR,SUN MICROSYSTEMS INC (2001-12-03);;ORACLE AMERICA INC (2010-02-12),https://lens.org/014-764-920-789-744,Patent Application,yes,3,8,2,2,0,G06F30/33;;G06F30/33;;G06F2119/06;;G06F2119/06,G06F9/455;;G06F17/50;;G06G7/54,703/18,0,0,,,,EXPIRED
122,BR,A2,BR 112017002332 A2,024-165-260-144-534,2017-11-21,2017,BR 112017002332 A,2015-08-03,US 2015/0043402 W;;US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,terapia de combinação para o tratamento de um paramixovírus,"a presente invenção refere-se a uma combinação de compostos e a métodos de uso da combinação de compostos para melhorar, tratar e/ou prevenir uma infecção viral por paramixovírus.",ALIOS BIOPHARMA INC,DAVID BERNARD SMITH;;GUANGYI WANG;;LAWRENCE M BLATT;;LEONID BEIGELMAN,,https://lens.org/024-165-260-144-534,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/41;;A61K31/166;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K31/7068;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,DISCONTINUED
123,US,B2,US 6895561 B2,009-998-270-757-775,2005-05-17,2005,US 1023901 A,2001-12-07,US 1023901 A,2001-12-07,Power modeling methodology for a pipelined processor,"A method for modeling the power behavior of a pipelined processor has been developed. The method uses a power model integrated into a cycle accurate simulator. To create the power model, design blocks of the processor are divided into sub-blocks. Power modeling equations for each sub-block are developed by collaboration between the sub-block circuit designer and the simulator developer, using activity information relevant to the sub-block that is available in the simulator model. Each equation is calculated multiple times with different sets of power parameters to represent varying power conditions. Every simulation cycle, sub-block power is summed to generate full-chip power for multiple power conditions.",SUN MICROSYSTEMS INC,BLATT MIRIAM G;;KONGETIRA POONACHA;;GREENHILL DAVID J;;GANESAN VIDYASAGAR,SUN MICROSYSTEMS INC (2001-12-03);;ORACLE AMERICA INC (2010-02-12),https://lens.org/009-998-270-757-775,Granted Patent,yes,3,5,2,2,0,G06F30/33;;G06F30/33;;G06F2119/06;;G06F2119/06,G06F9/455;;G06F17/50;;G06G7/54,716/1;;716/4;;703/14;;703/23,1,1,075-156-550-108-457,10.1109/lpe.1996.547492,"Katkoori et al., Simulation based Architectural Power Estimation for PLA-based Controllers, Internation Symposium on Low Power Electronics and Design, pp. 121-124, Aug. 1996.",EXPIRED
124,KR,A,KR 20170031780 A,131-367-301-376-804,2017-03-21,2017,KR 20177005818 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"파라믹소바이러스 바이러스성 감염을 개선, 치료 및/또는 예방하기 위한 화합물들의 병용물 및 그러한 화합물들의 병용물의 사용 방법이 본 명세서에 개시된다.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/131-367-301-376-804,Patent Application,no,0,0,21,21,8,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/437;;A61K31/4436;;A61K31/7056;;A61K38/16;;A61K38/21;;A61K39/00;;A61K39/42;;C12N7/00,,0,0,,,,PENDING
125,SG,A,SG 11201700851W A,030-842-632-330-112,2017-03-30,2017,SG 11201700851W A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/030-842-632-330-112,Unknown,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,PENDING
126,WO,A1,WO 2017/034524 A1,040-764-484-858-098,2017-03-02,2017,US 2015/0046356 W,2015-08-21,US 2015/0046356 W,2015-08-21,STAND TO ACCOMMODATE DEVICES FOR WIRELESS CHARGING BACKGROUND,Examples disclosed herein provide a stand to allow simultaneous wireless charging of devices via receivers disposed within each of the devices. The stand can include a raised platform to support a number of the devices within a wireless range of a transmitter to wirelessly charge the number of the devices via the receivers. The stand can include an area below the raised platform to accommodate an additional number of the devices within the wireless range of the transmitter,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI G;;BLATT DAVID ISAAC;;MERKEL HAROLD;;LAGNADO ISAAC,,https://lens.org/040-764-484-858-098,Patent Application,yes,5,0,3,3,0,H02J7/0042;;H02J50/10;;H04B5/79;;H02J50/10;;H02J7/0042;;H04B5/79,H02J7/00;;H02J5/00;;H02J50/00;;H04B5/00,,0,0,,,,PENDING
127,TW,A,TW 201713193 A,093-527-079-927-495,2017-04-01,2017,TW 105122858 A,2016-07-20,US 2015/0046356 W,2015-08-21,Stand to accommodate devices for wireless charging,Examples disclosed herein provide a stand to allow simultaneous wireless charging of devices via receivers disposed within each of the devices. The stand can include a raised platform to support a number of the devices within a wireless range of a transmitter to wirelessly charge the number of the devices via the receivers. The stand can include an area below the raised platform to accommodate an additional number of the devices within the wireless range of the transmitter.,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI G;;BLATT DAVID ISAAC;;MERKEL HAROLD;;LAGNADO ISAAC,,https://lens.org/093-527-079-927-495,Patent of Addition,no,0,0,3,3,0,H02J7/0042;;H02J50/10;;H04B5/79;;H02J50/10;;H02J7/0042;;H04B5/79,H05K7/14;;G06F1/16;;H02J7/00,,0,0,,,,INACTIVE
128,AU,A1,AU 2015/301334 A1,115-669-898-078-95X,2017-02-23,2017,AU 2015/301334 A,2015-08-03,US 201562182913 P;;US 201462060445 P;;US 201462033551 P;;US 2015/0043402 W,2014-08-05,Combination therapy for treating a paramyxovirus,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/115-669-898-078-95X,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,DISCONTINUED
129,WO,A1,WO 2002/089911 A1,145-864-842-739-394,2002-11-14,2002,US 0214920 W,2002-05-10,US 85429701 A,2001-05-10,TWO PART TENS BANDAGE,"A sterile bandage is combined with a TENS device for use in covering a wound and providing electrical stimulation to promote healing and block pain. The treatment device (1) comprises an upper part (10) containing the electronics module (20) the control keys (22, 24, 26), and a lower part (40) comprising the outer electrode sections (45), an absorbent sterile gauze containing medication, and electrical conductive pads (62, 64) for connecting the electronics module the electrode.",CYCLOTEC ADVANCED MEDICAL TECH,DA SILVA LUIZ B;;BLATT DAVID I;;MANNHEIMER JEFFREY S,,https://lens.org/145-864-842-739-394,Patent Application,yes,11,0,2,2,0,A61N1/0456;;A61N1/36003;;A61N1/36021;;A61N1/36003;;A61N1/36021;;A61N1/0456,A61N1/34;;A61N1/36,,0,0,,,,PENDING
130,US,A1,US 2016/0045528 A1,139-280-322-323-903,2016-02-18,2016,US 201514816843 A,2015-08-03,US 201514816843 A;;US 201562182913 P;;US 201462060445 P;;US 201462033551 P,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"Disclosed herein are a combination of compounds and methods of using the combination of compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,ALIOS BIOPHARMA INC (2015-10-14),https://lens.org/139-280-322-323-903,Patent Application,yes,4,10,21,21,4,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/437;;A61K31/4436;;A61K31/7056;;A61K38/21;;A61K39/42;;C12N7/00,,0,0,,,,DISCONTINUED
131,WO,A2,WO 2013/182911 A2,168-112-178-015-824,2013-12-12,2013,IB 2013001858 W,2013-06-04,US 201261655316 P;;US 201313908576 A,2012-06-04,WATER RECOVERY SYSTEM AND METHOD,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BALL JAMES;;BECZE CHARLES;;BLATT DAVID;;FLYNN MICHAEL;;TELTZ RICHARD,,https://lens.org/168-112-178-015-824,Patent Application,yes,2,20,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,,,0,0,,,,PENDING
132,AU,A,AU 1999/059974 A,190-274-496-192-411,2000-04-26,2000,AU 1999/059974 A,1999-10-05,IL 9900527 W;;US 39275498 A,1998-10-07,Controlled-release garlic formulations,,BIO DAR LTD,BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,,https://lens.org/190-274-496-192-411,Patent Application,no,0,0,7,7,0,A61K9/5073;;A61K9/5073;;A61K9/2081;;A61K9/2081;;A61K9/5042;;A61K9/5042;;A61K9/5047;;A61K9/5047;;A61K36/8962;;A61K36/8962,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K36/8962,,0,0,,,,DISCONTINUED
133,MX,A,MX 2017001587 A,024-158-255-038-811,2017-10-11,2017,MX 2017001587 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS.,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;WANG GUANGYI;;BLATT LAWRENCE M;;SMITH DAVID BERNARD,,https://lens.org/024-158-255-038-811,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,PENDING
134,WO,A2,WO 2000/020017 A2,123-700-295-500-341,2000-04-13,2000,IL 9900527 W,1999-10-05,US 39275498 A,1998-10-07,CONTROLLED-RELEASE GARLIC FORMULATIONS,"There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations reguired for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37°C. A process for preparing the formulations of the invention is also disclosed.",BIO DAR LTD;;BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,,https://lens.org/123-700-295-500-341,Patent Application,yes,0,5,7,7,0,A61K9/5073;;A61K9/5073;;A61K9/2081;;A61K9/2081;;A61K9/5042;;A61K9/5042;;A61K9/5047;;A61K9/5047;;A61K36/8962;;A61K36/8962,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K36/8962,,0,0,,,,PENDING
135,TW,B,TW 408104 B,064-757-835-598-992,2000-10-11,2000,TW 85109137 A,1996-07-26,US 44694895 A,1995-05-15,Dehydration and purification of isopropyl alcohol to an ultradry and ultrapure level,"A method and apparatus for the on-site reprocessing of isopropyl alcohol used in semiconductor manufacturing, to generate an ultradry and ultrapure isopropyl alcohol, produced through a pervaporation step, followed by a two distillation, wherein the first distillation step, an autonomous azeotropic self-stripping distillation column (78) is used to produce an ultradry and partially purified isopropyl alcohol, and in the next distillation step, the isopropyl alcohol is distilled in an overhead product distillation column (164), to produce an ultrapure and ultradry isopropyl alcohol.",INTEGRATED PROCESS EQUIPMENT C,ADAMS JOHN A;;KRULIK GERALD A;;BLATT CHRISTOPHER;;PERSICHINI DAVID,,https://lens.org/064-757-835-598-992,Granted Patent,no,0,1,8,8,0,B01D3/146;;B01D61/362;;C07C29/80;;C07C29/82;;Y10S159/27;;Y10S203/17;;C07C31/18;;B01D3/146;;B01D61/362;;C07C29/82;;B01D61/362;;C07C29/80;;B01D3/146;;C07C29/82;;Y10S159/27;;Y10S203/17,B01D3/14;;B01D61/36;;C07C29/80;;C07C29/82;;C07C31/10,,0,0,,,,EXPIRED
136,WO,A3,WO 2000/020017 A3,184-045-610-515-290,2000-09-08,2000,IL 9900527 W,1999-10-05,US 39275498 A,1998-10-07,CONTROLLED-RELEASE GARLIC FORMULATIONS,"There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations reguired for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37°C. A process for preparing the formulations of the invention is also disclosed.",BIO DAR LTD;;BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,BLATT YOAV;;COHEN DAVID;;KIMMELMAN EUGENE;;FRIEDMAN ODED;;ROTMAN AVNER,,https://lens.org/184-045-610-515-290,Search Report,yes,4,0,7,7,0,A61K9/5073;;A61K9/5073;;A61K9/2081;;A61K9/2081;;A61K9/5042;;A61K9/5042;;A61K9/5047;;A61K9/5047;;A61K36/8962;;A61K36/8962,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K36/8962,,1,0,,,"DATABASE WPI Section Ch Week 198923, Derwent World Patents Index; Class B04, AN 1989-167839, XP002134264",PENDING
137,WO,A1,WO 2016/022464 A1,077-275-963-296-745,2016-02-11,2016,US 2015/0043402 W,2015-08-03,US 201462060445 P;;US 201462033551 P;;US 201562182913 P,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/077-275-963-296-745,Patent Application,yes,18,51,21,21,4,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,1,0,,,See also references of EP 3177299A4,PENDING
138,CA,A1,CA 2957017 A1,146-426-574-842-008,2016-02-11,2016,CA 2957017 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/146-426-574-842-008,Patent Application,no,0,0,21,21,4,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,DISCONTINUED
139,PE,A1,PE 20170673 A1,068-302-494-363-865,2017-05-22,2017,PE 2017000164 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,TERAPIA DE COMBINACION PARA TRATAR UNA PARAMIXOVIRUS,"Se refiere a un metodo para aliviar o tratar una infeccion por virus paramixovirus, que comprende administrar a un sujeto infectado una cantidad eficaz de una combinacion del compuesto (A) y uno o mas del compuesto (B), o un producto farmaceutico aceptable de la sal de cualquiera de los anteriores, en donde para (A): R1 es H, acilo opcionalmente sustituido, entre otros; R2 es cloro o azido; R3 es OH, -OC(=O)RA1, entre otros; R4 y R5 son H, entre otros; RA1 es un alquilo C1-C24 opcionalmente sustituido; y (B) es un anticuerpo anti-RSV, un inhibidor de proteina de fusion, entre otros. Es un compuesto seleccionado de (A): (1). Dicho conjugado es util en el tratamiento de infecciones respiratorias",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/068-302-494-363-865,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,PENDING
140,ZA,B,ZA 201701578 B,076-173-308-368-251,2019-09-25,2019,ZA 201701578 A,2017-03-03,US 201562182913 P;;US 201462060445 P;;US 201462033551 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/076-173-308-368-251,Granted Patent,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,,,0,0,,,,ACTIVE
141,EP,A1,EP 3177299 A1,123-082-553-452-624,2017-06-14,2017,EP 15829092 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P;;US 2015/0043402 W,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,"JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/123-082-553-452-624,Patent Application,yes,0,0,21,21,4,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,DISCONTINUED
142,TN,A1,TN 2016000566 A1,165-027-010-124-132,2018-04-04,2018,TN 2016000566 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE;;DYATKINA NATALIA;;SMITH DAVID;;SYMONS JULIAN,,https://lens.org/165-027-010-124-132,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
143,TW,A,TW 201618778 A,005-774-750-704-99X,2016-06-01,2016,TW 104125463 A,2015-08-05,US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,Combination therapy for treating a paramyxovirus infection,"Disclosed herein are a combination of compounds and methods of using the combination of compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/005-774-750-704-99X,Patent of Addition,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/4436;;A61K31/437;;A61K31/7056;;A61K31/7068;;A61K38/21;;A61K39/42;;A61P31/14,,0,0,,,,PENDING
144,MA,A,MA 40404 A,020-037-809-092-275,2017-06-14,2017,MA 40404 A,2015-08-03,US 201462033551 P;;US 201462060445 P;;US 201562182913 P,2014-08-05,COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS,"Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;SMITH DAVID BERNARD;;WANG GUANGYI,,https://lens.org/020-037-809-092-275,Unknown,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K31/7068;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,PENDING
145,US,A1,US 2002/0019652 A1,043-696-427-224-07X,2002-02-14,2002,US 85429701 A,2001-05-10,US 85429701 A;;US 35042699 A,1999-07-08,Two part tens bandage,"
   A sterile bandage is combined with a TENS device for use in covering a wound and providing electrical stimulation to promote healing and block pain. 
",CYCLOTEC ADVANCED MEDICAL TECH,DA SILVA LUIZ B;;BLATT DAVID I;;MANNHEIMER JEFFREY S,CYCLOTEC ADVANCED MEDICAL TECHNOLOGIES INC (2001-09-11),https://lens.org/043-696-427-224-07X,Patent Application,yes,0,96,2,2,0,A61N1/0456;;A61N1/36003;;A61N1/36021;;A61N1/36003;;A61N1/36021;;A61N1/0456,A61N1/34;;A61N1/36,607/72,0,0,,,,DISCONTINUED
146,TW,B,TW I600365 B,116-033-270-460-996,2017-09-21,2017,TW 105122858 A,2016-07-20,US 2015/0046356 W,2015-08-21,System for wireless charging device and stand therefor,,HEWLETT PACKARD DEVELOPMENT CO LP,JABORI MONJI G;;BLATT DAVID ISAAC;;MERKEL HAROLD;;LAGNADO ISAAC,,https://lens.org/116-033-270-460-996,Granted Patent,no,0,0,3,3,0,H02J7/0042;;H02J50/10;;H04B5/79;;H02J50/10;;H02J7/0042;;H04B5/79,,,0,0,,,,INACTIVE
147,NZ,A,NZ 727582 A,122-454-541-115-477,2018-06-29,2018,NZ 72758215 A,2015-06-22,US 2015/0036958 W;;US 201462061819 P;;US 201462034629 P;;US 201462016219 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;SMITH DAVID;;DYATKINA NATALIA;;BLATT LAWRENCE;;SYMONS JULIAN,,https://lens.org/122-454-541-115-477,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,DISCONTINUED
148,CO,A2,CO 2017002170 A2,137-888-837-812-223,2017-05-19,2017,CO 2017002170 A,2017-03-03,US 2015/0043402 W;;US 201462060445 P;;US 201462033551 P;;US 201562182913 P,2014-08-05,Terapia de combinación para tratar un paramixovirus,"En la presente descripción se describe una combinación de compuestos y métodos de uso de la combinación de compuestos para aliviar, tratar y/o prevenir una infección viral por paramixovirus.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;SMITH DAVID BERNARD;;WANG GUANGYI;;BLATT LAWRENCE M,,https://lens.org/137-888-837-812-223,Patent Application,no,0,0,21,21,0,A61K38/162;;A61K38/21;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K31/437;;A61K31/7056;;A61P11/00;;A61P31/14;;A61P31/16;;A61P43/00;;A61K31/7068;;A61K31/7056;;A61K38/21;;A61K38/162;;A61K31/4436;;A61K31/437;;A61K39/42;;C12N7/00;;A61K2300/00;;A61K2039/505;;C12N2760/18511;;A61K31/7068;;C12N7/00;;A61K31/4436;;A61K39/42;;A61K31/437;;A61K31/7056;;C12N2760/18511;;A61K38/21;;A61K2039/505;;A61K38/162,A61K31/7068;;A61K31/166;;A61K31/41;;A61K31/4184;;A61K31/4188;;A61K31/437;;A61K31/4709;;A61K31/506;;A61K31/513;;A61K31/517;;A61K31/519;;A61K31/675;;A61K38/16;;A61K38/21;;A61K39/155;;A61K39/42;;A61P11/00;;A61P31/14,,0,0,,,,PENDING
149,US,A1,US 2013/0319244 A1,139-140-921-662-419,2013-12-05,2013,US 201313908576 A,2013-06-03,US 201313908576 A;;US 201261655316 P,2012-06-04,WATER RECOVERY SYSTEM AND METHOD,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BALL JAMES;;BECZE CHARLES;;BLATT DAVID;;FLYNN MICHAEL;;TELTZ RICHARD,Z124 (2012-10-25);;FLEXTRONICS INTERNATIONAL USA INC (2012-08-02);;SUN TO WATER TECHNOLOGIES LLC (2017-09-11),https://lens.org/139-140-921-662-419,Patent Application,yes,0,15,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/04,96/111;;96/146;;96/109;;96/115,0,0,,,,ACTIVE
150,US,A,US 5868906 A,165-527-570-821-930,1999-02-09,1999,US 69142796 A,1996-08-02,US 69142796 A;;US 44694895 A,1995-05-15,Dehydration and purification of isopropyl alcohol to an ultradry and ultrapure level,"A method for the on-site reprocessing of isopropyl alcohol used in semiconductor manufacturing, to generate an ultradry and ultrapure isopropyl alcohol. This ultradry and ultrapure isopropyl alcohol is produced through a pervaporation step, followed by double distillation. In the first distillation step, an autonomous azeotropic self-stripping distillation column is used to produce an ultradry and partially purified isopropyl alcohol. In the next step, the isopropyl alcohol is distilled in an overhead product distillation column, to produce an ultrapure and ultradry isopropyl alcohol. Alternatively, if the feed isopropyl alcohol contains less than 2000 ppm water, the pervaporation step may be omitted. The resulting isopropyl alcohol has between a high of 100 parts per million (ppm) and a low of 0.1 ppm of water in the isopropyl alcohol. It also has zero particles per milliliter of a size larger than 2.0 microns, zero to 2 particles per milliliter of a size of 0.5 micron to 2.0 microns, zero to 30 particles per milliliter of a size between 0.1 microns and 0.5 microns, an unspecified number of particles per milliliter below 0.1 microns, 1 part per trillion (ppt) to 1 part per billion (ppb) of any specific trace impurity such as metals, anions, and cations, and 10 ppt to 10 ppm of any other specific trace organic substances.",ATHENS CORP,ADAMS JOHN A;;KRULIK GERALD A;;BLATT CHRISTOPHER;;PERSICHINI DAVID,SPEEDFAM-IPEC CORPORATION (1999-05-26);;IPEC CLEAN INC (1996-03-28);;INTEGRATED PROCESS EQUIPMENT CORP. (IPEC) (1999-05-11);;IPEC PLANAR INC (1998-06-24),https://lens.org/165-527-570-821-930,Granted Patent,yes,17,38,8,8,0,B01D3/146;;B01D61/362;;C07C29/80;;C07C29/82;;Y10S159/27;;Y10S203/17;;C07C31/18;;B01D3/146;;B01D61/362;;C07C29/82;;B01D61/362;;C07C29/80;;B01D3/146;;C07C29/82;;Y10S159/27;;Y10S203/17,B01D3/14;;B01D61/36;;C07C29/80;;C07C29/82;;C07C31/10,203/18;;X159DIG  27;;203/71;;X203DIG  16;;210/634;;210/774;;210/640;;568/913;;568/916,14,1,080-594-536-619-534,10.1021/ie50520a041,"Purified Reagents for Trace Metal Analysis (John R. Moody and Ellyn S. Beary U.S. National Bureau of Standards, Center for Analytical Chemistry, Inorganic Analytical Research Division. Washington, DC 20234, U.S.A.).;;WACOM IPA Recovery Refinery System (Introduction of IPA Recovery Refinery Function into IPA Vapor Drying System).;;Surface Cleanliness Products in Action New Drying Technique Controls Watermarks (Circle Reader Service No.346 Microcontamination Aug. 1993).;;Kimmon International Fax (Mar. 21, 1994) Kimmon IPA Vapor Dryers.;;Vapor Liquid Equilibria at 760 Mm. Pressure (Louis H. Ballard and M. Van Winkle University of Texas, Austin, Texas).;;Vapor Liquid Equilibria 2 Propanol Water System (Abraham Wilson and Edward L. Simons Rutgers University, New Brunswick, N.J.).;;Ultra pure IPA Purification and Recycling System (Yukio Yanaga, Mgr., Production Technology and Engineering Ctr, Kurosaki Plant).;;Consider Membrane Pervaporation (Hubert L. Fleming, Zenon Environmental, Inc. Chemical Engineering Progress Jul. 1992).;;Carbone Lorraine Carbone of America (Jun. 9, 1994) Project PV7167R1.;;S&K Products International Inc. (Jul. 25, 1994) Model I.G. 200 IPA Cleaning, Degreasing, Drying System.;;SCI Systems, Inc. (Aug. 30, 1994) Technical Data IPA High Purity Recycling System SCI Model 7175.;;Mitsubishi Kasei (Sep. 13, 1994) IPA Vapor Dryer.;;Wafer Cleaning (Christopher F. McConnell Microcontamination Feb. 1991) Examining the Effects of Wafer Surface Chemistry on Particle Removal Using Direct Displacement Isopropyl Alcohol Drying.;;Ultrapure Chemicals (Alan E. Walter and Christopher F. McConnell Microcontamination Jan. 1990) Direct Displacement Wet Processing: How It Affects Wafer Surface Phenomena.",EXPIRED
151,US,B2,US 9017456 B2,016-121-011-850-070,2015-04-28,2015,US 201213714006 A,2012-12-13,US 201213714006 A;;US 201261655316 P,2012-06-04,Apparatus for water recovery including stackable desiccant trays,"A device recovers water from an ambient airstream. The device includes a chamber having a group of trays that hold respective amounts of liquid desiccant. A foam media element in each tray absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and control device operation. The desiccant trays may be selectively configurable in an array to best suit the intended installation. The trays may be arranged in column and row configurations, along with adjustable airflow patterns between each of the trays.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-01-28);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/016-121-011-850-070,Granted Patent,yes,62,3,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B37/00;;F25B43/00;;F25D21/14,96/112;;96/140;;96/141;;95/117;;95/118;;95/199;;95/223;;95/231,42,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,398, mailed May 16, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014 10 pages.;;Website ""Co-Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/co-generation.html.;;Website ""Direct Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/direct-generation.html.;;Website ""Energy Harvesting,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/energy-harvesting.html.;;Website ""Waste Heat Recovery,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/waste-heat-recovery.html.;;Venkatasubramanian, ""Efficient Thermoelectric Power Conversion of Waste Heat for Deplyed Forces (EW-1651),"" SERDP, Arlington, VA, 2012, 3 pages, retrieved from www.serdp.org/content/view/pdf/6791.;;Notice of Allowance for U.S. Appl. No. 13/908,576 mailed Jun. 30, 2014, 8 pages.;;Corrected Notice of Allowance for U.S. Appl. No. 13/713,972, mailed Aug. 1, 2014 4 pages.;;Official Action for U.S. Appl. No. 13/660,572 mailed Jun. 26, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Jul. 16, 2014, 5 pages.;;Official Action for U.S. Appl. No. 13/693,451 mailed Aug. 19, 2014, 5 pages.;;U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/713,972, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,398, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,418, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/693,451, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/723,113, filed Dec. 20, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec . . . ).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;International Preliminary Report on Patentability for International Patent Application No. PCT/IB2013/001858, mailed Dec. 18, 2014 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,572, mailed Dec. 4, 2014, 5 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Dec. 23, 2014, 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,451, mailed Jan. 13, 2015, 9 pages.;;Restriction Requirement for U.S. Appl. No. 13/723,113, mailed Nov. 12, 2014, 12 pages.;;Notice of Allowance for U.S. Appl. No. 13/723,113, mailed Jan. 27, 2015, 14 pages.;;Official Action for U.S. Appl. No. 13/746,824, mailed Jan. 21, 2015, 7 pages.",ACTIVE
152,EP,A1,EP 3160476 A1,110-428-124-369-279,2017-05-03,2017,EP 15812231 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,"JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/110-428-124-369-279,Patent Application,yes,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
153,US,B2,US 7421382 B2,021-880-626-129-78X,2008-09-02,2008,US 1023801 A,2001-12-07,US 1023801 A,2001-12-07,Data analysis techniques for dynamic power simulation of a CPU,A method for data analysis of power modeling for a microprocessor has been developed. The method takes multiple values of power data from a power modeling simulator and generates summary data to characterize the power data behavior. Summary data views include results characterizing behavior in a single cycle and behavior across multiple cycles. Data is viewed both at an absolute level to characterize total power and relative to previous levels to characterize power derivatives. Summary data is derived from power generated every cycle when running specific benchmark programs on the power simulator.,SUN MICROSYSTEMS INC,BLATT MIRIAM G;;GREENHILL DAVID J;;GAUTHIER CLAUDE R;;AINGARAN KATHIRGAMAR,SUN MICROSYSTEMS INC (2001-11-30);;ORACLE AMERICA INC (2010-02-12),https://lens.org/021-880-626-129-78X,Granted Patent,yes,14,5,2,2,0,G06F30/33;;G06F30/33,G06F17/50;;G06F9/45,703/13;;716/1;;716/5;;703/14,12,8,024-228-694-046-435;;039-532-141-478-95X;;028-096-596-786-361;;084-285-404-474-659;;020-388-394-665-944;;024-426-644-227-147;;161-476-372-894-140;;035-469-826-483-271,10.1109/92.335012;;10.1109/92.661245;;10.1145/288548.289071;;10.1109/43.851996;;10.1109/iccad.1997.643360;;10.1109/2.917539;;10.1145/224486.224523;;10.1109/iccd.2000.878286,"Christesen et al., ""Analog and Mixed-Signal Modeling Using the VHDL-AMS Language"" 36th Design Automation Conference 1999. p. 1-199.;;Tiwari et al., ""Power Analysis of Embedded Software: A First Step Towards Software Power Minization"" IEEE 1994. p. 437-445.;;Greenhill-D. ""The Impact of Technology Scaling on Microprocessor Design"" Seminar abstract 1999 p. 1.;;Booba et al., ""IC Power Distribution Challenges"" Jan. 2001. International Conference on Computer-Aided Design IEEE/ACM p. 643-650.;;Bogliolo et al., ""Gate-Level Power and Current Simulation of CMOS Integrated Circuits"" 1997 IEEE p. 473-488.;;Brown et al., ""Overview of Complementary GaAs Technology for High-Speed VLSI Circuits"" 1998 IEEE p. 47-51.;;Bogliolo et al., ""Node Sampling: a Robust RTL Power Modeling Approach"" 1998 ACM p. 461-467.;;Gupta et al., ""Analytical Models for RTL Power Estimation of Combinational and Sequential Circuits"" 2000 IEEE p. 808-813.;;Hsiao et al., ""Effects of Delay Models on Peak Power Estimation of VLSI Sequential Circuits"", IEEE 1997 p. 45-51.;;Mudge, T., ""Power: A First-Class Architectural Design Contraint"" INSPEC p. -52-58.;;Musoll et al., ""Scheduling and Resource Binding for Low Power"" 1995 8th International Symposium on System Synthesis p. 104-109.;;Seng et al., ""Power-Sensitive Multithreaded Architecture"" Sep. 2000, p. 17-20.",EXPIRED
154,ES,T3,ES 2841310 T3,087-787-330-066-829,2021-07-08,2021,ES 15812231 T,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"Nucleósidos, nucleótidos y análogos sustituidos para su uso en el tratamiento de infecciones virales","Un compuesto de Fórmula (I), o una sal farmacéuticamente aceptable de este, para su uso en la mejora o tratamiento de una infección viral, donde el compuesto de Fórmula (I) tiene la estructura: **(Ver fórmula)** donde: B1A es **(Ver fórmula)** donde RG2 es un alquilo C1-6 no sustituido; R3A se selecciona del grupo constituido por halo, OH, -OC(=O)R""A y un α-aminoácido unido a O opcionalmente sustituido; R4A se selecciona del grupo constituido por OH o halo; Ra1 y Ra2 son independientemente hidrógeno o deuterio; RA es hidrógeno o deuterio; R1A se selecciona del grupo constituido por hidrógeno, **(Ver fórmula)** R2A es halo o -(CH2)1-6 halógeno; R5A se selecciona del grupo constituido por un alquilo C1-6 no sustituido, un alquenilo C2-6 no sustituido y un alquinilo C2-6 no sustituido; R6A y R7A se seleccionan independientemente del grupo constituido por ausente, hidrógeno, **(Ver fórmula)** o R6A es **(Ver fórmula)** y R7A es ausente o es hidrógeno; R8A es ausente, hidrógeno, un fenilo opcionalmente sustituido o un naftilo opcionalmente sustituido; R9A es un α-aminoácido unido a N opcionalmente sustituido que se selecciona del grupo que consiste en alanina unida a N, asparagina unida a N, aspartato unido a N, cisteína unida a N, glutamato unido a N, glutamina unida a N, glicina unida a N, prolina unida a N, serina unida a N, tirosina unida a N, arginina unida a N, histidina unida a N, isoleucina unida a N, leucina unida a N, lisina unida a N, metionina unida a N, fenilalanina unida a N, treonina unida a N, triptófano unido a N y valina unida a N, o un derivado de éster de α-aminoácido unido a N opcionalmente sustituido, donde el derivado de éster de α-aminoácido unido a N opcionalmente sustituido es un éster alquilo C1-6 no sustituido, un éster cicloalquilo C3-6 opcionalmente sustituido, un éster arilo C6 opcionalmente sustituido, un éster arilo C10 opcionalmente sustituido o un éster bencílico opcionalmente sustituido de un α-aminoácido unido a N seleccionado del grupo que consiste en alanina unida a N, asparagina unida a N, aspartato unido a N, cisteína unida a N, glutamato unido a N, glutamina unida a N, glicina unida a N, prolina unida a N, serina unida a N, tirosina unida a N, arginina unida a N, histidina unida a N, isoleucina unida a N, leucina unida a N, lisina unida a N, metionina unida a N, fenilalanina unida a N, treonina unida a N, triptófano unido a N y valina unida a N; R10A y R11A son independientemente un α-aminoácido unido a N opcionalmente sustituido seleccionado del grupo que consiste en alanina unida a N, asparagina unida a N, aspartato unido a N, cisteína unida a N, glutamato unido a N, glutamina unida a N, glicina unida a N, prolina unida a N, serina unida a N, tirosina unida a N, arginina unida a N, histidina unida a N, isoleucina unida a N, leucina unida a N, lisina unida a N, metionina unida a N, fenilalanina unida a N, treonina unida a N, triptófano unido a N y valina unida a N, o un derivado de éster de α-aminoácido unido a N opcionalmente sustituido, donde el derivado de éster de α-aminoácido unido a N opcionalmente sustituido es un éster alquilo C1-6 no sustituido, un éster cicloalquilo C3-6 opcionalmente sustituido, un éster arilo C6 opcionalmente sustituido, un éster arilo C10 opcionalmente sustituido o un éster bencílico opcionalmente sustituido de un α-aminoácido unido a N seleccionado del grupo que consiste en alanina unida a N, asparagina unida a N, aspartato unido a N, cisteína unida a N, glutamato unido a N, glutamina unida a N, glicina unida a N, prolina unida a N, serina unida a N, tirosina unida a N, arginina unida a N, histidina unida a N, isoleucina unida a N, leucina unida a N, lisina unida a N, metionina unida a N, fenilalanina unida a N, treonina unida a N, N-unida a triptófano y valina unida a N; R12A y R13A son independientemente ausente o hidrógeno; R14A es O-, OH o metilo; R22A y R23A son cada uno hidrógeno; R24A se selecciona del grupo constituido por hidrógeno, un alquilo C1-24 no sustituido y un alquilo -O-C1-24 no sustituido; R""A es un alquilo C1-24 no sustituido; m es 0 o 1; s es 0; y Z1A, Z2A, Z3A y Z4A son cada uno O; donde la infección viral es causada por un virus que se selecciona del grupo que consiste en un virus Coronaviridae, un virus Togaviridae, un virus Hepeviridae y un virus Bunyaviridae; y cuando un grupo es descrito como siendo opcionalmente sustituido, ese grupo puede ser no sustituido o sustituido con uno o más grupos seleccionados independientemente de alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclilo, aril(alquilo), heteroaril(alquilo), heterociclil(alquilo), hidroxi, alcoxi, acilo, ciano, halógeno, tiocarbonilo, O-carbamilo, N-carbamilo, O-tiocarbamilo, N-tiocarbamilo, C-amido, N-amido, S-sulfonamido, Nsulfonamido, C-carboxi, O-carboxi, isocianato, tiocianato, isotiocianato, azido, nitro, sililo, sulfenilo, sulfinilo, sulfonilo, haloalquilo, haloalcoxi, trihalometanosulfonilo, trihalometanosulfonamido, un amino, un grupo amino monosustituido y un grupo amino disustituido.",JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/087-787-330-066-829,Granted Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
155,AU,B2,AU 2021/204791 B2,101-283-394-384-195,2023-12-07,2023,AU 2021/204791 A,2021-07-08,AU 2021/204791 A;;AU 2015/280248 A;;US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/101-283-394-384-195,Granted Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
156,MA,B1,MA 40032 B1,124-279-786-689-88X,2021-02-26,2021,MA 40032 A,2015-06-22,US 201462016232 P;;US 2015/0037001 W,2014-06-24,"Nucléosides substitués, nucléotides et analogues de ceux-ci pour traiter les infections virales","L'invention concerne des nucléosides, des nucléotides et des analogues de nucléotides, des procédés de synthèse de ceux-ci et des procédés de traitement de maladies et/ou d'états pathologiques, tels qu'une infection virale par les coronaviridae, les togaviridae, les hepeviridae et/ou les bunyaviridae, avec un ou plusieurs nucléosides, nucléotides et analogues de nucléotides.",JANSSEN BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/124-279-786-689-88X,Granted Patent,no,0,0,1,36,0,,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
157,US,A1,US 2013/0319023 A1,159-509-855-253-133,2013-12-05,2013,US 201213713972 A,2012-12-13,US 201213713972 A;;US 201261655316 P,2012-06-04,METHOD FOR WATER RECOVERY FROM ATMOSPHERE,A method to recover water from the atmosphere is provided. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-01-28);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/159-509-855-253-133,Patent Application,yes,17,2,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F25B43/00,62/94,0,0,,,,ACTIVE
158,WO,A2,WO 2007/136926 A2,187-515-546-386-131,2007-11-29,2007,US 2007/0064979 W,2007-03-27,US 41904106 A,2006-05-18,MULTI-FUNCTION KEYPAD USING COLORED LIGHT SOURCES AND OPTICAL FILMS,"A multi-function key system for use with an electronic device can include at least one key (230) and an optical film (255) optically coupled to the key. The optical film (255) can include a first optical filter (260) corresponding to a first color of light and a second optical filter (265) corresponding to a second color of light. The multi-function key system further can include a first light source (275), disposed below the key, that emits the first color of light and a second light source (280), disposed below the key, that emits the second color of light. A controller (215) can selectively activate the first light source (275) or second light source (280) responsive to an event detected within the electronic device.",MOTOROLA INC;;TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,,https://lens.org/187-515-546-386-131,Patent Application,yes,0,0,4,4,0,H04M1/22;;H04M1/23;;H04M1/22;;H04M1/23,G06K7/10;;G06K19/06,,0,0,,,,PENDING
159,AU,B2,AU 2015/280248 B2,152-463-740-592-72X,2021-04-08,2021,AU 2015/280248 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/152-463-740-592-72X,Granted Patent,no,2,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
160,US,A1,US 2017/0143749 A1,068-778-208-181-264,2017-05-25,2017,US 201715423270 A,2017-02-02,US 201715423270 A;;US 201514746500 A;;US 201462016232 P;;US 201462061770 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN BIOPHARMA INC (2015-07-21),https://lens.org/068-778-208-181-264,Patent Application,yes,0,19,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076,,0,0,,,,ACTIVE
161,DK,T3,DK 3160476 T3,044-048-973-808-938,2020-12-21,2020,DK 15812231 T,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUEREDE NUKLEOSIDER, NUKLEOTIDER OG ANALOGER DERTIL TIL ANVENDELSE TIL BEHANDLING AF VIRUSINFEKTIONER",,JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/044-048-973-808-938,Granted Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
162,US,B2,US 9603864 B2,084-478-099-183-943,2017-03-28,2017,US 201514746500 A,2015-06-22,US 201514746500 A;;US 201462016232 P;;US 201462061770 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA INC (2015-07-21),https://lens.org/084-478-099-183-943,Granted Patent,yes,60,45,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A01N43/04;;A61K31/70;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K45/06;;C07F9/6558;;C07F9/6574,,20,12,011-984-838-562-79X;;000-638-858-308-747;;030-796-481-909-914;;063-288-243-415-763;;038-991-544-045-020;;057-300-792-956-759;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;026-537-378-582-916;;044-973-700-542-810;;015-163-106-031-675,pmc7108317;;23684571;;10.1016/j.drudis.2013.05.002;;pmc7126875;;10.1016/j.bmcl.2007.02.026;;17336519;;18031187;;10.2165/00063030-199912050-00003;;10.1089/jir.1996.16.489;;8836913;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1016/0003-9861(72)90537-1;;5045935;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s;;10.1016/s0163-7258(00)00048-6;;11008000,"Kaur et al. Drug Discovery Today (2013), vol. 18, pp. 969-963.;;Ikejiri et al. Bioorganic & Medicinal Chemistry Letters (2007), vol. 17, pp. 2470-2473.;;“Derivative.” Merriam-Webster.com. Merriam-Webster, n.d. Web. Jun. 2, 2016.;;Alberti, A., “Interferon Alfacon-1” BioDrugs (1999) 12(5):343-357.;;Blatt, L., et al., “The Biologic Activity and Molecular Characterization of a Novel Synthetic Interferon-Alpha Species, Consensus Interferon” J. Interferon Cytokine Res. (1996) 16(7):489-499.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates As Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses” ACS Medicinal Chemistry Letters,(2013) 4(8):747-751.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)* Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;McOmie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pages only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′-α-fluoro-2′- β -C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76(10):3782-3790.;;Villard et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/037001, filed Jun. 22, 2015.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.;;Van Rompay et al., “Phosphorylation of nucleosides and nucleotide analogs by mammalian nucleoside monophosphate kinases”Pharmacology & Therapeutics (2000) 87:189-98.;;International Preliminary Report on Patentability issued Dec. 27, 2016 for PCT Application No. PCT/US2015/037001 filed Jun. 22, 2015.",ACTIVE
163,AU,A1,AU 2015/280248 A1,160-625-614-496-015,2017-01-12,2017,AU 2015/280248 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/160-625-614-496-015,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
164,US,B2,US 8882888 B2,011-053-233-714-038,2014-11-11,2014,US 201313908576 A,2013-06-03,US 201313908576 A;;US 201261655316 P,2012-06-04,Water recovery system and method,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BALL JAMES;;BECZE CHARLES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2012-10-25);;FLEXTRONICS INTERNATIONAL USA INC (2012-08-02);;SUN TO WATER TECHNOLOGIES LLC (2017-09-11),https://lens.org/011-053-233-714-038,Granted Patent,yes,67,4,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B43/00;;F25D21/14,95/112;;96/140;;96/141;;95/117;;95/118;;95/199;;95/223;;95/231,13,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec . . . ).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,398, mailed May 16, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014 10 pages.",ACTIVE
165,US,B2,US 9061239 B2,037-215-184-351-21X,2015-06-23,2015,US 201213723113 A,2012-12-20,US 201213723113 A;;US 201261655316 P,2012-06-04,Method of manufacture and assembly for modular water recovery system,"A device recovers water from an ambient airstream. The device includes a chamber having a group of trays that hold respective amounts of liquid desiccant. A foam media element in each tray absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and control device operation. The desiccant trays may be selectively configurable in an array to best suit the intended installation. The trays may be arranged in column and row configurations, along with adjustable airflow patterns between each of the trays.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-27);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/037-215-184-351-21X,Granted Patent,yes,62,0,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/78;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B37/00;;F25B43/00;;F25D21/14,,41,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014, 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014, 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014, 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,398, mailed May 16, 2014, 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014, 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014, 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014, 10 pages.;;U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/713,972, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/714,006, filed Dec, 13, 2012, Becze et al.;;U.S. Appl. No. 13/693,398, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et all.;;U.S. Appl. No. 13/693,418, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/693,451, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec . . .).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Website ""Co-Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/co-generation.html.;;Website ""Direct Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/direct-generation.html.;;Website ""Energy Harvesting,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/energy-harvesting.html.;;Website ""Waste Heat Recovery,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/waste-heat-recovery.html.;;Venkatasubramanian, ""Efficient Thermoelectric Power Conversion of Waste Heat for Deplyed Forces (EW-1651),"" SERDP, Arlington, VA, 2012, 3 pages, retrieved from www.serdp.org/content/view/pdf/6791.;;Notice of Allowance for U.S. Appl. No. 13/908,576, mailed Jun. 30, 2014, 8 pages.;;Corrected Notice of Allowance for U.S. Appl. No. 13/713,972, mailed Aug. 1, 2014, 4 pages.;;Official Action for U.S. Appl. No. 13/660,572, mailed Jun. 26, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,620, mailed Jul. 16, 2014, 5 pages.;;Official Action for U.S. Appl. No. 13/693,451, mailed Aug. 19, 2014, 5 pages.;;International Preliminary Report on Patentability for International Patent Application No. PCT/IB2013/001858, mailed Dec. 18, 2014 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/714,006, mailed Dec. 19, 2014 5 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,572, mailed Dec. 4, 2014, 5 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Dec. 23, 2014, 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,451, mailed Jan. 13, 2015, 9 pages.;;Official Action for U.S. Appl. No. 13/746,824, mailed Jan. 21, 2015, 7 pages.",ACTIVE
166,US,B2,US 8858684 B2,028-926-216-808-224,2014-10-14,2014,US 201213713972 A,2012-12-13,US 201213713972 A;;US 201261655316 P,2012-06-04,Method for water recovery from atmosphere,A method to recover water from the atmosphere is provided. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-01-28);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/028-926-216-808-224,Granted Patent,yes,51,2,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B43/00;;F25D21/14,95/117;;95/118;;95/199;;95/223;;95/231;;96/112;;96/140;;96/141,21,0,,,"Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec . . . ).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/714,006, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/693,398, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,418, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/693,451, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/723,113, filed Dec. 20, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Notice of Allowance for U.S. Appl. No. 13/908,576 mailed Jun. 30, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,572 mailed Jun. 26, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Jul. 16, 2014, 5 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014, 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014, 10 pages.",ACTIVE
167,WO,A1,WO 2015/200219 A1,152-264-389-990-453,2015-12-30,2015,US 2015/0037001 W,2015-06-22,US 201462061770 P;;US 201462016232 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/152-264-389-990-453,Patent Application,yes,23,34,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,9,5,077-295-491-167-117;;022-668-731-415-436;;026-537-378-582-916;;038-991-544-045-020;;040-895-383-437-294,10.1002/0471220574;;10.1021/jo200060f;;21469736;;10.1016/j.bmc.2008.06.024;;18585917;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1021/jm800594c;;18714981,"BIOCHEM., vol. 11, 1972, pages 942 - 944;;T. W. GREENEP. G. M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;REDDY ET AL., J. ORG. CHEM., vol. 76, no. 10, 2011, pages 3782 - 3790;;VILLARD ET AL., BIOORG. MED. CHEM., vol. 16, 2008, pages 7321 - 7329;;BONDADA, L. ET AL., ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 8, 2013, pages 747 - 751;;MCGUIGAN ET AL., J. MED. CHEM., vol. 51, 2008, pages 5807 - 5812;;LEFEBRE ET AL., J. MED. CHEM., vol. 38, 1995, pages 3941 - 3950;;See also references of EP 3160476A4",PENDING
168,US,S,US D0388094 S,154-654-183-451-653,1997-12-23,1997,US 4992596 F,1996-02-05,US 4992596 F,1996-02-05,Combined speaker and microphone,,MOTOROLA INC,TOKIYAMA MASARU;;BLATT DAVID ISAAC;;BEASLEY JEFF ROBERT;;HENNING MICHAEL SCOTT,MOTOROLA SOLUTIONS INC (1996-04-26),https://lens.org/154-654-183-451-653,Design Right,yes,8,10,1,1,0,,,D14/226;;1401,0,0,,,,EXPIRED
169,MX,A,MX 2016017383 A,166-791-433-565-482,2017-08-02,2017,MX 2016017383 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF.","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;SMITH DAVID BERNARD;;JULIAN ALEXANDER SYMONS,,https://lens.org/166-791-433-565-482,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
170,LT,T,LT 3160476 T,012-076-177-838-631,2021-04-12,2021,LT 15812231 T,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/012-076-177-838-631,Unknown,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
171,AU,A1,AU 2021/204791 A1,020-769-033-973-713,2021-08-05,2021,AU 2021/204791 A,2021-07-08,AU 2021/204791 A;;AU 2015/280248 A;;US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/020-769-033-973-713,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
172,SI,T1,SI 3160476 T1,038-273-649-683-559,2021-05-31,2021,SI 201531469 T,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W;;EP 15812231 A,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/038-273-649-683-559,Granted Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/00;;A61P31/00,,0,0,,,,ACTIVE
173,US,A1,US 2007/0267497 A1,076-788-456-349-379,2007-11-22,2007,US 41904106 A,2006-05-18,US 41904106 A,2006-05-18,MULTI-FUNCTION KEYPAD USING COLORED LIGHT SOURCES AND OPTICAL FILMS,"A multi-function key system for use with an electronic device can include at least one key ( 230 ) and an optical film ( 255 ) optically coupled to the key. The optical film ( 255 ) can include a first optical filter ( 260 ) corresponding to a first color of light and a second optical filter ( 265 ) corresponding to a second color of light. The multi-function key system further can include a first light source ( 275 ), disposed below the key, that emits the first color of light and a second light source ( 280 ), disposed below the key, that emits the second color of light. A controller ( 215 ) can selectively activate the first light source ( 275 ) or second light source ( 280 ) responsive to an event detected within the electronic device.",MOTOROLA INC,TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2006-05-17),https://lens.org/076-788-456-349-379,Patent Application,yes,36,17,4,4,0,H04M1/22;;H04M1/23;;H04M1/22;;H04M1/23,G06K19/06;;G06K7/10,235/454;;235/491,0,0,,,,INACTIVE
174,CA,A1,CA 2952966 A1,106-223-409-480-049,2015-12-30,2015,CA 2952966 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/106-223-409-480-049,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
175,US,B2,US 7523862 B2,006-936-751-421-305,2009-04-28,2009,US 41904106 A,2006-05-18,US 41904106 A,2006-05-18,Multi-function keypad using colored light sources and optical films,"A multi-function key system for use with an electronic device can include at least one key ( 230 ) and an optical film ( 255 ) optically coupled to the key. The optical film ( 255 ) can include a first optical filter ( 260 ) corresponding to a first color of light and a second optical filter ( 265 ) corresponding to a second color of light. The multi-function key system further can include a first light source ( 275 ), disposed below the key, that emits the first color of light and a second light source ( 280 ), disposed below the key, that emits the second color of light. A controller ( 215 ) can selectively activate the first light source ( 275 ) or second light source ( 280 ) responsive to an event detected within the electronic device.",MOTOROLA INC,TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2006-05-17),https://lens.org/006-936-751-421-305,Granted Patent,yes,27,10,4,4,0,H04M1/22;;H04M1/23;;H04M1/22;;H04M1/23,G06K7/10,235/454;;X235145 R,3,0,,,"The Third Evolution, Programmable, RGB-backlit LCD Push-button Switches, Technical Datasheet, http://www.lcd-keys.com/downloads/SA-Technical-Datasheet-v1-1.pdf, accessed May 17, 2006.;;International Search Report, PCT (Patent Cooperation Treaty), International Application No. PCT/US 07/64979, International Filing Date: Mar. 27, 2007, Priority Date: May 18, 2006, 7 pages.;;PCT (Patent Cooperation Treaty) International Search Report dated Feb. 21, 2008 relating to Application No. PCT/US07/60200 filed Jan. 8, 2007 - 7 Pages.",INACTIVE
176,EP,A1,EP 3797782 A1,031-025-513-106-43X,2021-03-31,2021,EP 20192890 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;EP 15812231 A;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/031-025-513-106-43X,Patent Application,yes,9,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,1,1,031-185-860-550-896,10.1073/pnas.0907010106;;pmc2787148;;19918064,"Z. YIN ET AL: ""An adenosine nucleoside inhibitor of dengue virus"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 106, no. 48, 1 December 2009 (2009-12-01), US, pages 20435 - 20439, XP055430670, ISSN: 0027-8424, DOI: 10.1073/pnas.0907010106",PENDING
177,EP,A4,EP 3160476 A4,059-309-928-957-739,2018-01-10,2018,EP 15812231 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,"JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/059-309-928-957-739,Search Report,no,5,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,2,1,031-185-860-550-896,10.1073/pnas.0907010106;;pmc2787148;;19918064,"Z. YIN ET AL: ""An adenosine nucleoside inhibitor of dengue virus"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 106, no. 48, 1 December 2009 (2009-12-01), US, pages 20435 - 20439, XP055430670, ISSN: 0027-8424, DOI: 10.1073/pnas.0907010106;;See also references of WO 2015200219A1",ACTIVE
178,WO,A3,WO 2007/136926 A3,114-940-745-214-462,2008-04-10,2008,US 2007/0064979 W,2007-03-27,US 41904106 A,2006-05-18,MULTI-FUNCTION KEYPAD USING COLORED LIGHT SOURCES AND OPTICAL FILMS,"A multi-function key system for use with an electronic device can include at least one key (230) and an optical film (255) optically coupled to the key. The optical film (255) can include a first optical filter (260) corresponding to a first color of light and a second optical filter (265) corresponding to a second color of light. The multi-function key system further can include a first light source (275), disposed below the key, that emits the first color of light and a second light source (280), disposed below the key, that emits the second color of light. A controller (215) can selectively activate the first light source (275) or second light source (280) responsive to an event detected within the electronic device.",MOTOROLA INC;;TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,TRACY JAMES L;;AMIRZADEH HABIB;;BLATT DAVID I;;CASTANEDA JULIO C,,https://lens.org/114-940-745-214-462,Search Report,yes,5,0,4,4,0,H04M1/22;;H04M1/23;;H04M1/22;;H04M1/23,F21V7/04,,0,0,,,,PENDING
179,SG,A,SG 11201610599T A,144-293-141-958-276,2017-01-27,2017,SG 11201610599T A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/144-293-141-958-276,Unknown,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
180,HU,T2,HU E051986 T2,016-667-166-096-329,2021-04-28,2021,HU E15812231 A,2015-06-22,US 201462016232 P;;US 201462061770 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/016-667-166-096-329,Amended Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61P31/14,,0,0,,,,PENDING
181,EP,B1,EP 3160476 B1,134-328-925-010-71X,2020-09-30,2020,EP 15812231 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,JANSSEN BIOPHARMA INC,SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;BEIGELMAN LEONID,"JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/134-328-925-010-71X,Granted Patent,yes,13,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,1,0,,,"Z. YIN ET AL: ""An adenosine nucleoside inhibitor of dengue virus"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 106, no. 48, 1 December 2009 (2009-12-01), pages 20435-20439, XP55430670, US ISSN: 0027-8424, DOI: 10.1073/pnas.0907010106",ACTIVE
182,US,A1,US 2013/0318790 A1,173-747-596-784-60X,2013-12-05,2013,US 201213723113 A,2012-12-20,US 201213723113 A;;US 201261655316 P,2012-06-04,METHOD OF MANUFACTURE AND ASSEMBLY FOR MODULAR WATER RECOVERY SYSTEM,"A device recovers water from an ambient airstream. The device includes a chamber having a group of trays that hold respective amounts of liquid desiccant. A foam media element in each tray absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and control device operation. The desiccant trays may be selectively configurable in an array to best suit the intended installation. The trays may be arranged in column and row configurations, along with adjustable airflow patterns between each of the trays.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-27);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/173-747-596-784-60X,Patent Application,yes,2,32,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/26,29/890.07,0,0,,,,ACTIVE
183,TW,A,TW 201613612 A,025-070-103-177-345,2016-04-16,2016,TW 104120371 A,2015-06-24,US 201462016232 P;;US 201462061770 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/025-070-103-177-345,Patent of Addition,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
184,PH,A1,PH 12016502564 A1,083-750-510-796-058,2017-04-17,2017,PH 12016502564 A,2016-12-21,US 201462061770 P;;US 201462016232 P;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOSIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;LEONID BEIGELMAN;;ALEXANDER SYMONS JULIAN;;BERNARD SMITH DAVID,,https://lens.org/083-750-510-796-058,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7072;;A61K31/7068;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
185,US,A1,US 2013/0319250 A1,129-602-828-105-58X,2013-12-05,2013,US 201213714006 A,2012-12-13,US 201213714006 A;;US 201261655316 P,2012-06-04,APPARATUS FOR WATER RECOVERY INCLUDING STACKABLE DESICCANT TRAYS,"A device recovers water from an ambient airstream. The device includes a chamber having a group of trays that hold respective amounts of liquid desiccant. A foam media element in each tray absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and control device operation. The desiccant trays may be selectively configurable in an array to best suit the intended installation. The trays may be arranged in column and row configurations, along with adjustable airflow patterns between each of the trays.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-01-28);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/129-602-828-105-58X,Patent Application,yes,0,6,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/18,96/242;;29/428,0,0,,,,ACTIVE
186,CA,A1,CA 3207106 A1,157-091-518-754-270,2015-12-30,2015,CA 3207106 A,2015-06-22,US 201462016232 P;;US 201462061770 P;;CA 2952966 A,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/157-091-518-754-270,Patent Application,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,,,0,0,,,,PENDING
187,HR,T1,HR P20202014 T1,115-485-410-714-662,2021-04-02,2021,HR P20202014 T,2020-12-16,US 201462016232 P;;US 201462061770 P;;EP 15812231 A;;US 2015/0037001 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION",,JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/115-485-410-714-662,Granted Patent,no,0,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
188,US,A1,US 2015/0366888 A1,175-468-349-184-974,2015-12-24,2015,US 201514746500 A,2015-06-22,US 201514746500 A;;US 201462016232 P;;US 201462061770 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA INC (2015-07-21),https://lens.org/175-468-349-184-974,Patent Application,yes,0,43,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076,,3,2,011-984-838-562-79X;;000-638-858-308-747,pmc7108317;;23684571;;10.1016/j.drudis.2013.05.002;;pmc7126875;;10.1016/j.bmcl.2007.02.026;;17336519,"Kaur et al. Drug Discovery Today (2013), Vol. 18, pages 969-963.;;Ikejiri et al. Bioorganic & Medicinal Chemistry Letters (2007), Vol. 17, pages 2470-2473.;;""Derivative."" Merriam-Webster.com. Merriam-Webster, n.d. Web. 2 June 2016.",ACTIVE
189,US,A1,US 2003/0110019 A1,198-416-594-624-160,2003-06-12,2003,US 1023801 A,2001-12-07,US 1023801 A,2001-12-07,Data analysis techniques for dynamic power simulation of a CPU,"
   A method for data analysis of power modeling for a microprocessor has been developed. The method takes multiple values of power data from a power modeling simulator and generates summary data to characterize the power data behavior. Summary data views include results characterizing behavior in a single cycle and behavior across multiple cycles. Data is viewed both at an absolute level to characterize total power and relative to previous levels to characterize power derivatives. Summary data is derived from power generated every cycle when running specific benchmark programs on the power simulator. 
",BLATT MIRIAM G.;;GREENHILL DAVID J.;;GAUTHIER CLAUDE R.;;AINGARAN KATHIRGAMAR,BLATT MIRIAM G;;GREENHILL DAVID J;;GAUTHIER CLAUDE R;;AINGARAN KATHIRGAMAR,SUN MICROSYSTEMS INC (2001-11-30);;ORACLE AMERICA INC (2010-02-12),https://lens.org/198-416-594-624-160,Patent Application,yes,12,4,2,2,0,G06F30/33;;G06F30/33,G06F17/50,703/18,0,0,,,,EXPIRED
190,US,B2,US 10307439 B2,011-163-615-819-799,2019-06-04,2019,US 201715423270 A,2017-02-02,US 201715423270 A;;US 201514746500 A;;US 201462016232 P;;US 201462061770 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN BIOPHARMA INC (2015-07-21),https://lens.org/011-163-615-819-799,Granted Patent,yes,82,19,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A01N43/04;;A61K31/70;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K45/06;;C07F9/6558;;C07F9/6574,,32,14,030-796-481-909-914;;063-288-243-415-763;;038-991-544-045-020;;000-638-858-308-747;;057-300-792-956-759;;011-984-838-562-79X;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;015-163-106-031-675;;026-537-378-582-916;;044-973-700-542-810;;076-899-709-794-748;;031-185-860-550-896,18031187;;10.2165/00063030-199912050-00003;;10.1089/jir.1996.16.489;;8836913;;24015326;;pmc3763849;;10.1021/ml4001497;;pmc7126875;;10.1016/j.bmcl.2007.02.026;;17336519;;10.1016/0003-9861(72)90537-1;;5045935;;pmc7108317;;23684571;;10.1016/j.drudis.2013.05.002;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;10.1016/s0163-7258(00)00048-6;;11008000;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s;;10.1111/j.1471-4159.1986.tb12982.x;;3941313;;10.1073/pnas.0907010106;;pmc2787148;;19918064,"Office Action dated Sep. 20, 2017 for EA Application No. 201692535, filed Jun. 22, 2015.;;Alberti, A., “Interferon Alfacon-1” BioDrugs (1999) 12(5):343-357.;;Blatt, L., et al., “The Biologic Activity and Molecular Characterization of a Novel Synthetic Interferon-Alpha Species, Consensus Interferon” J. Interferon Cytokine Res. (1996) 16(7):489-499.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates As Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses” ACS Medicinal Chemistry Letters,(2013) 4(8):747-751.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;Ikejiri et al., “Synthesis and Biological Evaluation of Nucleoside Analogues Having 6-chloropurine as Anti-SARS-CoV Agents” Bioorganic & Medicinal Chemistry Letters (2007) 17:2470-2473.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)* Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Kaur et al., “Chikungunya virus: an update on antiviral development and challenges.” Drug Discovery Today (2013) 18:969-983.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.;;McOmie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pages only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76 (10):3782-3790.;;Van Rompay et al., “Phosphorylation of nucleosides and nucleotide analogs by mammalian nucleoside monophosphate kinases” Pharmacology & Therapeutics (2000) 87:189-98.;;Villard et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Preliminary Report on Patentability dated Dec. 27, 2016 for PCT Application No. PCT/US2015/037001 filed Jun. 22, 2015.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/037001, filed Jun. 22, 2015.;;Derivative, Merriam-Webster.com, Merriam-Webster, n. d. Web. Jun. 2, 2016.;;Dyck, et al. “Effects of Deuterium Substitution on the Catabolism of beta-Phenylethylamine: An in Vivo Study”, J Neurochem. 1986; 46(2): 399-404.;;Tung, R., “The development of deuterium-containing drugs” Innovations in Pharmaceutical Technology 2010; 32(32):24-28.;;Office Action dated Jun. 10, 2016 for U.S. Appl. No. 14/746,500, filed Jun. 22, 2015.;;Examination Report dated Jun. 7, 2017 for New Zealand Patent Application No. 727580, filed Jun. 22, 2015.;;Examination Report dated Jan. 9, 2018 for New Zealand Patent Application No. 727580, filed Jun. 22, 2015.;;Search Report and Written Opinion dated Jul. 11, 2017 for SG Application No. 11201610599T, filed Jun. 22, 2015.;;Yin et al., “An adenosine nucleoside inhibitor of dengue virus” PNAS (2009) 106(48):20435-20439.;;Extended European Search Report dated Dec. 11, 2017 for EP Application No. 15812231.7, filed Jun. 22, 2015.;;Examination Report dated Jun. 7, 2018 for New Zealand Patent Application No. 727580, filed Jun. 22, 2015.;;Second Written Opinion dated May 28, 2018 for Singapore Application No. 11201610599T, filed Jun. 22, 2015.;;Office Action dated Sep. 27, 2018 for CN Application No. 201580045439.9, filed Jun. 22, 2015.",ACTIVE
191,JP,A,JP 2020172511 A,089-424-990-043-50X,2020-10-22,2020,JP 2020114136 A,2020-07-01,US 201462061770 P;;US 201462016232 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","To provide use of a nucleic acid derivative in the preparation of a pharmaceutical for improving or treating virus infection, or a pharmaceutically acceptable salt thereof.SOLUTION: The present invention relates to use of a compound of formula (I) (where, B1A is a heterocyclic base, --- is absent or a single bond, provided that, when both of --- are absent, Z1 is absent, O1 is O or R1A, R1A is H, acyl or the like, R3A is H, halo or the like, R4A is H, halo or the like, or R3A and R4A each represent an oxygen atom connected via carbonyl to form a 5-membered ring; when both of --- are single bonds, Z1 is a phosphate group, O1 is O, R3A is O, R4A is H, halo or the like. Ra1 and Ra2 independently represent H or D, RA is H, D, unsubstituted alkyl or the like, R2A is H, halo, unsubstituted alkyl or the like, R5A is H, halo or the like).SELECTED DRAWING: None",JANSSEN BIOPHARMA INC,LAWRENCE M BLATT;;BEIGELMAN LEONID;;JULIAN ALEXANDER SYMONS;;DAVID BERNARD SMITH,,https://lens.org/089-424-990-043-50X,Patent Application,no,4,0,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14;;A61P43/00,,0,0,,,,ACTIVE
192,CN,A,CN 106573011 A,194-235-947-495-504,2017-04-19,2017,CN 201580045439 A,2015-06-22,US 2015/0037001 W;;US 201462016232 P;;US 201462061770 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/194-235-947-495-504,Patent Application,no,8,13,35,36,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/14;;Y02A50/30;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K45/06;;C07F9/65586;;C07F9/65742,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,DISCONTINUED
193,AU,A,AU 2000/065914 A,035-876-256-605-166,2001-03-19,2001,AU 2000/065914 A,2000-08-15,IL 13150899 A;;IL 0000494 W,1999-08-19,Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants,,BIO DAR LTD,BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE;;COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER,,https://lens.org/035-876-256-605-166,Patent Application,no,0,0,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,,0,0,,,,DISCONTINUED
194,WO,A1,WO 2001/013890 A1,085-536-875-478-584,2001-03-01,2001,IL 0000494 W,2000-08-15,IL 13150899 A,1999-08-19,MICROENCAPSULATED AND CONTROLLED-RELEASE FORMULATIONS OF ISOFLAVONE FROM ENRICHED FRACTIONS OF SOY AND OTHER PLANTS,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone-enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75 % of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37 °C. A process for the preparation of such a formulation is also provided.",BIO DAR LTD;;BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE;;COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER,BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE;;COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER,,https://lens.org/085-536-875-478-584,Patent Application,yes,2,5,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,,0,0,,,,PENDING
195,EP,A1,EP 1210066 A1,004-405-502-394-873,2002-06-05,2002,EP 00953415 A,2000-08-15,IL 0000494 W;;IL 13150899 A,1999-08-19,MICROENCAPSULATED AND CONTROLLED-RELEASE FORMULATIONS OF ISOFLAVONE FROM ENRICHED FRACTIONS OF SOY AND OTHER PLANTS,,BIO DAR LTD,BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE;;COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER,,https://lens.org/004-405-502-394-873,Patent Application,yes,0,0,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,,0,0,,,,DISCONTINUED
196,IL,A,IL 131508 A,193-830-450-292-146,2006-12-10,2006,IL 13150899 A,1999-08-19,IL 13150899 A,1999-08-19,MICROENCAPSULATED AND CONTROLLED-RELEASE FORMULATIONS OF ISOFLAVONE FROM ENRICHED FRACTIONS OF SOY AND OTHER PLANTS,,COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER;;BLATT YOAV;;LYCORED BIO LTD;;ARAD ODED;;KIMELMAN EUGENE,COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER;;BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE,,https://lens.org/193-830-450-292-146,Patent Application,no,0,0,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,,0,0,,,,EXPIRED
197,EP,A1,EP 0825894 A1,043-952-177-244-755,1998-03-04,1998,EP 95923872 A,1995-06-14,US 9507569 W;;US 44694895 A,1995-05-15,DEHYDRATION AND PURIFICATION OF ISOPROPYL ALCOHOL,,ATHENS CORP,ADAMS JOHN A;;KRULIK GERALD A;;BLATT CHRISTOPHER;;PERSICHINI DAVID;;GANZ BRIAN,INTEGRATED PROCESS EQUIPMENT CORP. ( IPEC) (1998-04-29),https://lens.org/043-952-177-244-755,Patent Application,yes,0,0,8,8,0,B01D3/146;;B01D61/362;;C07C29/80;;C07C29/82;;Y10S159/27;;Y10S203/17;;C07C31/18;;B01D3/146;;B01D61/362;;C07C29/82;;B01D61/362;;C07C29/80;;B01D3/146;;C07C29/82;;Y10S159/27;;Y10S203/17,B01D3/14;;B01D61/36;;C07C29/80;;C07C29/82;;C07C31/10,,0,0,,,,DISCONTINUED
198,US,S,US D0558709 S,035-171-079-060-467,2008-01-01,2008,US 24722606 F,2006-06-07,US 24722606 F,2006-06-07,Communication device,,MOTOROLA INC,NILSEN RYAN M;;BLATT DAVID I;;KARL DAVE H;;WOLF MONIKA R,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2006-06-05),https://lens.org/035-171-079-060-467,Design Right,no,0,0,1,1,0,,,1403;;D14/138,0,0,,,,EXPIRED
199,US,B1,US 6890561 B1,061-285-668-746-107,2005-05-10,2005,US 6938802 A,2002-06-28,IL 13150899 A;;IL 0000494 W,1999-08-19,Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone-enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37° C. A process for the preparation of such a formulation is also provided.",BIO DAR LTD,BLATT YOAV;;ARAD ODED;;KIMELMAN EUGENE;;COHEN DAVID;;PINTO RIKA;;ROTMAN AVNER,LYCORED BIO LTD (2002-05-07),https://lens.org/061-285-668-746-107,Granted Patent,yes,18,73,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,424/490;;424/451;;424/457;;424/458;;424/464;;424/465;;424/468;;424/469;;424/470;;424/489;;424/493;;424/494;;424/495,4,0,,,"Bauer et al., Coated Pharmaceutical Dosage Forms. Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Row Materials, CRC Press, Washington, D.C. 1998.;;Remington's Pharmaceutical Sciences, 8th Edition, Mack Publishing Company, 1990, pp. 1288-1300.;;Handbook of Pharmaceutical Excipients, pp. 81-90, 1986, by the American Pharmaceutical Association & Pharmaceutical Society of Great Britain.;;USP 24, Test 786, pp. 1969-1970.",EXPIRED
200,EP,A4,EP 0825894 A4,058-364-177-522-827,1999-01-20,1999,EP 95923872 A,1995-06-14,US 9507569 W;;US 44694895 A,1995-05-15,DEHYDRATION AND PURIFICATION OF ISOPROPYL ALCOHOL,,ATHENS CORP,ADAMS JOHN A;;KRULIK GERALD A;;BLATT CHRISTOPHER;;PERSICHINI DAVID;;GANZ BRIAN,INTEGRATED PROCESS EQUIPMENT CORP. ( IPEC) (1998-04-29),https://lens.org/058-364-177-522-827,Search Report,no,1,0,8,8,0,B01D3/146;;B01D61/362;;C07C29/80;;C07C29/82;;Y10S159/27;;Y10S203/17;;C07C31/18;;B01D3/146;;B01D61/362;;C07C29/82;;B01D61/362;;C07C29/80;;B01D3/146;;C07C29/82;;Y10S159/27;;Y10S203/17,B01D3/14;;B01D61/36;;C07C29/80;;C07C29/82;;C07C31/10,,3,0,,,"""Ullmann's Encyclopedia of Industrial Chemistry, Volume B3: Unit Operations II"", 1988, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM (D), XP002084537;;PATENT ABSTRACTS OF JAPAN vol. 012, no. 202 (C - 503) 10 June 1988 (1988-06-10);;See also references of WO 9636412A1",DISCONTINUED
201,CA,A1,CA 2382218 A1,087-061-318-047-278,2001-03-01,2001,CA 2382218 A,2000-08-15,IL 13150899 A;;IL 0000494 W,1999-08-19,MICROENCAPSULATED AND CONTROLLED-RELEASE FORMULATIONS OF ISOFLAVONE FROM ENRICHED FRACTIONS OF SOY AND OTHER PLANTS,"There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone- enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75 % of the active ingredients available from the formulation is between about 4 and abo ut 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37 ~C. A process for the preparation of such a formulation is also provided.",BIO DAR LTD,COHEN DAVID;;PINTO RIVKA;;ROTMAN AVNER;;ARAD ODED;;BLATT YOAV;;KIMELMAN EUGENE,,https://lens.org/087-061-318-047-278,Patent Application,no,0,0,7,7,0,A61K9/1635;;A61K9/1652;;A61K9/5047;;A61K31/352;;A61K9/1652;;A61K31/352;;A61K9/5047;;A61K9/1635,A61K9/16;;A61K9/26;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/352,,0,0,,,,DISCONTINUED
202,WO,A1,WO 1996/036412 A1,150-261-579-621-070,1996-11-21,1996,US 9507569 W,1995-06-14,US 44694895 A,1995-05-15,DEHYDRATION AND PURIFICATION OF ISOPROPYL ALCOHOL,"A method and apparatus for the on-site reprocessing of isopropyl alcohol used in semiconductor manufacturing, to generate an ultradry and ultrapure isopropyl alcohol, produced through a pervaporation step, followed by a two-step distillation, wherein the first distillation step, an autonomous azeotropic self-stripping distillation column (78) is used to produce an ultradry and partially purified isopropyl alcohol, and in the next distillation step, the isopropyl alcohol is distilled in an overhead product distillation column (164), to produce an ultrapure and ultradry isopropyl alcohol.",ATHENS CORP,ADAMS JOHN A;;KRULIK GERALD A;;BLATT CHRISTOPHER;;PERSICHINI DAVID;;GANZ BRIAN,,https://lens.org/150-261-579-621-070,Patent Application,yes,4,3,8,8,0,B01D3/146;;B01D61/362;;C07C29/80;;C07C29/82;;Y10S159/27;;Y10S203/17;;C07C31/18;;B01D3/146;;B01D61/362;;C07C29/82;;B01D61/362;;C07C29/80;;B01D3/146;;C07C29/82;;Y10S159/27;;Y10S203/17,B01D3/14;;B01D61/36;;C07C29/80;;C07C29/82;;C07C31/10,,1,0,,,See also references of EP 0825894A4,PATENTED
203,US,S,US D0599766 S,122-705-704-691-836,2009-09-08,2009,US 32223608 F,2008-07-31,US 32223608 F,2008-07-31,Communication device,,MOTOROLA INC,PAGE MICHAEL J;;BLATT DAVID I;;ROBERTSON JR WILLIAM H;;BUTAN ALINA R,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2008-08-27),https://lens.org/122-705-704-691-836,Design Right,no,0,0,1,1,0,,,1403;;D14138AB,0,0,,,,EXPIRED
204,EP,B1,EP 3160475 B1,029-148-609-549-41X,2024-01-03,2024,EP 15810951 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS,,JANSSEN PHARMACEUTICALS INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,"JANSSEN PHARMACEUTICALS, INC. (2023-12-20);;JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/029-148-609-549-41X,Granted Patent,yes,13,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,5,0,,,"UEBELHOER LUKE S ET AL: ""High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses"", ANTIVIRAL RESEARCH, vol. 106, 5 April 2014 (2014-04-05), pages 86-94, XP028653124, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2014.03.018;;REKHA G. PANCHAL ET AL: ""Development of High-Content Imaging Assays for Lethal Viral Pathogens"", JOURNAL OF BIOMOLECULAR SCREENING, vol. 15, no. 7, 1 August 2010 (2010-08-01) , pages 755-765, XP55439118, US ISSN: 1087-0571, DOI: 10.1177/1087057110374357;;HUGGINS JOHN ET AL: ""Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model"", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 179, no. SUPPL. 1, 1 February 1999 (1999-02-01), pages S240-S247, XP002574255, ISSN: 0022-1899;;SIMONS C ET AL: ""RECENT ADVANCES IN ANTIVIRAL NUCLEOSIDE AND NUCLEOTIDE THERAPEUTICS"", CURRENT TOPICS IN MEDICINAL CHEMI, BENTHAM SCIENCE PUBLISHERS LTD, HILVERSUM; NL, vol. 5, no. 13, 1 January 2005 (2005-01-01), pages 1191-1203, XP009083872, ISSN: 1568-0266, DOI: 10.2174/156802605774463051;;LAUREN M. SMITH ET AL: ""Interferon-[beta] Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever"", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 208, no. 2, 15 July 2013 (2013-07-15) , pages 310-318, XP55439746, CHICAGO, IL. ISSN: 0022-1899, DOI: 10.1093/infdis/jis921",ACTIVE
205,US,A1,US 2021/0106604 A1,106-703-102-274-710,2021-04-15,2021,US 202017001512 A,2020-08-24,US 202017001512 A;;US 201816105859 A;;US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/106-703-102-274-710,Patent Application,yes,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,0,0,,,,ACTIVE
206,CN,A,CN 104813107 A,151-715-742-725-786,2015-07-29,2015,CN 201380040414 A,2013-06-04,IB 2013001858 W;;US 201261655316 P;;US 201313908576 A,2012-06-04,Water recovery system and method with liquid desiccant,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,JOHNSON BRENT P;;BALL JAMES;;BECZE CHARLES;;BLATT DAVID;;FLYNN MICHAEL;;TELTZ RICHARD,,https://lens.org/151-715-742-725-786,Patent Application,no,8,23,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F24F3/14;;B01D53/18;;B01D53/26;;B01D53/28,,0,0,,,,ACTIVE
207,US,B2,US 10780105 B2,117-070-783-560-203,2020-09-22,2020,US 201816105859 A,2018-08-20,US 201816105859 A;;US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",JANSSEN BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/117-070-783-560-203,Granted Patent,yes,88,3,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A01N43/04;;A61K31/70;;A61K31/7052;;A61K31/706;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,40,15,045-553-904-833-295;;038-991-544-045-020;;076-899-709-794-748;;117-868-360-058-820;;026-060-348-038-076;;057-300-792-956-759;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;088-800-936-812-806;;020-498-789-715-173;;015-172-418-744-935;;029-409-167-046-876;;026-537-378-582-916;;044-973-700-542-810,18336927;;10.1016/j.antiviral.2008.01.152;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1111/j.1471-4159.1986.tb12982.x;;3941313;;10.1016/s0140-6736(10)60357-1;;pmc7138079;;20511019;;10.1086/514316;;9988190;;10.1016/0003-9861(72)90537-1;;5045935;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;23966302;;10.1126/scitranslmed.3006608;;10.1126/scitranslmed.3003876;;22700957;;10.2174/156802605774463051;;16305526;;10.1016/j.antiviral.2014.03.018;;24713118;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s,"Office Action dated Jul. 14, 2017 for U.S. Appl. No. 15/427,964, filed Feb. 8, 2017.;;Examination Report dated Jun. 6, 2018 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Search Report and Form 18 dated Sep. 20, 2018 for ARIPO Application No. AP/P/2016/009653, filed Jun. 22, 2015.;;Office Action dated Oct. 23, 2018 for Chinese Application No. 201580045400.7 filed Jun. 22, 2015.;;Bausch et al., “Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions,” Antiviral Research (2008) 150-161.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses” ACS Medicinal Chemistry Letters,(2013) 4(8):747-751.;;Derivative, Merriam-Webster.com, Merriam-Webster, n.d. Web. Jun. 2, 2016.;;Dyck, et al. “Effects of Deuterium Substitution on the Catabolism of beta-Phenylethylamine: An in Vivo Study”, J Neurochem. 1986; 46(2): 399-404.;;Geisbert, T.W. et al., “Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study” The Lancet (2010) 375(9729):1896-1905.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;Huggins et al., “Antiviral Drug Therapy of Filovirus Infections: S-Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus In Vitro and in a Lethal Mouse Model” Journal of Infectious Disease (1999) 179 (Suppl. 1):S240-S247.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)* Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.;;McOmie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pages only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Pettitt, J., et al., “Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monocolonal Antibody Cocktail” Sci Transl Med (2013) 5(199):199ra113 (1-6).;;Qiu, X., et al., “Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies” Sci Transl Med (2012) 4(138):138ra81 (1-11).;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76 (10):3782-3790.;;Simons et al., “Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics” Current Topics in Medicinal Chemistry (2005) 5(13):1191-1203.;;Smith et al., “Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever” Journal of Infectious Diseases (2013) 208(2):310-318.;;Tung, R., “The development of deuterium-containing drugs” Innovations in Pharmaceutical Technology 2010; 32(32):24-28.;;Uebelhoer et al., “High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses” Antiviral Research (2014) 106:86-94.;;Villard et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Preliminary Report on Patentability dated Jan. 5, 2017 for PCT Application No. PCT/US2015/036958 filed Jun. 22, 2015.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/036958, filed Jun. 22, 2015.;;Office Action dated Jun. 10, 2016 for U.S. Appl. No. 14/746,138, filed Jun. 22, 2015.;;Examination Report dated Jun. 7, 2017 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Office Action dated Aug. 11, 2017 for Eurasian Application No. 201692537, filed Jun. 22, 2015.;;Search Report and Written Opinion dated Jul. 11, 2017 for SG Application No. 11201610597Q, filed Jun. 22, 2015.;;Examination Report dated Jan. 9, 2018 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Extended European Search Report dated Jan. 22, 2018 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Office Action dated May 22, 2019 for Israeli Patent Application No. 249627, filed Jun. 22, 2015.;;Examination Report dated Jan. 2, 2019 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Search Report and Form 21 dated Mar. 26, 2019 for ARIPO Application No. AP/P/2016/009653, filed Jun. 22, 2015.;;Office Action dated Jul. 30, 2019 for Japanese Patent Application No. 2016-575325, filed Jun. 22, 2015.;;Office Action and Search Report dated Apr. 23, 2019 for TW Application No. 104120407, filed Jun. 24, 2015.",ACTIVE
208,AU,A1,AU 2015/280234 A1,126-450-038-328-763,2017-01-12,2017,AU 2015/280234 A,2015-06-22,US 201462034629 P;;US 201462016219 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/126-450-038-328-763,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
209,EP,A1,EP 3160475 A1,020-660-182-490-505,2017-05-03,2017,EP 15810951 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,"JANSSEN PHARMACEUTICALS, INC. (2023-12-20);;JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/020-660-182-490-505,Patent Application,yes,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
210,US,B2,US 6607500 B2,107-662-978-913-845,2003-08-19,2003,US 85344001 A,2001-05-10,US 85344001 A;;US 35042699 A,1999-07-08,Integrated cast and muscle stimulation system,"
    The present invention is a device that allows electrical stimulation to an anatomical site that is covered by a cast. The electrode is applied to achieve a desired physiological response (e.g., bone growth), treatment of pain, or the prevention of muscle atrophy. 
",CYCLOTEC ADVANCED MEDICAL TECH,DA SILVA LUIZ B;;WEBER MICHAEL R;;BLATT DAVID I;;MANNHEIMER JEFFREY S,KEY MEDICAL LLC (2007-03-30);;CYCLOTEC ADVANCED MEDICAL TECHNOLOGIES INC (2001-09-11);;ALTA MEDICAL SOLUTIONS LLC (2007-04-04),https://lens.org/107-662-978-913-845,Granted Patent,yes,9,60,3,3,0,A61N1/0452;;A61N1/0456;;A61N1/0464;;A61N1/0472;;A61N1/32;;A61N1/326;;A61N1/36003;;A61N1/36021;;A61N1/36003;;A61N1/0464;;A61N1/0452;;A61N1/326;;A61N1/32;;A61N1/36021;;A61N1/0472;;A61N1/0456,A61N/;;A61N1/04;;A61N1/32;;A61N1/34;;A61N1/36,602/2;;607/51;;607/115;;607/149;;600/386;;206/438,0,0,,,,EXPIRED
211,US,B2,US 11590155 B2,100-363-175-203-247,2023-02-28,2023,US 202017001512 A,2020-08-24,US 202017001512 A;;US 201816105859 A;;US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",JANSSEN PHARMACEUTICA NV,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/100-363-175-203-247,Granted Patent,yes,96,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A01N43/04;;A61K31/70;;A61K31/7052;;A61K31/706;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,45,15,045-553-904-833-295;;038-991-544-045-020;;076-899-709-794-748;;117-868-360-058-820;;026-060-348-038-076;;057-300-792-956-759;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;088-800-936-812-806;;020-498-789-715-173;;015-172-418-744-935;;029-409-167-046-876;;026-537-378-582-916;;044-973-700-542-810,18336927;;10.1016/j.antiviral.2008.01.152;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1111/j.1471-4159.1986.tb12982.x;;3941313;;10.1016/s0140-6736(10)60357-1;;pmc7138079;;20511019;;10.1086/514316;;9988190;;10.1016/0003-9861(72)90537-1;;5045935;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;23966302;;10.1126/scitranslmed.3006608;;10.1126/scitranslmed.3003876;;22700957;;10.2174/156802605774463051;;16305526;;10.1016/j.antiviral.2014.03.018;;24713118;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s,"Bausch et al., “Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions,” Antiviral Research (2008) 150-161.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses”ACS Medicinal Chemistry Letters, (2013) 4(8):747-751.;;Derivative, Merriam-Webster.com, Merriam-Webster, n.d. Web. Jun. 2, 2016.;;Dyck, et al. “Effects of Deuterium Substitution on the Catabolism of beta-Phenylethylamine: An in Vivo Study”, J Neurochem. 1986; 46(2): 399-404.;;Geisbert, T.W. et al., “Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study” The Lancet (2010) 375(9729):1896-1905.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;Huggins et al., “Antiviral Drug Therapy of Filovirus Infections: S-Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus In Vitro and in a Lethal Mouse Model” Journal of Infectious Disease (1999) 179 (Suppl. 1):S240-S247.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids) Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.;;McOmie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pages only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Pettitt, J., et al., “Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monocolonal Antibody Cocktail” Sci Transl Med (2013) 5(199):199ra113 (1-6).;;Qiu, X., et al., “Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies” Sci Transl Med (2012) 4(138):138ra81 (1-11).;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′-α-fluoro-2′- β -C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76 (10):3782-3790.;;Simons et al., “Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics” Current Topics in Medicinal Chemistry (2005) 5(13):1191-1203.;;Smith et al., “Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever” Journal of Infectious Diseases (2013) 208(2):310-318.;;Tung, R., “The development of deuterium-containing drugs” Innovations in Pharmaceutical Technology 2010; 32(32):24-28.;;Uebelhoer et al., “High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses” Antiviral Research (2014) 106:86-94.;;VILLARD et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Preliminary Report on Patentability dated Jan. 5, 2017 for PCT Application No. PCT/US2015/036958 filed Jun. 22, 2015.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/036958, filed Jun. 22, 2015.;;Office Action dated Jun. 10, 2016 for U.S. Appl. No. 14/746,138, filed Jun. 22, 2015.;;Examination Report dated Jun. 7, 2017 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Office Action dated Aug. 11, 2017 for Eurasian Application No. 201692537, filed Jun. 22, 2015.;;Search Report and Written Opinion dated Jul. 11, 2017 for SG Application No. 11201610597Q, filed Jun. 22, 2015.;;Examination Report dated Jan. 9, 2018 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Extended European Search Report dated Jan. 22, 2018 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Office Action dated Jul. 14, 2017 for U.S. Appl. No. 15/427,964, filed Feb. 8, 2017.;;Examination Report dated Jun. 6, 2018 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Search Report and Form 18 dated Sep. 20, 2018 for ARIPO Application No. AP/P/2016/009653, filed Jun. 22, 2015.;;Office Action dated Oct. 23, 2018 for Chinese Application No. 201580045400.7 filed Jun. 22, 2015.;;Examination Report dated Jan. 2, 2019 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Search Report and Form 21 dated Mar. 26, 2019 for ARIPO Application No. AP/P/2016/009653, filed Jun. 22, 2015.;;Office Action and Search Report dated Apr. 23, 2019 for TW Application No. 104120407, filed Jun. 24, 2015.;;Office Action dated May 22, 2019 for Israeli Patent Application No. 249627, filed Jun. 22, 2015.;;Office Action dated Jul. 30, 2019 for Japanese Patent Application No. 2016-575325, filed Jun. 22, 2015.;;Examination Report dated Sep. 9, 2019 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Examination Report dated Mar. 25, 2020 for AU Application No. 2015280234, filed Dec. 15, 2016.;;Office Action dated Sep. 19, 2019 for U.S. Appl. No. 16/105,859, filed Aug. 20, 2018.;;Office Action dated Jun. 12, 2020 for Chinese Application No. 201580045400.7 filed Jun. 22, 2015.;;European Examination Report dated Jul. 27, 2020, for European Application No. 15810951.2, 3 pages.",ACTIVE
212,US,A1,US 2007/0133830 A1,135-705-209-665-78X,2007-06-14,2007,US 30005905 A,2005-12-14,US 30005905 A,2005-12-14,Low profile liquid sealed audio component assembly,"The invention concerns a low profile, liquid sealed audio component assembly ( 100 ). The assembly can include a seal ( 112 ) having an opening ( 114 ), a membrane ( 120 ) that can cover the opening and that can substantially block liquid from entering the seal and an audio component ( 122 ) contained within the seal and positioned outside a coverage area (C) underneath the membrane. The membrane can transfer acoustic signals to or from the audio component. In addition, the coverage area underneath the membrane can correspond to the area of the membrane that can receive acoustic signals. As an example, the audio component can be a microphone.",VERNE ADEMA D;;BLATT DAVID I;;NGUYEN BACH L;;NOGUEIRAS EDUARDO;;MORRIS ORRETTE,VERNE ADEMA D;;BLATT DAVID I;;NGUYEN BACH L;;NOGUEIRAS EDUARDO;;MORRIS ORRETTE,MOTOROLA INC (2005-12-09),https://lens.org/135-705-209-665-78X,Patent Application,yes,5,10,1,1,0,H04R1/083;;H04R1/086;;H04R2499/11;;H04R1/083;;H04R1/086;;H04R2499/11,H04R5/02,381/308,0,0,,,,DISCONTINUED
213,WO,A1,WO 2015/200205 A1,178-384-691-000-166,2015-12-30,2015,US 2015/0036958 W,2015-06-22,US 201462061819 P;;US 201462034629 P;;US 201462016219 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/178-384-691-000-166,Patent Application,yes,21,16,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,13,7,029-409-167-046-876;;060-046-399-831-084;;015-172-418-744-935;;077-295-491-167-117;;020-498-789-715-173;;117-868-360-058-820;;022-668-731-415-436,10.1016/j.antiviral.2014.03.018;;24713118;;20639507;;10.1177/1087057110374357;;10.2174/156802605774463051;;16305526;;10.1002/0471220574;;10.1126/scitranslmed.3003876;;22700957;;10.1016/s0140-6736(10)60357-1;;pmc7138079;;20511019;;10.1021/jo200060f;;21469736,"UEBELHOER LUKE S ET AL., ANTIVIRAL RESEARCH, vol. 106, 5 April 2014 (2014-04-05), pages 86 - 94;;REKHA G. PANCHAL ET AL., JOURNAL OF BIOMOLECULAR SCREENING, US, vol. 15, no. 7, 1 August 2010 (2010-08-01), pages 755 - 765;;HUGGINS JOHN ET AL.: ""JOURNAL OF INFECTIOUS DISEASES"", 1 February 1999, UNIVERSITY OF CHICAGO PRESS;;SIMONS C ET AL.: ""CURRENT TOPICS IN MEDICINAL CHEMI"", vol. 5, 1 January 2005, BENTHAM SCIENCE PUBLISHERS LTD, article ""RECENT ADVANCES IN ANTIVIRAL NUCLEOSIDE AND NUCLEOTIDE THERAPEUTICS"", pages: 1191 - 1203;;LAUREN M. SMITH ET AL., JOURNAL OF INFECTIOUS DISEASES. JID, CHICAGO, IL, vol. 208, no. 2, 15 July 2013 (2013-07-15), pages 310 - 318;;BIOCHEM., vol. 11, 1972, pages 942 - 944;;T. W. GREENEP. G. M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;PETTITT, J. ET AL., SCI TRANSL MED, vol. 5, no. 199, 21 August 2013 (2013-08-21), pages 199ral 13;;QIU, X. ET AL., SCI TRANSL MED, vol. 4, no. 138, 13 June 2012 (2012-06-13), pages 138ra81;;GEISBERT, T.W. ET AL., THE LANCET, vol. 375, no. 9729, 29 May 2010 (2010-05-29), pages 1896 - 1905;;REDDY ET AL., J. ORG. CHEM., vol. 76, no. 10, 2011, pages 3782 - 3790;;See also references of EP 3160475A4",PENDING
214,AR,A1,AR 083069 A1,092-515-460-086-141,2013-01-30,2013,AR P110103444 A,2011-09-21,US 38542510 P;;US 201061426467 P,2010-09-22,ANALOGOS DE NUCLEOTIDOS SUSTITUIDOS,"Métodos de sintetización de fosforoamidatos análogos de nucleótidos y métodos de tratamiento de enfermedades y/o afecciones tales como infecciones virales, cáncer y/o enfermedades parasitarias con los fosforoamidatos análogos de nucleótidos.Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo en donde B1 es una base heterocíclica opcionalmente sustituida o una base heterocíclica opcionalmente sustituida con uno o más grupos amino protegidos; R1 es un aminoácido unido a N opcionalmente sustituido o un derivado de éster de aminoácido unido a N opcionalmente sustituido; R2 se selecciona del grupo que consiste en un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido y un heterociclilo opcionalmente sustituido; R3a y R3b se seleccionan independientemente del grupo que consiste en hidrógeno, un alquilo C1-6 opcionalmente sustituido, un alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, haloalquilo C1-6 opcionalmente sustituido y aril(alquilo C1-6), siempre que al menos uno de R3a y R3b no sea hidrógeno; o R3a y R3b se toman juntos para formar un grupo que se selecciona del grupo que consiste en un cicloalquilo C3-6 opcionalmente sustituido, cicloalquenilo C3-6 opcionalmente sustituido, arilo C3-6 opcionalmente sustituido y un heteroarilo C3-6 opcionalmente sustituido; R4 es hidrógeno; R5 se selecciona del grupo que consiste en hidrógeno, -OR9 y -OC(=O)R10; R6 se selecciona del grupo que consiste en hidrógeno, halógeno, -OR11 y -OC(=O)R12; o R5 y R6 son ambos átomos de oxígeno y están unidos mediante un grupo carbonilo; R7 se selecciona del grupo que consiste en hidrógeno, halógeno, alquilo C1-6 opcionalmente sustituido, -OR13 y -OC(=O)R14; R8 es hidrógeno o un alquilo C1-6 opcionalmente sustituido; R9, R11 y R13 se seleccionan independientemente del grupo que consiste en hidrógeno y un alquilo C1-6 opcionalmente sustituido; y R10, R12 y R14 se seleccionan independientemente del grupo que consiste en un alquilo C1-6 opcionalmente sustituido y un cicloalquilo C3-6 opcionalmente sustituido; siempre que un compuesto de fórmula (1) no pueda tener un estructura que se selecciona del grupo que consiste cualquiera del grupo de fórmulas (2).",ALIOS BIOPHARMA INC,DYATKINA NATALIA;;WANG GUANGYI;;RAJWANSHI VIVEK;;BEIGELMAN LEONID;;SMITH DAVID BERNARD;;BLATT LAWRENCE,,https://lens.org/092-515-460-086-141,Patent Application,no,0,0,4,5,0,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K38/21;;A61K45/06;;C07H19/067;;C07H19/167;;A61P31/00;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P35/00;;A61P35/02;;Y02A50/30;;C07H19/067;;A61K31/708;;A61K45/06;;C07H19/167;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61K31/7076;;Y02A50/30,C07H19/10;;A61K31/7064;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/20,,0,0,,,,PENDING
215,US,A1,US 2015/0366887 A1,090-833-614-137-564,2015-12-24,2015,US 201514746138 A,2015-06-22,US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/090-833-614-137-564,Patent Application,yes,0,35,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076,,2,1,045-553-904-833-295,18336927;;10.1016/j.antiviral.2008.01.152,"Bausch et al. Antiviral Research (2008), Vol. 78, pages 150-161.;;""Derivative."" Merriam-Webster.com. Merriam-Webster, n.d. Web. 2 June 2016.",ACTIVE
216,EP,A4,EP 3160475 A4,039-065-999-041-425,2018-02-21,2018,EP 15810951 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,"JANSSEN PHARMACEUTICALS, INC. (2023-12-20);;JANSSEN BIOPHARMA, INC. (2019-04-10)",https://lens.org/039-065-999-041-425,Search Report,no,5,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,6,5,029-409-167-046-876;;060-046-399-831-084;;026-060-348-038-076;;015-172-418-744-935;;006-141-882-295-311,10.1016/j.antiviral.2014.03.018;;24713118;;20639507;;10.1177/1087057110374357;;10.1086/514316;;9988190;;10.2174/156802605774463051;;16305526;;10.1093/infdis/jis921;;pmc3685222;;23255566,"UEBELHOER LUKE S ET AL: ""High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses"", ANTIVIRAL RESEARCH, vol. 106, 5 April 2014 (2014-04-05), pages 86 - 94, XP028653124, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2014.03.018;;REKHA G. PANCHAL ET AL: ""Development of High-Content Imaging Assays for Lethal Viral Pathogens"", JOURNAL OF BIOMOLECULAR SCREENING, vol. 15, no. 7, 1 August 2010 (2010-08-01), US, pages 755 - 765, XP055439118, ISSN: 1087-0571, DOI: 10.1177/1087057110374357;;HUGGINS JOHN ET AL: ""Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model"", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 179, no. SUPPL. 1, 1 February 1999 (1999-02-01), pages S240 - S247, XP002574255, ISSN: 0022-1899;;SIMONS C ET AL: ""RECENT ADVANCES IN ANTIVIRAL NUCLEOSIDE AND NUCLEOTIDE THERAPEUTICS"", CURRENT TOPICS IN MEDICINAL CHEMI, BENTHAM SCIENCE PUBLISHERS LTD, HILVERSUM; NL, vol. 5, no. 13, 1 January 2005 (2005-01-01), pages 1191 - 1203, XP009083872, ISSN: 1568-0266, DOI: 10.2174/156802605774463051;;LAUREN M. SMITH ET AL: ""Interferon-[beta] Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever"", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 208, no. 2, 15 July 2013 (2013-07-15), CHICAGO, IL., pages 310 - 318, XP055439746, ISSN: 0022-1899, DOI: 10.1093/infdis/jis921;;See also references of WO 2015200205A1",ACTIVE
217,PH,A1,PH 12016502563 A1,079-044-557-835-074,2017-04-17,2017,PH 12016502563 A,2016-12-21,US 201462034629 P;;US 201462016219 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;LEONID BEIGELMAN;;NATALIA DYATKINA;;ALEXANDER SYMONS JULIAN;;BERNARD SMITH DAVID,,https://lens.org/079-044-557-835-074,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7076;;A61K31/7068;;A61K31/7072;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
218,WO,A2,WO 2002/089903 A2,146-544-629-696-122,2002-11-14,2002,US 0214921 W,2002-05-10,US 85344001 A,2001-05-10,INTEGRATED CAST AND MUSCLE STIMULATION SYSTEM,"The present invention is a device that allows electrical stimulation to an anatomical site that is covered by a cast. The electrode is applied to achieve a desired physiological response (e.g., bone growth), treatment of pain, or the prevention of muscle atrophy.",CYCLOTEC ADVANCED MEDICAL TECH,DA SILVA LUIZ B;;WEBER MICHAEL R;;BLATT DAVID I;;MANNHEIMER JEFFREY S,,https://lens.org/146-544-629-696-122,Patent Application,yes,0,0,3,3,0,A61N1/0452;;A61N1/0456;;A61N1/0464;;A61N1/0472;;A61N1/32;;A61N1/326;;A61N1/36003;;A61N1/36021;;A61N1/36003;;A61N1/0464;;A61N1/0452;;A61N1/326;;A61N1/32;;A61N1/36021;;A61N1/0472;;A61N1/0456,A61N/;;A61N1/04;;A61N1/32;;A61N1/34;;A61N1/36,,0,0,,,,PENDING
219,CN,A,CN 106604734 A,119-097-861-409-043,2017-04-26,2017,CN 201580045400 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/119-097-861-409-043,Patent Application,no,4,3,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
220,US,A1,US 2017/0112945 A1,164-862-908-802-019,2017-04-27,2017,US 201615332572 A,2016-10-24,US 201615332572 A;;US 201562285226 P,2015-10-22,Anchoring and/or Impregnation of Biological Vehicles with Cargo Molecules using a Subcritical or Supercritical Fluid,"A method and a composition of matter formed in accordance with the method for anchoring and/or impregnation of a biological vehicle with a cargo molecule includes mixing the biological vehicle and the cargo molecule in suspension to create a cargo molecule and biological vehicle mixture, placing the cargo molecule and biological vehicle mixture inside a pressure vessel, subjecting the cargo molecule and biological vehicle mixture to subcritical or supercritical fluid, returning pressure and temperature within the pressure vessel to ambient conditions, and recovering a biological vehicle bound cargo molecule.",NOVASTERILIS INC,FEY JULIEN P;;BLATT KELLY M S;;BURNS DAVID C;;EISENHUT ANTHONY R,NOVASTERILIS INC (2016-10-21),https://lens.org/164-862-908-802-019,Patent Application,yes,7,1,1,1,0,A61K49/0097;;A61K35/74;;A61K49/0097,A61K39/395;;A61K35/74,,2,2,037-435-196-561-577;;037-435-196-561-577,10.1111/j.1541-4337.2010.00126.x;;33467829;;10.1111/j.1541-4337.2010.00126.x;;33467829,"Jamshidian et al. 2010 (Poly-Lactic Acid: Production, Applications, Nanocomposites, and Release Studies; Comprehensive Reviews in Food Science and Safety 9:552-571);;Jamshidian et al. 2010 (Poly-Lactic Acid: Production, Applications, Nanocomposites, and Release Studies; Comprehensive Reviews in Food Science and Safety 9:552-571)",DISCONTINUED
221,US,B2,US 9603863 B2,153-751-700-024-86X,2017-03-28,2017,US 201514746138 A,2015-06-22,US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/153-751-700-024-86X,Granted Patent,yes,53,34,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/70;;A01N43/04;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,18,11,045-553-904-833-295;;038-991-544-045-020;;117-868-360-058-820;;057-300-792-956-759;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;088-800-936-812-806;;020-498-789-715-173;;026-537-378-582-916;;044-973-700-542-810,18336927;;10.1016/j.antiviral.2008.01.152;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1016/s0140-6736(10)60357-1;;pmc7138079;;20511019;;10.1016/0003-9861(72)90537-1;;5045935;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;23966302;;10.1126/scitranslmed.3006608;;10.1126/scitranslmed.3003876;;22700957;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s,"Bausch et al. Antiviral Research (2008), vol. 78, pp. 150-161.;;“Derivative.” Merriam-Webster.com. Merriam-Webster, n.d. Web. Jun. 2, 2016.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates As Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses” ACS Medicinal Chemistry Letters,(2013) 4(8):747-751.;;Geisbert, T.W. et al., “Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study” The Lancet (2010) 375(9729):1896-1905.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)* Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;Mcomie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pages only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Pettitt, J., et al., “Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monocolonal Antibody Cocktail” Sci Transl Med (2013) 5(199):199ra113 (1-6).;;Qiu, X., et al., “Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies” Sci Transl Med (2012) 4(138):138ra81 (1-11).;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76 (10):3782-3790.;;Villard et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/036958, filed Jun. 22, 2015.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.",ACTIVE
222,AP,A0,AP 2016009653 A0,069-569-753-168-677,2016-12-31,2016,AP 2016009653 A,2015-06-22,US 201462034629 P;;US 201462016219 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/069-569-753-168-677,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7076;;A61K31/7068;;A61K31/7072;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
223,AU,B2,AU 2015/280234 B2,153-152-452-782-834,2021-04-01,2021,AU 2015/280234 A,2015-06-22,US 201462034629 P;;US 201462016219 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/153-152-452-782-834,Granted Patent,no,1,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,ACTIVE
224,MX,A,MX 2016017381 A,167-737-288-597-451,2017-08-14,2017,MX 2016017381 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF.","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;SMITH DAVID BERNARD;;NATALIA DYATKINA;;JULIAN ALEXANDER SYMONS,,https://lens.org/167-737-288-597-451,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
225,SG,A,SG 11201610597Q A,064-885-783-035-86X,2017-01-27,2017,SG 11201610597Q A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF",,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/064-885-783-035-86X,Unknown,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
226,TW,A,TW 201613613 A,082-132-438-885-165,2016-04-16,2016,TW 104120407 A,2015-06-24,US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/082-132-438-885-165,Patent of Addition,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
227,US,B2,US 10052342 B2,150-333-606-555-049,2018-08-21,2018,US 201715427964 A,2017-02-08,US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"Substituted nucleosides, nucleotides and analogs thereof","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/150-333-606-555-049,Granted Patent,yes,69,15,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A01N43/04;;A61K31/70;;A61K31/7052;;A61K31/706;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,32,16,026-060-348-038-076;;026-060-348-038-076;;015-172-418-744-935;;029-409-167-046-876;;045-553-904-833-295;;038-991-544-045-020;;076-899-709-794-748;;117-868-360-058-820;;057-300-792-956-759;;048-856-832-965-666;;040-895-383-437-294;;060-046-399-831-084;;088-800-936-812-806;;020-498-789-715-173;;026-537-378-582-916;;044-973-700-542-810,10.1086/514316;;9988190;;10.1086/514316;;9988190;;10.2174/156802605774463051;;16305526;;10.1016/j.antiviral.2014.03.018;;24713118;;18336927;;10.1016/j.antiviral.2008.01.152;;24015326;;pmc3763849;;10.1021/ml4001497;;10.1111/j.1471-4159.1986.tb12982.x;;3941313;;10.1016/s0140-6736(10)60357-1;;pmc7138079;;20511019;;10.1016/0003-9861(72)90537-1;;5045935;;7562927;;10.1021/jm00020a007;;10.1021/jm800594c;;18714981;;20639507;;10.1177/1087057110374357;;23966302;;10.1126/scitranslmed.3006608;;10.1126/scitranslmed.3003876;;22700957;;10.1016/j.bmc.2008.06.024;;18585917;;18189407;;10.1021/ol702890s,"Huggins et al. JID (1999), vol. 179 (Suppl 1), pp. S240-S247.;;Examination Report dated Jan. 9, 2018 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Huggins et al., “Antiviral Drug Therapy of Filovirus Infections: S-Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus In Vitro and in a Lethal Mouse Model” Journal of Infectious Disease (1999) 179 (Suppl. 1):S240-S247.;;Simons et al., “Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics” Current Topics in Medicinal Chemistry (2005) 5(13):1191-1203.;;Smith et al., “Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever” Journal of Infectious Diseases (2013) 208(2):310-318.;;Uebelhoer et al., “High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses” Antiviral Research (2014) 106:86-94.;;Extended European Search Report dated Jan. 22, 2018 for EP Application No. 15810951.2, filed Jun. 22, 2015.;;Bausch et al., “Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions,” Antiviral Research (2008) 150-161.;;Bondada, L. et al., “Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses” ACS Medicinal Chemistry Letters,(2013) 4(8):747-751.;;Derivative, Merriam-Webster.com, Merriam-Webster, n.d. Web. Jun. 2, 2016.;;Dyck, et al. “Effects of Deuterium Substitution on the Catabolism of beta-Phenylethylamine: An in Vivo Study”, J Neurochem. 1986; 46(2): 399-404.;;Geisbert, T.W. et al., “Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study” The Lancet (2010) 375(9729):1896-1905.;;Greene, et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;“IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)* Revised Recommendations (1971)” Biochemistry. (1972) 11(5) :942-944.;;Katritzky et al., Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-α-Aminoacyl)benzotriazoles Synthesis (2004) 2004(16):2645-2652.;;Lefebre et al., “Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-Monophosphate” J. Med. Chem. (1995) 38:3941-3950.;;Lewin, Benjamin, Genes V, (1994) Oxford University Press, pp. 87-90.;;McOmie, J. F. W., Protective Groups in Organic Chemistry, Plenum Press, 1973. Cover & Contents pp. only.;;McGuigan et al., “Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discover” J. Med. Chem. (2008) 51:5807-5812.;;Panchal et al., “Development of High-Content Imaging Assays for Lethal Viral Pathogens” J. Biomolecular Screening (2010) 15(7):755-765.;;Pettitt, J., et al., “Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monocolonal Antibody Cocktail” Sci Transl Med (2013) 5(199):199ra113 (1-6).;;Qiu, X., et al., “Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies” Sci Transl Med (2012) 4(138):138ra81 (1-11).;;Reddy et al., “Stereoselective Synthesis of PSI-352938: A β-D-2′-Deoxy-2′α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV” J. Org. Chem. (2011) 76 (10):3782-3790.;;Tung, R., “The development of deuterium-containing drugs” Innovations in Pharmaceutical Technology 2010; 32(32):24-28.;;Villard et al., “Phenyl phosphotriester derivaties of AZT: Variations upon the SATE moiety” Bioorg. Med. Chem. (2008) 16:7321-7329.;;Zhang et al., “Click-Connected Ligand Scaffolds: Macrocyclic Chelates for Asymmetric Hydrogenation” Org. Lett. (2008) 10:545-548.;;International Preliminary Report on Patentability dated Jan. 5, 2017 for PCT Application No. PCT/US2015/036958 filed Jun. 22, 2015.;;International Search Report and Written Opinion dated Aug. 6, 2015 for PCT Application No. PCT/US2015/036958, filed Jun. 22, 2015.;;Office Action dated Jun. 10, 2016 for U.S. Appl. No. 14/746,138, filed Jun. 22, 2015.;;Examination Report dated Jun. 7, 2017 for New Zealand Patent Application No. 727582, filed Jun. 22, 2015.;;Office Action dated Aug. 11, 2017 for Eurasian Application No. 201692537, filed Jun. 22, 2015.;;Search Report and Written Opinion dated Jul. 11, 2017 for SG Application No. 11201610597Q, filed Jun. 22, 2015.",ACTIVE
228,WO,A3,WO 2013/182911 A3,075-842-241-383-359,2014-02-20,2014,IB 2013001858 W,2013-06-04,US 201261655316 P;;US 201313908576 A,2012-06-04,WATER RECOVERY SYSTEM AND METHOD WITH LIQUID DESICCANT,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124;;JOHNSON BRENT P,JOHNSON BRENT P;;BALL JAMES;;BECZE CHARLES;;BLATT DAVID;;FLYNN MICHAEL;;TELTZ RICHARD,,https://lens.org/075-842-241-383-359,Search Report,yes,5,0,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F24F3/14;;B01D53/18;;B01D53/26;;B01D53/28,,1,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"HUNG B N ET AL: ""Integration of desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate"", BIOSYSTEMS ENGINEERING, ACADEMIC PRESS, UK, vol. 102, no. 1, 1 January 2009 (2009-01-01), pages 75 - 82, XP025799314, ISSN: 1537-5110, [retrieved on 20081128], DOI: 10.1016/J.BIOSYSTEMSENG.2008.09.029",PENDING
229,US,A1,US 2019/0054108 A1,160-102-024-294-20X,2019-02-21,2019,US 201816105859 A,2018-08-20,US 201816105859 A;;US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/160-102-024-294-20X,Patent Application,yes,0,11,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076,,0,0,,,,ACTIVE
230,CA,A1,CA 2952959 A1,170-903-429-579-951,2015-12-30,2015,CA 2952959 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,USE OF NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE VIRAL INFECTION,"Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/170-903-429-579-951,Patent Application,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
231,MA,A,MA 40031 A,092-079-411-059-771,2015-12-30,2015,MA 40031 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;DYATKINA NATALIA;;SMITH DAVID BERNARD;;SYMONS JULIAN ALEXANDER,,https://lens.org/092-079-411-059-771,Unknown,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
232,CA,C,CA 2952959 C,153-164-434-859-824,2023-03-07,2023,CA 2952959 A,2015-06-22,US 201462016219 P;;US 201462034629 P;;US 201462061819 P;;US 2015/0036958 W,2014-06-24,USE OF NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE VIRAL INFECTION,"Disclosed herein are nucleoside or nucleotide analog compounds and uses of same for ameliorating or treating diseases such as viral infections, The compound has the structure: where RlA is selected from the group consisting of hydrogen, an optionally substituted acyl, an unsubstituted 0-linked a-amino acid, and .",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,,https://lens.org/153-164-434-859-824,Granted Patent,no,0,0,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/14,,0,0,,,,PENDING
233,US,A1,US 2002/0016618 A1,162-814-018-534-121,2002-02-07,2002,US 85344001 A,2001-05-10,US 85344001 A;;US 35042699 A,1999-07-08,Integrated cast and muscle stimulation system,"
   The present invention is a device that allows electrical stimulation to an anatomical site that is covered by a cast. The electrode is applied to achieve a desired physiological response (e.g., bone growth), treatment of pain, or the prevention of muscle atrophy. 
",CYCLOTEC ADVANCED MEDICAL TECH,DA SILVA LUIZ B;;WEBER MICHAEL R;;BLATT DAVID I;;MANNHEIMER JEFFREY S,KEY MEDICAL LLC (2007-03-30);;CYCLOTEC ADVANCED MEDICAL TECHNOLOGIES INC (2001-09-11);;ALTA MEDICAL SOLUTIONS LLC (2007-04-04),https://lens.org/162-814-018-534-121,Patent Application,yes,0,27,3,3,0,A61N1/0452;;A61N1/0456;;A61N1/0464;;A61N1/0472;;A61N1/32;;A61N1/326;;A61N1/36003;;A61N1/36021;;A61N1/36003;;A61N1/0464;;A61N1/0452;;A61N1/326;;A61N1/32;;A61N1/36021;;A61N1/0472;;A61N1/0456,A61N/;;A61N1/04;;A61N1/32;;A61N1/34;;A61N1/36,607/72,0,0,,,,EXPIRED
234,US,A1,US 2017/0143751 A1,177-506-137-459-283,2017-05-25,2017,US 201715427964 A,2017-02-08,US 201715427964 A;;US 201514746138 A;;US 201462016219 P;;US 201462034629 P;;US 201462061819 P,2014-06-24,"SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF","Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.",ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;DYATKINA NATALIA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD,JANSSEN PHARMACEUTICALS INC (2023-04-06);;JANSSEN PHARMACEUTICA NV (2022-03-22);;JANSSEN BIOPHARMA LLC (2021-12-31),https://lens.org/177-506-137-459-283,Patent Application,yes,0,18,30,30,0,A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61P31/14;;A61K31/708;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/7052;;A61K31/706;;A61K31/7064,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708,,1,1,026-060-348-038-076,10.1086/514316;;9988190,"Huggins et al. JID (1999), Vol. 179 (Suppl 1), pages S240-S247.",ACTIVE
235,WO,A1,WO 1998/010851 A1,120-719-779-652-14X,1998-03-19,1998,US 9715765 W,1997-09-08,US 70790796 A,1996-09-11,SEPARATION AND PURIFICATION OF FLUORIDE FROM INDUSTRIAL WASTE,"A method for the removal and purification of substantially all of the fluoride ions contained in a solution containing greater than 10 parts per million (ppm) fluoride ion, a mixture of other anions, silicon in the form of a fluorosilicic acid, silicic acid, silicates, or silicon tetrafluoride, and optionally also containing complex metal fluorides, to produce an ultrapure hydrofluoric acid, comprising the steps of: (a) adjusting the pH of the solution (10) to an alkaline pH to hydrolyze the fluorosilicic acid and any complex metal fluorides; (b) removing the fluoride ions and other anions from the solution by passing the solution through an ion exchange resin (90), where the ion exchange resin is adapted to adsorb substantially all of the fluoride passed over the ion exchange resin; (c) displacing the fluoride ions and other anions bound to the ion exchange resin, thereby forming a mixture of anions in an effluent emanating from resin; (d) optionally concentrating the effluent at a high pH and then lowering the pH; and (e) distilling (145) the mixture of anions in the effluent from a sulfuric acid solution to generate ultrapure hydrofluoric acid. An apparatus useful for practising the method is also disclosed.",IPEC CLEAN INC,KRULIK GERALD A;;ADAMS JOHN A;;DORNISCH DIETER;;PERSICHINI DAVID W;;BLATT CHRISTOPHER S,,https://lens.org/120-719-779-652-14X,Patent Application,yes,2,3,3,3,0,C01B7/191;;C01B7/196;;C02F1/04;;C02F1/42;;C02F1/583;;C02F1/60;;C02F1/66;;C02F9/00;;C02F2101/14;;C02F2103/346;;Y02C20/30;;C02F9/00;;C01B7/196;;C02F1/60;;C02F1/42;;C02F2101/14;;C02F2103/346;;C02F1/66;;C02F1/583;;C02F1/04;;C01B7/191;;Y02C20/30,B01D15/04;;C01B7/19;;C02F1/04;;C02F1/42;;C02F1/58;;C02F1/60;;C02F1/66;;C02F9/00,,0,0,,,,PENDING
236,US,A1,US 2012/0070411 A1,055-662-552-409-647,2012-03-22,2012,US 201113236450 A,2011-09-19,US 201113236450 A;;US 38542510 P;;US 201061426467 P,2010-09-22,SUBSTITUTED NUCLEOTIDE ANALOGS,"Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.",BEIGELMAN LEONID;;BLATT LAWRENCE;;WANG GUANGYI;;RAJWANSHI VIVEK KUMAR;;DYATKINA NATALIA;;SMITH DAVID BERNARD;;ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE;;WANG GUANGYI;;RAJWANSHI VIVEK KUMAR;;DYATKINA NATALIA;;SMITH DAVID BERNARD,ALIOS BIOPHARMA INC (2011-10-24),https://lens.org/055-662-552-409-647,Patent Application,yes,0,103,4,5,0,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K38/21;;A61K45/06;;C07H19/067;;C07H19/167;;A61P31/00;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P35/00;;A61P35/02;;Y02A50/30;;C07H19/067;;A61K31/708;;A61K45/06;;C07H19/167;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61K31/7076;;Y02A50/30,A61K38/21;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;A61P31/14;;A61P31/20;;A61P31/22;;C07H19/10;;C07H19/207;;C12N5/071;;C12N9/99,424/85.4;;536/26.7;;536/26.8;;514/47;;514/48;;514/49;;514/51;;435/184;;435/375,0,0,,,,DISCONTINUED
237,WO,A1,WO 2012/040126 A1,031-795-690-392-570,2012-03-29,2012,US 2011/0052219 W,2011-09-19,US 201061426467 P;;US 38542510 P,2010-09-22,SUBSTITUTED NUCLEOTIDE ANALOGS,"Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.",ALIOS BIOPHARMA INC;;BEIGELMAN LEONID;;BLATT LAWRENCE;;WANG GUANGYI;;RAJWANSHI VIVEK KUMAR;;DYATKINA NATALIA;;SMITH DAVID BERNARD,BEIGELMAN LEONID;;BLATT LAWRENCE;;WANG GUANGYI;;RAJWANSHI VIVEK KUMAR;;DYATKINA NATALIA;;SMITH DAVID BERNARD,,https://lens.org/031-795-690-392-570,Patent Application,yes,2,73,4,5,0,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K38/21;;A61K45/06;;C07H19/067;;C07H19/167;;A61P31/00;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P35/00;;A61P35/02;;Y02A50/30;;C07H19/067;;A61K31/708;;A61K45/06;;C07H19/167;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61K31/7076;;Y02A50/30,A61K31/7068;;C07H19/20;;A61K31/7072;;A61K31/7076;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;C07H19/10,,0,0,,,,PENDING
238,TW,A,TW 201215395 A,051-520-222-692-639,2012-04-16,2012,TW 100134048 A,2011-09-21,US 38542510 P;;US 42646710 P,2010-09-22,Substituted nucleotide analogs,"Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE;;WANG GUANGYI;;RAJWANSHI VIVEK KUMAR;;DYATKINA NATALIA;;SMITH DAVID BERNARD,,https://lens.org/051-520-222-692-639,Patent of Addition,no,0,0,1,5,0,Y02A50/30,A61K31/7076;;A61K31/661;;A61P31/14;;C07F9/6561;;C07F9/6571;;C07H19/213,,0,0,,,,PENDING
239,TW,B,TW 342345 B,124-127-467-038-745,1998-10-11,1998,TW 86112976 A,1997-09-08,US 70790796 A,1996-09-11,Method for separation and purification of fluoride from industrial wastes,"A method for the removal and purification of substantially all of the fluoride ions contained in a solution containing greater than 10 parts per million (ppm) fluoride ion, a mixture of other anions, silicon in the form of a fluorosilicic acid, silicic acid, silicates, or silicon tetrafluoride, and optionally also containing complex metal fluorides, to produce an ultrapure hydrofluoric acid, comprising the steps of (a) adjusting the pH of the solution to an alkaline pH to hydrolyze the fluorosilicic acid and any complex metal fluorides; (b) removing the fluoride ions and other anions from the solution by passing the solution through an ion exchange resin, where the ion exchange resin is adapted to absorb substantially all of the fluoride passed over the ion exchange resin; (c) displacing the fluoride ions and other anions bound to the ion exchange resin, thereby forming a mixture of anions in an effluent emanating from resin; and (d) distilling the mixture of anions in the effluent from a sulfuric acid solution to generate ultrapure hydrofluoric acid.",IPEC CLEAN INC,GERALD A KRULIK;;JOHN A ADAMS;;DIETER DORNISCH;;DAVID W PERSICHINI;;CHRISTOPHER S BLATT,,https://lens.org/124-127-467-038-745,Granted Patent,no,0,0,3,3,0,C01B7/191;;C01B7/196;;C02F1/04;;C02F1/42;;C02F1/583;;C02F1/60;;C02F1/66;;C02F9/00;;C02F2101/14;;C02F2103/346;;Y02C20/30;;C02F9/00;;C01B7/196;;C02F1/60;;C02F1/42;;C02F2101/14;;C02F2103/346;;C02F1/66;;C02F1/583;;C02F1/04;;C01B7/191;;Y02C20/30,B01D15/04;;C01B7/19;;C02F1/04;;C02F1/42;;C02F1/58;;C02F1/60;;C02F1/66;;C02F9/00,,0,0,,,,EXPIRED
240,US,A,US 5876685 A,039-657-091-671-266,1999-03-02,1999,US 70790796 A,1996-09-11,US 70790796 A,1996-09-11,Separation and purification of fluoride from industrial wastes,"A method for the removal and purification of substantially all of the fluoride ions contained in a solution containing greater than 10 parts per million (ppm) fluoride ion, a mixture of other anions, silicon in the form of a fluorosilicic acid, silicic acid, silicates, or silicon tetrafluoride, and optionally also containing complex metal fluorides, to produce an ultrapure hydrofluoric acid, comprising the steps of (a) adjusting the pH of the solution to an alkaline pH to hydrolyze the fluorosilicic acid and any complex metal fluorides; (b) removing the fluoride ions and other anions from the solution by passing the solution through an ion exchange resin, where the ion exchange resin is adapted to adsorb substantially all of the fluoride passed over the ion exchange resin; (c) displacing the fluoride ions and other anions bound to the ion exchange resin, thereby forming a mixture of anions in an effluent emanating from resin; (d) optionally concentrating the effluent at a high pH and then lowering the pH; and (e) distilling the mixture of anions in the effluent from a sulfuric acid solution to generate ultrapure hydrofluoric acid. An apparatus useful for practicing the method is also disclosed.",IPEC CLEAN INC,KRULIK GERALD A;;ADAMS JOHN A;;DORNISCH DIETER;;PERSICHINI DAVID W;;BLATT CHRISTOPHER S,SPEEDFAM-IPEC CORPORATION (1999-05-26);;IPEC CLEAN INC (1996-08-23);;INTEGRATED PROCESS EQUIPMENT CORP. (IPEC) (1999-05-11);;IPEC PLANAR INC (1998-06-24),https://lens.org/039-657-091-671-266,Granted Patent,yes,10,74,3,3,0,C01B7/191;;C01B7/196;;C02F1/04;;C02F1/42;;C02F1/583;;C02F1/60;;C02F1/66;;C02F9/00;;C02F2101/14;;C02F2103/346;;Y02C20/30;;C02F9/00;;C01B7/196;;C02F1/60;;C02F1/42;;C02F2101/14;;C02F2103/346;;C02F1/66;;C02F1/583;;C02F1/04;;C01B7/191;;Y02C20/30,B01D15/04;;C01B7/19;;C02F1/04;;C02F1/42;;C02F1/58;;C02F1/60;;C02F1/66;;C02F9/00,423/488;;203/41;;210/662;;210/664;;210/683;;423/483,0,0,,,,EXPIRED
241,US,S,US D0587666 S,104-577-791-041-64X,2009-03-03,2009,US 28176207 F,2007-06-29,US 28176207 F,2007-06-29,Communication device,,MOTOROLA INC,PAGE MICHAEL J;;BLATT DAVID I;;CASTANEDA JULIO C;;MOTTA-VEIGA DANIEL;;THETARD ETIENNE,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2007-07-05),https://lens.org/104-577-791-041-64X,Design Right,no,0,0,1,1,0,,,1403;;D14138AA;;D14/248,0,0,,,,EXPIRED
242,UY,A,UY 33619 A,135-042-334-103-060,2012-04-30,2012,UY 33619 A,2011-09-21,US 38542510 P;;US 201061426467 P,2010-09-22,ANALOGOS DE NUCLEOTIDOS SUSTITUIDOS,"Se divulgan en la presente fosforoamidatos análogos de nucleótidos, métodos de sintetización de fos foroamidatos análogos de nucleótidos y métodos de tratamiento de enfermedades y/o afecciones tales como infecciones virales, cáncer y/o enfermedades parasitarias con los fosforoamidatos análogos de n ucleótidos.",ALIOS BIOPHARMA INC,LEONID BEIGELMAN;;LAWRENCE BLATT;;GUANGYI WANG;;NATALIA DYATKINA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD,,https://lens.org/135-042-334-103-060,Patent Application,no,0,0,4,5,0,A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K38/21;;A61K45/06;;C07H19/067;;C07H19/167;;A61P31/00;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P35/00;;A61P35/02;;Y02A50/30;;C07H19/067;;A61K31/708;;A61K45/06;;C07H19/167;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61K31/7076;;Y02A50/30,A61K31/7064;;A61K31/7052;;A61K31/7076;;A61P31/12;;A61P35/00;;C07H19/048;;C07H19/06;;C07H19/10;;C07H19/167,,0,0,,,,DISCONTINUED
243,MX,A,MX 2021005357 A,066-212-399-687-536,2021-06-30,2021,MX 2021005357 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS.,"Various embodiments provide STOPSâ¢ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPSâ¢ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPSâ¢ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BEIGELMAN LEONID;;HONG JIN;;PANDEY RAJENDRA;;BLATT LAWRENCE M,,https://lens.org/066-212-399-687-536,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
244,EP,A1,EP 3853240 A1,177-724-536-292-316,2021-07-28,2021,EP 19880948 A,2019-11-07,US 201862757632 P;;US 2019/0060283 W;;US 201962907845 P;;US 201962855323 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,,ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/177-724-536-292-316,Patent Application,yes,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
245,KR,A,KR 20210090217 A,182-426-504-703-69X,2021-07-19,2021,KR 20217017323 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-항원 수송 저해 올리고뉴클레오타이드 중합체 및 방법,"다양한 실시형태는 S-항원 수송 저해 올리고뉴클레오타이드 중합체인 STOPS™ 중합체, 이를 제조하는 방법 및 질환 및 병태를 치료하기 위해 이를 사용하는 방법을 제공한다. 일부 실시형태에서, STOPS™ 변형된 올리고뉴클레오타이드는 본 명세서에 기재된 바와 같은 변형을 갖는 교대성의 A 단위와 C 단위의 적어도 부분적으로 포스포로티오에이트화된 서열을 포함한다. HBsAg 분비 검정에 의해 결정된 바와 같이, STOPS™ 변형된 올리고뉴클레오타이드의 실시형태의 B형 간염에 대한 서열 독립적 항바이러스 활성은 참조 화합물보다 더 크다.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/182-426-504-703-69X,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/7115;;A61P31/20;;C12N15/113;;C12N15/117,,0,0,,,,PENDING
246,US,A1,US 2022/0125825 A1,012-293-035-273-592,2022-04-28,2022,US 202117511366 A,2021-10-26,US 202117511366 A;;US 202017018822 A;;US 201916676929 A;;US 201962907845 P;;US 201962855323 P;;US 201862757632 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,ALIGOS THERAPEUTICS INC (2020-09-23),https://lens.org/012-293-035-273-592,Patent Application,yes,1,1,3,24,169,C07H21/02;;A61K31/7125;;A61P31/20;;C12N15/1131;;C12N2310/13;;C12N2310/315;;C12N2310/3519;;C12N2310/321;;C12N2310/3515;;C12N2310/3231;;A61K9/0019;;A61K31/7125;;A61K9/0019;;A61P31/20;;C12N15/1131;;C07H21/02,A61K31/7125;;A61K9/00;;A61P31/20;;C07H21/02;;C12N15/113,,0,0,,,,PENDING
247,US,A1,US 2020/0147124 A1,141-109-219-447-889,2020-05-14,2020,US 201916676929 A,2019-11-07,US 201916676929 A;;US 201962907845 P;;US 201962855323 P;;US 201862757632 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,ALIGOS THERAPEUTICS INC (2020-02-20),https://lens.org/141-109-219-447-889,Patent Application,yes,2,13,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,A61K31/7115;;A61K9/00;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/113,,0,0,,,,PENDING
248,WO,A1,WO 2020/097342 A1,185-328-064-182-172,2020-05-14,2020,US 2019/0060283 W,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/185-328-064-182-172,Patent Application,yes,2,19,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,6,5,043-891-252-910-695;;033-441-671-239-794;;009-756-246-081-267;;097-189-122-195-653;;051-011-097-776-001,28918011;;10.1016/j.omtn.2017.04.019;;pmc5466589;;27400989;;10.1016/j.antiviral.2016.07.004;;29212929;;10.1128/jvi.01416-17;;pmc5790928;;10.1038/nbt.3765;;28244990;;pmc5517098;;10.1016/j.chembiol.2012.07.011;;22921062,"ROEHL, INGO ET AL.: ""Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy"", MOLECULAR THERAPY: NUCLEIC ACIDS, vol. 8, 2017, pages 1 - 12, XP055707785, DOI: 10.1016/j.omtn.2017.04.019;;VAILLANT, A.: ""Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection"", ANTIVIRAL RESEARCH, vol. 133, 2016, pages 32 - 40, XP029727986, DOI: 10.1016/j.antiviral.2016.07.004;;BEILSTEIN, F. ET AL.: ""Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro"", JOURNAL OF VIROLOGY, vol. 92, no. 4, 2018, pages 1 - 13, XP055707789, DOI: 10.1128/JVI.01416-17;;KHVOROVA, A. ET AL.: ""The Chemical Evolution of Oligonucleotide Therapies of Clinical Utility"", NATURE BIOTECHNOLOGY, vol. 35, no. 3, 2017, pages 238 - 248, XP055410409, DOI: 10.1038/nbt.3765;;DELEAVEY, G. F. ET AL.: ""Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing"", CHEMISTRY & BIOLOGY, vol. 19, 2012, pages 937 - 954, XP055107150, DOI: 10.1016/j.chembiol.2012.07.011;;See also references of EP 3853240A4",PENDING
249,AU,A1,AU 2019/376079 A1,001-968-669-697-913,2021-05-27,2021,AU 2019/376079 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-antigen transport inhibiting oligonucleotide polymers and methods,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/001-968-669-697-913,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
250,AR,A1,AR 117009 A1,105-236-544-480-54X,2021-07-07,2021,AR P190103255 A,2019-11-06,US 201862757632 P,2018-11-08,POLÍMEROS OLIGONUCLEÓTIDOS QUE INHIBEN EL TRANSPORTE DE ANTÍGENOS Y MÉTODOS,"Varias modalidades proporcionan polímeros STOPSÔ que son oligonucleótidos que inhiben el transporte de antígeno S, procesos para elaborarlos y métodos para usarlos para tratar enfermedades y condiciones. En algunas modalidades los oligonucleótidos modificados STOPSÔ incluyen una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes que tienen modificaciones como se describe en la presente descripción. La actividad antiviral independiente de la secuencia contra hepatitis B de modalidades de oligonucleótidos modificados STOPSÔ, según se determinó por ensayo de secreción de HBsAg, es mayor que la de un compuesto de referencia. Reivindicación 1: Un oligonucleótido o complejo modificado de este que tiene actividad antiviral independiente de la secuencia contra la hepatitis B; caracterizado porque comprende una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes, en donde: las unidades A comprenden uno o más seleccionados de: los compuestos del grupo de fórmulas (1); las unidades C comprenden uno o más seleccionados de: los compuestos del grupo de fórmula (2); cada ~~~O es independientemente hidroxilo, un O,O-dihidrógeno fosforotioato, un dihidrógeno fosfato, un extremo terminal o un grupo de enlace; cada ~~~O interno es un enlace que contiene fósforo a una unidad A o C vecina, el enlace que contiene fósforo es un enlace fosforotioato o un enlace modificado seleccionado de fosfodiéster, fosforoditioato, metilfosfonato, difosforotioato 5’-fosforamidato, 3’,5’-fosfordiamidato, 5’-tiofosforamidato, 3’,5’-tiofosfordiamidato o difosfodiéster; y la actividad antiviral independiente de la secuencia contra la hepatitis B, según se determinó por ensayo de secreción de HBsAg, es mayor que la de un compuesto de referencia; con la condición de que, cuando la secuencia de unidades A y C alternantes comprende una unidad Ribo-A, la secuencia comprende, además, al menos una unidad A que no es una unidad Ribo-A; y con la condición de que, cuando la secuencia de unidades A y C alternantes comprende una unidad Ribo-C, la secuencia comprende, además, al menos una unidad C que no es una unidad Ribo-C.",ALIGOS THERAPEUTICS INC,HONG JIN;;BLATT LAWRENCE M;;SMITH DAVID BERNARD;;RAJWANSHI VIVEK KUMAR;;PANDEY RAJENDRA;;BEIGELMAN LEONID,,https://lens.org/105-236-544-480-54X,Patent Application,no,0,0,1,24,0,,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
251,US,A1,US 2013/0319226 A1,107-944-892-206-686,2013-12-05,2013,US 201213693398 A,2012-12-04,US 201213693398 A;;US 201261655316 P,2012-06-04,DESICCANT CARTRIDGE FOR WATER RECOVERY DEVICE,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A media material absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. The configuration of the media material enables maximal water extraction and is dynamically configurable. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30);;SUN TO WATER TECHNOLOGLIES LLC (2012-10-30),https://lens.org/107-944-892-206-686,Patent Application,yes,17,8,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F24F3/14,95/10;;96/242;;95/26,0,0,,,,ACTIVE
252,US,S,US D0555615 S,152-378-806-548-005,2007-11-20,2007,US 24513505 F,2005-12-19,US 24513505 F,2005-12-19,Communication device,,MOTOROLA INC,LODATO FRANCO;;BLATT DAVID I;;JOSS STEVE M;;NGUYEN BACH L;;ZUFFO MARCELLO;;THETARD ETIENNE,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2005-12-16),https://lens.org/152-378-806-548-005,Design Right,no,0,1,1,1,0,,,1403;;D14/138,0,0,,,,EXPIRED
253,BR,A2,BR 112021008539 A2,012-765-674-127-877,2021-08-03,2021,BR 112021008539 A,2019-11-07,US 2019/0060283 W;;US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s,"várias modalidades fornecem polímeros stops? que são polímeros de oligonucleotídeos que inibem o transporte do antígeno s, processos de produção dos mesmos e métodos de utilização dos mesmos para tratar doenças e condições. em algumas modalidades os oligonucleotídeos modificados stops? incluem uma sequência pelo menos parcialmente fosforotioada de unidades a e c alternadas que têm modificações que são descritas aqui. a atividade antiviral independente da sequência contra hepatite b das modalidades de oligonucleotídeos modificados stops?, que é determinada através do hbsag secretion assay, é maior que aquela de um composto de referência.",ALIGOS THERAPEUTICS INC,DAVID BERNARD SMITH;;JIN HONG;;LAWRENCE M BLATT;;LEONID BEIGELMAN;;RAJENDRA PANDEY;;VIVEK KUMAR RAJWANSHI,,https://lens.org/012-765-674-127-877,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
254,US,A1,US 2006/0246964 A1,096-883-254-964-331,2006-11-02,2006,US 11843605 A,2005-04-29,US 11843605 A,2005-04-29,Electronic device comprising a single hinge twist mechanism and a method to use same,An electronic device ( 100 ) can include a base portion ( 105 ) and a flip portion ( 110 ) moveably attached to the base portion ( 105 ) through a single hinge twist mechanism ( 200 ) such that the flip portion ( 110 ) is capable of rotating about a first axis ( 115 ) to a first open position and twisting about a second axis ( 120 ) to a second open position. The second axis ( 120 ) can be substantially perpendicular to the first axis ( 115 ).,CASTANEDA JULIO C;;BLATT DAVID I;;BURNETTE DONALD W;;MOSKOWITZ DOUGLAS W;;NGUYEN BACH L,CASTANEDA JULIO C;;BLATT DAVID I;;BURNETTE DONALD W;;MOSKOWITZ DOUGLAS W;;NGUYEN BACH L,MOTOROLA INC (2005-04-29),https://lens.org/096-883-254-964-331,Patent Application,yes,8,14,2,2,0,H04M1/0212;;H04M1/0212,A47G19/00;;B65D21/02,455/575.3,0,0,,,,DISCONTINUED
255,CL,A1,CL 2021001202 A1,048-305-044-900-262,2021-12-17,2021,CL 2021001202 A,2021-05-06,US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,Polímeros oligonucleótidos que inhiben el transporte de antígeno s y métodos,"Varias modalidades proporcionan polímeros STOPS™ que son oligonucleótidos que inhiben el transporte de antígeno S, procesos para elaborarlos y métodos para usarlos para tratar enfermedades y condiciones. En algunas modalidades los oligonucleótidos modificados STOPS™ incluyen una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes que tienen modificaciones como se describe en la presente descripción. La actividad antiviral independiente de la secuencia contra hepatitis B de modalidades de oligonucleótidos modificados STOPS™, según se determinó por ensayo de secreción de HBsAg, es mayor que la de un compuesto de referencia.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/048-305-044-900-262,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/02;;C07H21/04,,0,0,,,,PENDING
256,US,A1,US 2020/0405743 A1,071-157-199-559-689,2020-12-31,2020,US 202017018822 A,2020-09-11,US 202017018822 A;;US 201916676929 A;;US 201962907845 P;;US 201962855323 P;;US 201862757632 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,ALIGOS THERAPEUTICS INC (2020-09-23),https://lens.org/071-157-199-559-689,Patent Application,yes,0,1,3,24,0,C07H21/02;;A61K31/7125;;A61P31/20;;C12N15/1131;;C12N2310/13;;C12N2310/315;;C12N2310/3519;;C12N2310/321;;C12N2310/3515;;C12N2310/3231;;A61K9/0019;;A61K31/7125;;A61K9/0019;;A61P31/20;;C12N15/1131;;C07H21/02,A61K31/7125;;A61K9/00;;A61P31/20;;C07H21/02;;C12N15/113,,0,0,,,,ACTIVE
257,US,B2,US 11166976 B2,071-273-751-125-576,2021-11-09,2021,US 202017018822 A,2020-09-11,US 202017018822 A;;US 201916676929 A;;US 201962907845 P;;US 201962855323 P;;US 201862757632 P,2018-11-08,S-antigen transport inhibiting oligonucleotide polymers and methods,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,ALIGOS THERAPEUTICS INC (2020-09-23),https://lens.org/071-273-751-125-576,Granted Patent,yes,65,1,3,24,169,C07H21/02;;A61K31/7125;;A61P31/20;;C12N15/1131;;C12N2310/13;;C12N2310/315;;C12N2310/3519;;C12N2310/321;;C12N2310/3515;;C12N2310/3231;;A61K9/0019;;A61K31/7125;;A61K9/0019;;A61P31/20;;C12N15/1131;;C07H21/02,A61K31/7125;;A61K9/00;;A61P31/20;;C07H21/02;;C12N15/113,,29,26,051-011-097-776-001;;009-410-018-253-145;;060-848-548-319-83X;;009-756-246-081-267;;031-884-424-607-318;;047-635-090-214-701;;051-011-097-776-001;;046-325-711-443-428;;050-201-237-482-445;;050-201-237-482-445;;020-496-881-382-202;;057-010-474-438-715;;026-190-484-845-337;;068-589-105-435-994;;038-361-504-522-113;;021-312-322-733-595;;006-319-746-293-800;;097-189-122-195-653;;006-319-746-293-800;;037-722-022-605-957;;018-088-954-015-282;;043-891-252-910-695;;019-273-663-677-463;;025-590-730-831-720;;033-441-671-239-794;;005-894-064-239-73X,10.1016/j.chembiol.2012.07.011;;22921062;;27257978;;10.1371/journal.pone.0156667;;pmc4892580;;10.1016/s0168-8278(17)30821-8;;29212929;;10.1128/jvi.01416-17;;pmc5790928;;pmc2493138;;10.1128/aac.00279-08;;18505857;;10.1093/nar/25.20.4098;;pmc147004;;9321664;;10.1016/j.chembiol.2012.07.011;;22921062;;7665590;;10.1074/jbc.270.37.21718;;10.1074/jbc.270.6.2620;;7852327;;10.1074/jbc.270.6.2620;;7852327;;10.1021/bi9713557;;9425026;;14976262;;10.1126/science.1093620;;10.1038/374546a0;;7700380;;18022208;;pmc2821746;;10.1016/j.virol.2007.10.016;;pmc3811296;;10.1128/aac.01005-13;;23939904;;10.1371/journal.pone.0140909;;pmc4641618;;26560490;;10.1016/j.bmcl.2016.04.063;;27161280;;10.1038/nbt.3765;;28244990;;pmc5517098;;10.1016/j.bmcl.2016.04.063;;27161280;;10.1038/srep43838;;pmc5341074;;28272460;;10.1080/13543784.2017.1357695;;28730878;;28918011;;10.1016/j.omtn.2017.04.019;;pmc5466589;;29126900;;10.1016/j.antiviral.2017.10.022;;pmc5743593;;10.1080/13543784.2017.1333105;;28521532;;27400989;;10.1016/j.antiviral.2016.07.004;;10.1021/acsinfecdis.8b00156;;30199230,"Deleavey et al. Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing. Chemistry and Biology, 2012; 19(8): 937-954 (Year: 2012).;;Ai-Mahtab, Mamum, et al., “Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection” PLOS ONE (2016) 11 (6), 26 pages.;;Bazinet, Michel, et al., “Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection” The International Liver Congress, EASL 2017, Amsterdam, The Netherlands, Apr. 19-23.;;Beilstein, Frank, et al., “Nucleic acid polymers are active against hepatitis delta virus infection in vitro” Journal of Virology (2018), 92(4).;;Bernstein, et al., “Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo”, Antimicrobial Agents and Chemotherapy (2008), 52(8), 2727-2733.;;Clark, C.L., et al., “CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12-[d/r(GT/U)]12 and the influence of phosphorothioate substitution” Nucleic Acids Research (1997), 25(20), 4098-4105.;;Deleavey, G. F. et al., “Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing”, Chemistry & Biology, 2012, vol. 19, pp. 937-954.;;Fennewald, Susan M. and Robert F. Rando, “Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides” The Journal of Biological Chemistry (1995) vol. 270, No. 37, pp. 21718-21721.;;Guvakova, Marina A., et al., Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast.;;Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix The Journal of Biological Chemistry (1995) vol. 270, No. 6, pp. 2620-2627.;;Hashem, Gihan M., et al., “Hybrid Oligomer Duplexes Formed with Phosphorothioate DNAs: CD Spectra and Melting Temperatures of S-DNA-RNA Hybrids Are Sequence-Dependent but Consistent with Similar Heteronomous Conformations” Biochemistry (1998), 37(1), 61-72.;;Heil, Florian, et al., “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8” Science, (Mar. 5, 2004) vol. 303, 1526-1529.;;Krieg, Arthur M., et al., “CpG motifs in bacterial DNA trigger direct B-cell activation” Nature (Apr. 1995) vol. 374, pp. 546-549.;;Lee, Andrew M., et al., “Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers” Virology (2008), 372(1), 107-117.;;Noordeen, Faseeha, et al., “Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo” Antimicrobial Agents and Chemotherapy (2013), 57(11), 5299-5306.;;Noordeen, Faseeha, et al., “Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection” PLoS One (2015), 10(11).;;Prakash, Thazha P., et al., Synergistic effect of phosphorothioate, 50-vinylphosphonate and.;;Khvorova, A. et al., “The Chemical Evolution of Oligonucleotide Therapies of Clinical Utility”, Nature Biotechnology, 2017, vol. 35 (3), pp. 238-248.;;GalNAc modifications for enhancing activity of synthetic siRNA Bioorganic & Medicinal Chemistry Letters 26 (2016) pp. 2817-2820.;;Real, C. I. et al., “Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells” Sci. Rep. (2017) 7, 43838.;;Rizzetto, “Investigational drugs in development for Hepatitis D”, Expert Opinion on Investigational Drugs (2017) 26:9, 999-1005.;;Roehl, I, et al., “Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy” Molecular Therapy: Nucleic Acids, (2017) vol. 8, pp. 1-12.;;Schoeneweis, et al., “Activity of nucleic acid polymers in rodent models of HBV infection” Antiviral Research (Nov. 2017) vol. 149, pp. 26-33.;;Soriano, et al., “New antivirals for the treatment of chronic hepatitis B” Expert Opinion on Investigational Drugs (2017), 26(7), 843-851.;;Vaillant, Andrew, “Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection” Antiviral Research (2016) vol. 133, pp. 32-40.;;Vaillant, Andrew, “REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection” American Chemical Society, Infectious Diseases (2018).;;Search Report and Written Opinion dated Feb. 17, 2020 in PCT Application No. PCT/US2019/060283 filed Nov. 7, 2019.;;Written Opinion dated May 18, 2020 in PCT Application No. PCT/US2019/060283 filed Nov. 7, 2019.;;International Preliminary Report on Patentability dated Feb. 23, 2021 in PCT Application No. PCT/US2019/060283 filed Nov. 7, 2019.",ACTIVE
258,CN,A,CN 113286803 A,077-083-948-825-622,2021-08-20,2021,CN 201980088039 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS<TM> polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments, the STOPS<TM> modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS<TM> modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/077-083-948-825-622,Patent Application,no,5,1,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,3,2,033-441-671-239-794;;043-891-252-910-695,27400989;;10.1016/j.antiviral.2016.07.004;;28918011;;10.1016/j.omtn.2017.04.019;;pmc5466589,"MARIA J. BUZON ET AL.: ""Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro"", 《 JOURNAL OF VIROLOGY》, vol. 85, no. 18, pages 9646;;REPLICOR INC ET AL.: """"Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection"""", 《ANTIVIRAL RESEARCH》, vol. 133, pages 32 - 40, XP029727986, DOI: 10.1016/j.antiviral.2016.07.004;;ROEHL, INGO ET AL.: """"Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy"""", 《NUCLEIC ACIDS》, vol. 8, pages 1 - 12, XP055707785, DOI: 10.1016/j.omtn.2017.04.019",PENDING
259,SG,A,SG 11202104636X A,131-773-283-385-195,2021-06-29,2021,SG 11202104636X A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,,ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/131-773-283-385-195,Unknown,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
260,CO,A2,CO 2021005762 A2,145-609-240-121-599,2021-07-30,2021,CO 2021005762 A,2021-04-30,US 2019/0060283 W;;US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,Polímeros oligonucleótidos que inhiben el transporte de antígeno s y procedimientos,"Varias modalidades proporcionan polímeros STOPS™ que son oligonucleótidos que inhiben el transporte de antígeno S, procedimientos para elaborarlos y procedimientos para usarlos para tratar enfermedades y condiciones. En algunas modalidades los oligonucleótidos modificados STOPS™ incluyen una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes que tienen modificaciones como se describe en la presente descripción. La actividad antiviral independiente de la secuencia contra hepatitis B de modalidades de oligonucleótidos modificados STOPS™, según se determinó por ensayo de secreción de HBsAg, es mayor que la de un compuesto de referencia.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/145-609-240-121-599,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
261,CA,A1,CA 3117163 A1,010-674-108-464-231,2020-05-14,2020,CA 3117163 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/010-674-108-464-231,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
262,MA,A,MA 53674 A,025-279-202-033-58X,2021-07-28,2021,MA 53674 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,POLYMÈRES OLIGONUCLÉOTIDIQUES INHIBANT LE TRANSPORT DE L'ANTIGÈNE S ET PROCÉDÉS,,ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;HONG JIN;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD,,https://lens.org/025-279-202-033-58X,Unknown,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/02;;C07H21/04,,0,0,,,,PENDING
263,PE,A1,PE 20211783 A1,093-357-568-323-335,2021-09-08,2021,PE 2021000674 A,2019-11-07,US 201862757632 P;;US 201962855323 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,POLIMEROS OLIGONUCLEOTIDOS QUE INHIBEN EL TRANSPORTE DE ANTIGENOS Y METODOS,"Polimeros STOPS™ que son oligonucleotidos que inhiben el transporte de antigeno S, procesos para elaborarlos y metodos para usarlos para tratar enfermedades y condiciones. En algunas modalidades los oligonucleotidos modificados STOPS™ incluyen una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes. La actividad antiviral independiente de la secuencia contra hepatitis B de modalidades de oligonucleotidos modificados STOPS™.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/093-357-568-323-335,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04,,0,0,,,,PENDING
264,US,B2,US 8845795 B2,152-416-545-233-500,2014-09-30,2014,US 201213693398 A,2012-12-04,US 201213693398 A;;US 201261655316 P,2012-06-04,Desiccant cartridge for water recovery device,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A media material absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. The configuration of the media material enables maximal water extraction and is dynamically configurable. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30);;SUN TO WATER TECHNOLOGLIES LLC (2012-10-30),https://lens.org/152-416-545-233-500,Granted Patent,yes,56,4,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B43/00;;F25D21/14,96/112;;96/140;;96/141;;95/117;;95/118;;95/199;;95/223;;95/231,28,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/713,972, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/714,006, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,418, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/693,451, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/723,113, filed Dec. 20, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat. html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/arch ive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec...).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Notice of Allowance for U.S. Appl. No. 13/908,576 mailed Jun. 30, 2014, 8 pages.;;Corrected Notice of Allowance for U.S. Appl. No. 13/713,972, mailed Aug. 1, 2014 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014 11 pages.;;Official Action for U.S. Appl. No. 13/660,572 mailed Jun. 26, 2014, 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014 11 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Jul. 16, 2014, 5 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014 10 pages.;;Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014 11 pages.",ACTIVE
265,US,B1,US 6225998 B1,181-151-336-149-08X,2001-05-01,2001,US 98271697 A,1997-12-02,US 98271697 A,1997-12-02,Visual design of workflows for transaction processing,"A system, method, and article of manufacture for displaying visual primitives of a transaction flow through a transaction processing system. A visual representation of a transaction flow containing visual primitives is accessed from a storage device by a digital computer. The digital computer is then used to display the visual primitives of the transaction flow an a visual display in a flexible manner. The visual primitives can be dynamically sized and may display properties of each visual primitive. Configuration information associated with the transaction flow is also shown on the visual display.",ASPECT COMM,OKITA GLEN K;;AGARWAL SURESH K;;CHAN YIU MAN;;MCCALMONT DAVID T;;BLATT ROBERT A,ASPECT TELECOMMUNICATIONS (1998-04-20);;ASPECT COMMUNICATIONS CORPORATION (1999-09-24);;WILMINGTON TRUST NATIONAL ASSOCIATION AS ADMINISTRATIVE AGENT (2014-11-07);;INTERCONNECT SYSTEMS INC (1997-11-04),https://lens.org/181-151-336-149-08X,Granted Patent,yes,19,225,1,1,0,G06F8/34;;H04M3/51;;H04M3/5166;;H04M3/523;;G06F8/34;;H04M3/523;;H04M3/5166;;H04M3/51;;Y10S707/99943,G06F9/44;;H04M3/51;;H04M3/523,345/356;;345/335;;345/348;;707/102;;707/503,0,0,,,,EXPIRED
266,TW,A,TW 202031267 A,035-399-700-154-594,2020-09-01,2020,TW 108140604 A,2019-11-08,US 201862757632 P;;US 201962855323 P;;US 201962907845 P,2018-11-08,S-antigen transport inhibiting oligonucleotide polymers and methods,"Various embodiments provide STOPS<SP>TM</SP> polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS<SP>TM</SP> modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS<SP>TM</SP> modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/035-399-700-154-594,Patent of Addition,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/02;;C07H21/04,,0,0,,,,PENDING
267,WO,A1,WO 2006/118761 A1,113-910-159-166-118,2006-11-09,2006,US 2006/0013585 W,2006-04-12,US 11843605 A,2005-04-29,AN ELECTRONIC DEVICE COMPRISING A SINGLE HINGE TWIST MECHANISM AND A METHOD TO USE SAME,An electronic device (100) can include a base portion (105) and a flip portion (110) moveably attached to the base portion (105) through a single hinge twist mechanism (200) such that the flip portion (110) is capable of rotating about a first axis (115) to a first open position and twisting about a second axis (120) to a second open position. The second axis (120) can be substantially perpendicular to the first axis (115).,MOTOROLA INC;;CASTANEDA JULIO C;;BLATT DAVID I;;BURNETTE DONALD W;;MOSKOWITZ DOUGLAS W;;NGUYEN BACH L,CASTANEDA JULIO C;;BLATT DAVID I;;BURNETTE DONALD W;;MOSKOWITZ DOUGLAS W;;NGUYEN BACH L,,https://lens.org/113-910-159-166-118,Patent Application,yes,3,0,2,2,0,H04M1/0212;;H04M1/0212,H04B1/08;;H04B1/38;;H05K5/04,,0,0,,,,PENDING
268,EP,A4,EP 3853240 A4,015-035-316-936-441,2022-11-30,2022,EP 19880948 A,2019-11-07,US 201862757632 P;;US 2019/0060283 W;;US 201962907845 P;;US 201962855323 P,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,,ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/015-035-316-936-441,Search Report,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,C07H21/02;;A61K9/00;;A61K31/7115;;A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/04;;C12N15/117,,1,0,,,"NIE YUCHUN ET AL: ""ALG-010133, a Representative S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS TM ) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in Multiple Hepatitis B Virus (HBV) Cell Models"", 1 November 2020 (2020-11-01), XP055972653, Retrieved from the Internet <URL:https://www.aligos.com/wp-content/uploads/2020/11/ALG-010133-S-Antigen-Transport-inhibiting-Oligonucleotide-Polymer-STOPS-effectively-inhibits-HBsAg-secretion-in-multiple-Hepatitis-B-Virus-HBV-cell-models.pdf> [retrieved on 20221018]",PENDING
269,US,A1,US 2006/0148314 A1,065-037-753-405-270,2006-07-06,2006,US 2670904 A,2004-12-30,US 2670904 A,2004-12-30,PCB mounted audio jack,"An audio jack ( 10 ) is provided for being electrically connected with a PCB ( 20 ) and includes a jack body ( 12 ) and a plug port ( 14 ) configured for receiving an audio plug ( 16 ) therein. The jack ( 10 ) further includes a plurality of electrical contacts ( 88, 92, 112 ) for cooperating with corresponding contacts ( 42 ) of the PCB ( 20 ). In one form, the jack body ( 12 ) includes an integral holding portion ( 18 ) configured to engage the PCB ( 20 ) for maintaining the body electrical contacts ( 88, 92, 112 ) in secure electrical contact with the PCB contacts ( 42 ). In another form, gripping members ( 72 - 78 ) are spaced for receiving the PCB ( 20 ) therebetween. In this manner, the audio jack ( 10 ) can slide onto the PCB ( 20 ) for ease of assembly. Preferably, a cut-out opening ( 90 ) in the PCB ( 20 ) is provided and the jack body ( 12 ) is sized to be received therein.",MOTOROLA INC,CASTANEDA JULIO C;;BLATT DAVID I;;BURNETTE DONALD W;;MOSKOWITZ DOUGLAS W;;STASZESKY FRANCIS M,MOTOROLA INC (2005-04-07),https://lens.org/065-037-753-405-270,Patent Application,yes,4,26,1,1,0,H05K1/182;;H01R12/57;;H01R12/57;;H05K1/182,H01R9/05,439/581,0,0,,,,DISCONTINUED
270,PH,A1,PH 12021551007 A1,134-237-748-352-589,2021-10-04,2021,PH 12021551007 A,2021-05-03,US 201962855323 P;;US 201862757632 P;;US 201962907845 P;;US 2019/0060283 W,2018-11-08,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPST polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPST modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPST modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN,,https://lens.org/134-237-748-352-589,Patent Application,no,0,0,19,24,0,A61P31/20;;A61P1/16;;C07H21/02;;C07H21/04;;A61K31/7115;;A61P31/20;;C07H21/02;;A61K9/0019;;C12N2310/315;;C12N2310/17;;C12N15/117;;C12N2310/346;;C12N2310/3231;;C12N2310/323;;C12N2310/3341;;C12N2310/319;;A61K9/0019;;A61K31/7115;;A61K45/06;;A61P31/20;;C07H21/02;;C12N15/1131;;C12N15/117;;C12N2310/11;;C12N2310/17;;C12N2310/315;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;C12N2310/3521;;C12N2310/3525;;C12N2310/3527;;C12N2310/3533;;C12N2310/3535;;C12N2320/31;;C12N2320/35;;C07H21/02;;C12N15/117;;C12N15/1131;;A61K31/7115;;A61P31/20;;C12N2310/315;;C12N2310/17;;C12N2310/319;;C12N2310/323;;C12N2310/3231;;C12N2310/3341;;C12N2310/346;;A61K31/7115;;A61K9/0019;;A61P31/20;;A61K45/06;;C12N2320/35;;C07H21/02;;C12N2310/11;;C12N2320/31;;C12N15/1131,A61K31/712;;A61K31/7125;;A61P1/16;;A61P31/20;;C07H21/02;;C07H21/04,,0,0,,,,PENDING
271,EP,A1,EP 1383782 A1,010-888-811-445-052,2004-01-28,2004,EP 02728566 A,2002-03-26,US 0209187 W;;US 81787901 A;;US 87747801 A;;US 29687601 P;;US 33505901 P;;US 33705501 P,2001-03-26,OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS REPLICATION,,SIRNA THERPEUTICS INC;;BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA,BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA;;LEE PATRICE;;DRAPER KENNETH;;ROBERTS ELISABETH,,https://lens.org/010-888-811-445-052,Patent Application,yes,0,0,5,1181,0,A61K38/21;;A61K38/21;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C12N15/111;;C12N15/111;;C07H21/02;;C07H21/02;;C07H21/04;;C07H21/04;;C12N15/1131;;C12N15/1131;;C12N2310/11;;C12N2310/11;;C12N2310/12;;C12N2310/12;;C12N2310/13;;C12N2310/13;;C12N2310/16;;C12N2310/16;;C12N2310/315;;C12N2310/315;;C12N2310/317;;C12N2310/317;;C12N2310/319;;C12N2310/319;;C12N2310/321;;C12N2310/321;;C12N2310/322;;C12N2310/322;;C12N2310/332;;C12N2310/332;;C12N2310/3519;;C12N2310/3519;;C12N2320/31;;C12N2320/31;;C12N2320/51;;C12N2320/51;;C12Q1/706;;C12Q1/706,A01K67/027;;A61K9/127;;A61K31/513;;A61K31/712;;A61K31/7125;;A61K38/00;;A61K38/21;;A61K38/46;;A61K45/00;;A61K47/24;;A61K47/44;;A61K48/00;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C07H21/02;;C07H21/04;;C12N5/10;;C12N7/00;;C12N9/00;;C12N15/09;;C12N15/11;;C12N15/113;;C12Q1/70,,1,0,,,See references of WO 02081494A1,DISCONTINUED
272,CA,A1,CA 2442092 A1,141-863-914-652-491,2002-10-17,2002,CA 2442092 A,2002-03-26,US 81787901 A;;US 87747801 A;;US 29687601 P;;US 33505901 P;;US 33705501 P;;US 0209187 W,2001-03-26,OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS REPLICATION,"The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes , Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotide s that specifically bind the Enhancer I region of HBV DNA are further disclose d. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV animal models and methods of use are disclosed, including methods of screeni ng for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2',5'-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV).",RIBOZYME PHARM INC,PAVCO PAMELA;;LEE PATRICE;;MORRISSEY DAVID;;DRAPER KENNETH;;ROBERTS ELISABETH;;MCSWIGGEN JAMES;;MACEJAK DENNIS;;BLATT LAWRENCE,,https://lens.org/141-863-914-652-491,Patent Application,no,0,1,5,1181,16207,A61K38/21;;A61K38/21;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C12N15/111;;C12N15/111;;C07H21/02;;C07H21/02;;C07H21/04;;C07H21/04;;C12N15/1131;;C12N15/1131;;C12N2310/11;;C12N2310/11;;C12N2310/12;;C12N2310/12;;C12N2310/13;;C12N2310/13;;C12N2310/16;;C12N2310/16;;C12N2310/315;;C12N2310/315;;C12N2310/317;;C12N2310/317;;C12N2310/319;;C12N2310/319;;C12N2310/321;;C12N2310/321;;C12N2310/322;;C12N2310/322;;C12N2310/332;;C12N2310/332;;C12N2310/3519;;C12N2310/3519;;C12N2320/31;;C12N2320/31;;C12N2320/51;;C12N2320/51;;C12Q1/706;;C12Q1/706,A01K67/027;;A61K9/127;;A61K31/513;;A61K31/712;;A61K31/7125;;A61K38/00;;A61K38/21;;A61K38/46;;A61K45/00;;A61K47/24;;A61K47/44;;A61K48/00;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C07H21/02;;C07H21/04;;C12N5/10;;C12N7/00;;C12N9/00;;C12N15/09;;C12N15/11;;C12N15/113;;C12Q1/70,,0,0,,,,DISCONTINUED
273,US,A1,US 2004/0127446 A1,093-753-762-525-103,2004-07-01,2004,US 66984103 A,2003-09-23,US 66984103 A;;US 0209187 W;;US 81787901 A;;US 74033200 A;;US 61193100 A;;US 50423100 A;;US 27455399 A;;US 25760899 A;;US 87747801 A;;US 69634700 A;;US 63638500 A;;US 53102500 A;;US 43643099 A;;US 19362794 A;;US 88271292 A;;US 29687601 P;;US 33505901 P;;US 33705501 P;;US 35858002 P;;US 36312402 P;;US 10084298 P;;US 8321798 P,1992-05-14,Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication,"
   The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV animal models and methods of use are disclosed, including methods of screening for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2,5-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV). 
",BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA;;LEE PATRICE;;DRAPER KENNETH;;ROBERTS ELISABETH,BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA;;LEE PATRICE;;DRAPER KENNETH;;ROBERTS ELISABETH,SIRNA THERAPEUTICS INC (2004-01-08),https://lens.org/093-753-762-525-103,Patent Application,yes,48,40,1,1181,16207,A61K38/21;;C07H19/10;;C07H19/20;;C07H21/00;;C07K14/005;;C12N15/111;;C12N15/113;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N15/85;;C12N15/86;;C12N2310/11;;C12N2310/111;;C12N2310/12;;C12N2310/121;;C12N2310/122;;C12N2310/13;;C12N2310/14;;C12N2310/16;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/319;;C12N2310/321;;C12N2310/322;;C12N2310/332;;C12N2310/346;;C12N2310/3519;;C12N2310/3521;;C12N2310/3531;;C12N2310/3533;;C12N2310/3535;;C12N2310/53;;C12N2320/31;;C12N2320/51;;C12N2730/10122;;C12N2770/24222;;C12N2830/008;;C12P19/30;;C12P19/305;;C12Y104/03003;;C12Y114/19001;;C12Y207/07049;;C12Y207/11001;;C12Y207/11013;;C12Y301/03048;;A61K47/54;;C12P19/305;;C12N2310/3533;;C12N2310/318;;C07K14/005;;C07H19/10;;C12N2310/53;;C12N2310/122;;C12N2310/18;;C12N15/1137;;C12N2320/31;;C12Y114/19001;;C12N15/1131;;C12N2320/51;;C12N2310/3521;;C12Y207/11001;;C12N15/111;;C12N15/86;;C12N2310/11;;C12N2310/315;;C12N2310/319;;C12N2310/322;;C12N2310/3531;;C12Y301/03048;;C12N2830/008;;C12Y207/11013;;C12N2310/111;;C12N2310/321;;C12N15/85;;C12N2310/332;;C12N2310/346;;C12N15/113;;C12N2310/12;;C12Y104/03003;;C12N2310/3519;;C12N2310/121;;C12N2310/13;;C07H21/00;;C12Y207/07049;;C12N2310/16;;A61K38/21;;C12N15/1138;;C12N2310/3535;;C07H19/20;;C12N2730/10122;;C12N2770/24222;;C12N2310/14;;C12N2310/317;;C12P19/30;;A61K47/54,A61K38/00;;A61K38/21;;A61K47/48;;C07H19/10;;C07H19/20;;C07H21/00;;C07K14/08;;C12N15/11;;C12N15/113;;C12N15/85;;C12N15/86;;C12P19/30;;C12Q1/68;;C12Q1/70,514/44;;536/23.72,0,0,,,,DISCONTINUED
274,WO,A1,WO 2002/081494 A1,148-824-394-007-79X,2002-10-17,2002,US 0209187 W,2002-03-26,US 81787901 A;;US 87747801 A;;US 29687601 P;;US 33505901 P;;US 33705501 P,2001-03-26,OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS REPLICATION,"The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV animal models and methods of use are disclosed, including methods of screening for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2',5'-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV).",RIBOZYME PHARM INC;;BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA;;LEE PATRICE;;DRAPER KENNETH;;ROBERTS ELISABETH,BLATT LAWRENCE;;MACEJAK DENNIS;;MCSWIGGEN JAMES;;MORRISSEY DAVID;;PAVCO PAMELA;;LEE PATRICE;;DRAPER KENNETH;;ROBERTS ELISABETH,,https://lens.org/148-824-394-007-79X,Patent Application,yes,3,0,5,1181,0,A61K38/21;;A61K38/21;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C12N15/111;;C12N15/111;;C07H21/02;;C07H21/02;;C07H21/04;;C07H21/04;;C12N15/1131;;C12N15/1131;;C12N2310/11;;C12N2310/11;;C12N2310/12;;C12N2310/12;;C12N2310/13;;C12N2310/13;;C12N2310/16;;C12N2310/16;;C12N2310/315;;C12N2310/315;;C12N2310/317;;C12N2310/317;;C12N2310/319;;C12N2310/319;;C12N2310/321;;C12N2310/321;;C12N2310/322;;C12N2310/322;;C12N2310/332;;C12N2310/332;;C12N2310/3519;;C12N2310/3519;;C12N2320/31;;C12N2320/31;;C12N2320/51;;C12N2320/51;;C12Q1/706;;C12Q1/706,A01K67/027;;A61K9/127;;A61K31/513;;A61K31/712;;A61K31/7125;;A61K38/00;;A61K38/21;;A61K38/46;;A61K45/00;;A61K47/24;;A61K47/44;;A61K48/00;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/20;;A61P35/00;;A61P43/00;;C07H21/02;;C07H21/04;;C12N5/10;;C12N7/00;;C12N9/00;;C12N15/09;;C12N15/11;;C12N15/113;;C12Q1/70,,1,1,033-028-311-241-461,10.1006/viro.1994.1627;;7975208,"CHEN M. ET AL.: ""Regulation of hepatitis B virus ENI enhancer activity by hepatocyte-enriched transcription factor HNF3"", VIROLOGY, vol. 205, 1994, pages 127 - 132, XP002955140",PENDING
275,US,S,US D0501189 S,090-373-895-416-943,2005-01-25,2005,US 18611703 F,2003-07-09,US 18611703 F,2003-07-09,Communication device,,MOTOROLA INC,LODATO FRANCO;;BLATT DAVID I;;MOSKOWITZ DOUGLAS W;;STASZESKY FRANCIS M;;ESSLINGER HARTMUT H;;NUK HOWARD,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2004-05-06),https://lens.org/090-373-895-416-943,Design Right,yes,24,7,1,1,0,,,D14/138,0,0,,,,EXPIRED
276,US,A1,US 2013/0319033 A1,083-736-069-828-15X,2013-12-05,2013,US 201213693451 A,2012-12-04,US 201213693451 A;;US 201261655316 P,2012-06-04,DYNAMIC CONTROL OF DESICCANT CONCENTRATIONS IN A WATER RECOVERY DEVICE,"A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray, the concentration of the liquid desiccant may be dynamically changed based on changes within the system. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;FONG GARY;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/083-736-069-828-15X,Patent Application,yes,1,3,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F24F3/14,62/271,0,0,,,,ACTIVE
277,US,B2,US 7801571 B2,013-088-305-949-227,2010-09-21,2010,US 28990905 A,2005-11-30,US 28990905 A,2005-11-30,Multi-use acoustic leak path system,"The invention concerns a mobile communications unit ( 100 ) having at least one transducer ( 120 ) that can broadcast audio through a direct port ( 110 ), at least one leak port ( 114 ) for leak tolerance of the unit, in which the leak port can have a first opening ( 116 ) and a multi-use opening ( 118 ). The multi-use opening can be coupled to the first opening of the leak port to complete a path for the leak port, and the multi-use opening can also receive a part of an accessory. As an example, the mobile unit can be a monolith mobile unit. As another example, the accessory can be a holster having a hook mechanism that fits within the multi-use opening and can secure the mobile communications unit to the holster.",MOTOROLA MOBILITY INC,FRIEDMAN JOSEPH M;;BLATT DAVID I;;CHONG CHUN L;;GELBART SHLOMO;;MUELLER KARL F;;PENROD ERIC S,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2005-11-30),https://lens.org/013-088-305-949-227,Granted Patent,yes,6,5,2,2,0,H04M1/03;;H04M1/6041;;H04M1/6041;;H04M1/03,H04M1/00;;H04R25/00,455/569.1;;379/433.2;;381/184,0,0,,,,INACTIVE
278,US,A1,US 2007/0123312 A1,123-068-812-690-23X,2007-05-31,2007,US 28990905 A,2005-11-30,US 28990905 A,2005-11-30,Multi-use acoustic leak path system,"The invention concerns a mobile communications unit ( 100 ) having at least one transducer ( 120 ) that can broadcast audio through a direct port ( 110 ), at least one leak port ( 114 ) for leak tolerance of the unit, in which the leak port can have a first opening ( 116 ) and a multi-use opening ( 118 ). The multi-use opening can be coupled to the first opening of the leak port to complete a path for the leak port, and the multi-use opening can also receive a part of an accessory. As an example, the mobile unit can be a monolith mobile unit. As another example, the accessory can be a holster having a hook mechanism that fits within the multi-use opening and can secure the mobile communications unit to the holster.",FRIEDMAN JOSEPH M;;BLATT DAVID I;;CHONG CHUN L;;GELBART SHLOMO;;MUELLER KARL F;;PENROD ERIC S,FRIEDMAN JOSEPH M;;BLATT DAVID I;;CHONG CHUN L;;GELBART SHLOMO;;MUELLER KARL F;;PENROD ERIC S,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2005-11-30),https://lens.org/123-068-812-690-23X,Patent Application,yes,6,9,2,2,0,H04M1/03;;H04M1/6041;;H04M1/6041;;H04M1/03,H04M1/00;;H04M9/00,455/569.1;;379/433.02,0,0,,,,INACTIVE
279,US,A1,US 2013/0319022 A1,135-166-746-716-28X,2013-12-05,2013,US 201213693418 A,2012-12-04,US 201213693418 A;;US 201261655316 P,2012-06-04,SURFACE TREATMENTS FOR DESSICANT MEDIA IN A WATER RECOVERY DEVICE,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;FONG GARY;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/135-166-746-716-28X,Patent Application,yes,17,31,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,F25B17/02,62/94;;62/271,0,0,,,,ACTIVE
280,US,B2,US 9039816 B2,023-601-240-404-601,2015-05-26,2015,US 201213693451 A,2012-12-04,US 201213693451 A;;US 201261655316 P,2012-06-04,Dynamic control of desiccant concentrations in a water recovery device,"A system and method to recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray, the concentration of the liquid desiccant may be dynamically changed based on changes within the system. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.",Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;FONG GARY;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/023-601-240-404-601,Granted Patent,yes,62,2,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B37/00;;F25B43/00;;F25D21/14,96/112;;96/140;;96/141;;95/117;;95/118;;95/199;;95/223;;95/231,41,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/713,972, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/714,006, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/693,398, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,418, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/723,113, filed Dec. 20, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wi ki/Waste-heat-rec . . . ).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-futu re-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Website ""Co-Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/co-generation.html.;;Website ""Direct Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/direct-generation.html.;;Website ""Energy Harvesting,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/energy-harvesting.html.;;Website ""Waste Heat Recovery,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/waste-heat-recovery.html.;;Venkatasubramanian, ""Efficient Thermoelectric Power Conversion of Waste Heat for Deplyed Forces (EW-1651),"" SERDP, Arlington, VA, 2012, 3 pages, retrieved from www.serdp.org/content/view/pdf/6791.;;Notice of Allowance for U.S. Appl. No. 13/908,576 mailed Jun. 30, 2014, 8 pages.;;Corrected Notice of Allowance for U.S. Appl. No. 13/713,972, mailed Aug. 1, 2014 4 pages.;;Official Action for U.S. Appl. No. 13/660,572 mailed Jun. 26, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Jul. 16, 2014, 5 pages.;;Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,398, mailed May 16, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014 9 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,418, mailed May 29, 2014 10 pages.;;International Preliminary Report on Patentability for International Patent Application No. PCT/IB2013/001858, mailed Dec. 18, 2014 8 pages.;;Notice of Allowance for U.S. Appl. No. 13/714,006, mailed Dec. 19, 2014 5 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,572, mailed Dec. 4, 2014, 5 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Dec. 23, 2014, 8 pages.;;Restriction Requirement for U.S. Appl. No. 13/723,113, mailed Nov. 12, 2014, 12 pages.;;Notice of Allowance for U.S. Appl. No. 13/723,113, mailed Jan. 27, 2015, 14 pages.;;Official Action for U.S. Appl. No. 13/746,824, mailed Jan. 21, 2015, 7 pages.",ACTIVE
281,US,B2,US 8864883 B2,047-590-034-601-786,2014-10-21,2014,US 201213693418 A,2012-12-04,US 201213693418 A;;US 201261655316 P,2012-06-04,Surface treatments for dessicant media in a water recovery device,A system and method recover water from an ambient airstream. Dehumidification of the airstream is also achieved by removal of the water. A device of the system includes a chamber having a group of trays that hold respective amounts of liquid desiccant in each tray. A foam media absorbs the desiccant to increase an exposed surface of the desiccant to the airstream. Fans and valves are used to control airflow through the device. A charge cycle circulates air through the device to remove water vapor from the airstream. A subsequent extraction cycle removes water collected in the liquid desiccant by a condenser communicating with the chamber. An integral heat exchanger adds heat to the chamber during the extraction cycle. A controller is used to integrate and manage all system functions and input variables to achieve a high efficiency of operational energy use for water collection.,Z124,BECZE CHARLES;;BALL JAMES;;BLATT DAVID;;FLYNN MICHAEL J;;FONG GARY;;LAM KEAN WING KIN;;TELTZ RICHARD,Z124 (2013-04-24);;FLEXTRONICS INTERNATIONAL USA INC (2013-02-25);;SUN TO WATER TECHNOLOGIES LLC (2012-10-30),https://lens.org/047-590-034-601-786,Granted Patent,yes,56,12,32,32,0,B01D53/263;;B01D53/263;;B01D53/263;;B01D53/0454;;B01D53/0454;;B01D53/18;;B01D53/18;;B01D53/26;;B01D53/26;;B01D53/28;;B01D53/28;;B01D53/28;;F24F3/1417;;F24F3/1417;;F25B17/02;;F25B17/02;;F25B37/00;;F25B37/00;;F25B43/00;;F25B43/00;;F25D21/14;;F25D21/14;;Y02B30/62;;Y10T29/49396;;Y10T29/49396;;Y10T29/49826;;Y10T29/49826,B01D53/02;;B01D53/04;;B01D53/18;;B01D53/26;;B01D53/28;;F24F3/14;;F25B17/02;;F25B43/00;;F25D21/14,96/112;;96/140;;96/141;;95/117;;95/118;;95/199;;95/223;;95/231,34,1,147-520-419-562-441,10.1016/j.biosystemseng.2008.09.029,"Website ""Waste Heat Recovery Applications,"" Cool Energy, 2 pages, Jul. 16, 2012 webarchive, retrieved from (web/archive.org/web/20120716024750/htt;://www.coolenergyinc.com/wasteheat.html).;;Website ""Waste heat recovery unit,"" Wikipedia, modified May 28, 2012, retrieved from (web/archive.org/web/20120815192859/http://en.wikipedia.org/wiki/Waste-heat-rec...).;;Bhatia ""Desiccant Cooling Technology Resource Guide,"" Continuing Education and Development, Inc. Jan. 2000, 115 pages.;;U.S. Appl. No. 13/660,499, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/713,972, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/660,525, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/714,006, filed Dec. 13, 2012, Becze et al.;;U.S. Appl. No. 13/693,398, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/660,572, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,602, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,620, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/660,639, filed Oct. 25, 2012, Ball et al.;;U.S. Appl. No. 13/693,451, filed Dec. 4, 2012, Becze et al.;;U.S. Appl. No. 13/723,113, filed Dec. 20, 2012, Becze et al.;;U.S. Appl. No. 13/746,824, filed Mar. 26, 2013, Ball et al.;;Callier ""Military Aircraft May Produce Electricity from Waste Heat,"" RenewableEnergyWorld.com, Oct. 15, 2009, 1 page, found at (www.renewableenergyworld.com/rea/news/article/2009/10/the-future-of-electricity-may-be-found-in-environmentally-friendly-thermoelectric-cells).;;Notice of Allowance for U.S. Appl. No. 13/908,576 mailed Jun. 30, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,572 mailed Jun. 26, 2014, 8 pages.;;Official Action for U.S. Appl. No. 13/660,620 mailed Jul. 16, 2014, 5 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,639, mailed May 30, 2014, 9 pages.;;Corrected Notice of Allowance for U.S. Appl. No. 13/713,972, mailed Aug. 1, 2014, 4 pages.;;Official Action for U.S. Appl. No. 13/693,451 mailed Aug. 19, 2014, 5 pages.;;Hung et al. ""Integration of Desiccant tray unit with internal cooling for aeration of paddy silo in humid tropical climate,"" Biosystems Engineering, Jan. 2009, vol. 102, No. 1, pp. 75-82.;;Website ""Co-Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/co-generation.html.;;Website ""Direct Generation,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/direct-generation.html.;;Website ""Energy Harvesting,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/energy-harvesting.html.;;Website ""Waste Heat Recovery,"" E. Power Generation, Marlow Industries, Inc., 2012, 1 page, retrieved from www.marlow.com/resources/knowledgebase/ii-tem-primary-uses/e-power-generation/waste-heat-recovery.html.;;Venkatasubramanian, ""Efficient Thermoelectric Power Conversion of Waste Heat for Deplyed Forces (EW-1651),"" SERDP, Arlington, VA, 2012, 3 pages, retrieved from www.serdp.org/content/view/pdf/6791.;;International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2013/001858, mailed Dec. 4, 2013 4 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,499, mailed May 9, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/713,972, mailed May 21, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,525, mailed May 12, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/693,398, mailed May 16, 2014 11 pages.;;Notice of Allowance for U.S. Appl. No. 13/660,602, mailed May 14, 2014 11 pages.",ACTIVE
282,TW,A,TW 202237189 A,088-400-330-167-934,2022-10-01,2022,TW 110143150 A,2021-11-19,US 202063116368 P,2020-11-20,Conjugates of S-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting,"Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3' end and/or a 5' end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,,https://lens.org/088-400-330-167-934,Patent of Addition,no,0,0,6,6,0,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K47/54;;A61K31/7115;;A61P1/16;;A61P31/14;;A61P31/20,,0,0,,,,PENDING
283,US,A1,US 2021/0189392 A1,089-495-925-080-687,2021-06-24,2021,US 202017117494 A,2020-12-10,US 202017117494 A;;US 202063054380 P;;US 202063020923 P;;US 201962947401 P,2019-12-12,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC 50 that is less than 100 nM.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN;;FITZGERALD MEGAN ELIZABETH,ALIGOS THERAPEUTICS INC (2021-01-12),https://lens.org/089-495-925-080-687,Patent Application,yes,0,3,3,3,0,C07H21/02;;C07H21/04;;A61P31/14;;A61P31/20;;C12N2310/52;;C12N2310/3341;;C12N2310/346;;C12N2310/3231;;C12N2310/343;;C12N2310/334;;C12N2310/323;;C12N2310/3233;;C12N2310/315;;A61K47/549;;C12N2310/17;;C12N15/117;;C12N15/113;;C12N2310/315;;C12N2310/346;;C12N2310/334;;C12N2310/3233;;C12N2310/333,C12N15/113,,0,0,,,,PENDING
284,US,S,US D0504670 S,194-979-977-904-622,2005-05-03,2005,US 18629603 F,2003-07-14,US 18629603 F,2003-07-14,Communication device,,MOTOROLA INC,LODATO FRANCO;;BLATT DAVID I;;MOSKOWITZ DOUGLAS W;;HOSSEINI SAM V;;YORIO RUDY;;ESSLINGER HARTMUT H;;NUK HOWARD,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2004-05-06),https://lens.org/194-979-977-904-622,Design Right,no,0,0,2,2,0,,,1403;;D14/138,0,0,,,,EXPIRED
285,CA,A1,CA 3200094 A1,088-885-350-514-065,2022-05-27,2022,CA 3200094 A,2021-11-18,US 202063116368 P;;US 2021/0059877 W,2020-11-20,CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING,"Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3' end and/or a 5' end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,,https://lens.org/088-885-350-514-065,Patent Application,no,0,0,6,6,57,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K31/7115;;A61K47/54;;A61K47/55;;A61K47/60;;A61P1/16;;A61P31/14;;A61P31/20,,0,0,,,,PENDING
286,WO,A1,WO 2021/119325 A1,037-339-977-874-883,2021-06-17,2021,US 2020/0064328 W,2020-12-10,US 201962947401 P;;US 202063020923 P;;US 202063054380 P,2019-12-12,S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS,"Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC 50 that is less than 100 nM.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN;;FITZGERALD MEGAN ELIZABETH,,https://lens.org/037-339-977-874-883,Patent Application,yes,5,4,3,3,0,C07H21/02;;C07H21/04;;A61P31/14;;A61P31/20;;C12N2310/52;;C12N2310/3341;;C12N2310/346;;C12N2310/3231;;C12N2310/343;;C12N2310/334;;C12N2310/323;;C12N2310/3233;;C12N2310/315;;A61K47/549;;C12N2310/17;;C12N15/117;;C12N15/113;;C12N2310/315;;C12N2310/346;;C12N2310/334;;C12N2310/3233;;C12N2310/333,C07H21/02;;A61K31/7125;;A61P31/20;;C07H21/04,,2,2,012-033-814-595-469;;033-441-671-239-794,10.1371/journal.pone.0179697;;pmc5479567;;28636622;;27400989;;10.1016/j.antiviral.2016.07.004,"GUILLOT CLÉMENT, MARTEL NORA, BERBY FRANÇOISE, BORDES ISABELLE, HANTZ OLIVIER, BLANCHET MATTHIEU, SUREAU CAMILLE, VAILLANT ANDREW,: ""Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes"", PLOS ONE, 2017, pages 14, XP055837603, DOI: https://doi.org/10.1371/journal.pone.0179697;;VAILLANT, A.: ""Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection"", ANTIVIRAL RESEARCH, vol. 133, 2016, pages 32 - 40, XP029727986, DOI: 10.1016/j.antiviral.2016.07.004",PENDING
287,TW,A,TW 202135832 A,113-354-429-555-865,2021-10-01,2021,TW 109143928 A,2020-12-11,US 201962947401 P;;US 202063020923 P;;US 202063054380 P,2019-12-12,S-antigen transport inhibiting oligonucleotide polymers and methods,"Various embodiments provide STOPS<SP>TM</SP> polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS<SP>TM</SP> modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS<SP>TM</SP> modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;PANDEY RAJENDRA;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M;;HONG JIN;;FITZGERALD MEGAN ELIZABETH,,https://lens.org/113-354-429-555-865,Patent of Addition,no,0,0,3,3,0,C07H21/02;;C07H21/04;;A61P31/14;;A61P31/20;;C12N2310/52;;C12N2310/3341;;C12N2310/346;;C12N2310/3231;;C12N2310/343;;C12N2310/334;;C12N2310/323;;C12N2310/3233;;C12N2310/315;;A61K47/549;;C12N2310/17;;C12N15/117;;C12N15/113;;C12N2310/315;;C12N2310/346;;C12N2310/334;;C12N2310/3233;;C12N2310/333,A61K31/7125;;A61P31/20;;C07H21/00,,0,0,,,,PENDING
288,EP,A1,EP 4247393 A1,154-444-511-935-775,2023-09-27,2023,EP 21895580 A,2021-11-18,US 202063116368 P;;US 2021/0059877 W,2020-11-20,CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING,,ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,,https://lens.org/154-444-511-935-775,Patent Application,yes,0,0,6,6,57,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K31/7115;;A61K47/54;;A61K47/55;;A61K47/60;;A61P1/16;;A61P31/14;;A61P31/20,,0,0,,,,PENDING
289,US,A1,US 2010/0125290 A1,059-335-041-342-054,2010-05-20,2010,US 62025109 A,2009-11-17,US 62025109 A;;US 11647908 P,2008-11-20,GUARDED SURGICAL KNIFE HANDLE,"A guarded surgical knife handle includes a lower handle portion, an upper handle postion, and a button. The lower handle portion includes a blade holder, a proximal pair of lateral shelves, and a distal pair of lateral shelves. The upper handle portion includes a guard portion, a proximal post between the proximal pair of shelves with a first widened post portion wider than the lateral spacing between the shelves, and a distal post between the distal pair of shelves with a second widened post portion wider than the lateral spacing between the shelves. The button has a button waist narrower than the second lateral spacing and a widened button portion below the button waist wider than the second lateral spacing. A bias member connected to the button and at least one of the handle portions provides an upward force on the button.",AUCHTER GREGORY ALLEN;;BERARDI RANDAL LEE;;BLATT EDWIN WARREN;;LANDIS JEFFREY KIRK;;SCHIFF DAVID ROBERT;;GALEWYRICK SETH MCCUE,AUCHTER GREGORY ALLEN;;BERARDI RANDAL LEE;;BLATT EDWIN WARREN;;LANDIS JEFFREY KIRK;;SCHIFF DAVID ROBERT;;GALEWYRICK SETH MCCUE,ALCON RESEARCH LTD (2010-01-18);;ALCON RESEARCH LLC (2019-02-28),https://lens.org/059-335-041-342-054,Patent Application,yes,89,4,2,2,0,A61B17/3211;;A61B17/3211;;A61B2090/0801;;A61B2090/0801;;Y10T83/04;;Y10T83/04,A61B17/32;;B26B3/00,606/167;;30/151,0,0,,,,ACTIVE
290,AU,A1,AU 2021/383758 A1,079-745-309-378-97X,2023-06-15,2023,AU 2021/383758 A,2021-11-18,US 202063116368 P;;US 2021/0059877 W,2020-11-20,CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING,"Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3' end and/or a 5' end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,,https://lens.org/079-745-309-378-97X,Patent Application,no,0,0,6,6,0,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K31/7115;;A61K47/54;;A61K47/55;;A61K47/60;;A61P1/16;;A61P31/14;;A61P31/20,,0,0,,,,PENDING
291,US,A1,US 2022/0160748 A1,160-104-700-368-059,2022-05-26,2022,US 202117455528 A,2021-11-18,US 202117455528 A;;US 202063116368 P,2020-11-20,CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING,"Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3′ end and/or a 5′ end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,ALIGOS THERAPEUTICS INC (2021-11-23),https://lens.org/160-104-700-368-059,Patent Application,yes,7,1,6,6,57,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K31/7088;;A61K47/54;;A61P1/16,,2,1,055-428-645-185-392,26914862;;10.1021/acs.jmedchem.5b01948,E-oligos (Modification : GalNAc. Webpage capture by the Wayback Machine on 31 October 2020. http://www.e-oligos.com/eoweb/products/mod_detail.asp?modid=431) (Year: 2020);;Prakash et al. 2016. Comprehensive Structure−Activity Relationship of Triantennary N‑Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes. J. Med. Chem. 59:2718−2733. (Year: 2016),PENDING
292,WO,A1,WO 2022/109129 A1,028-419-746-115-760,2022-05-27,2022,US 2021/0059877 W,2021-11-18,US 202063116368 P,2020-11-20,CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING,"Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3' end and/or a 5' end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.",ALIGOS THERAPEUTICS INC,BEIGELMAN LEONID;;FITZGERALD MEGAN ELIZABETH;;PANDEY RAJENDRA;;HONG JIN;;RAJWANSHI VIVEK KUMAR;;SMITH DAVID BERNARD;;BLATT LAWRENCE M,,https://lens.org/028-419-746-115-760,Patent Application,yes,5,0,6,6,57,A61K47/555;;A61K47/60;;C12N15/115;;C12N2310/16;;C07H21/04;;A61K47/554;;A61K47/551;;A61K47/549;;A61K47/542;;A61K47/54;;C12N2310/315;;C12N2310/321;;C12N2310/3231;;C12N2310/3341;;C12N2320/32;;A61P1/16;;A61P31/14;;A61P31/20;;C07H21/02;;A61K31/7115;;A61P1/16;;A61K31/7088;;A61K47/542;;A61K47/549;;A61K47/554;;A61K47/551;;C12N2310/351;;C12N2310/3515;;C12N2310/315;;C12N2310/3341;;C12N2310/3231;;C12N2310/17;;C12N15/117;;A61K31/7088;;A61K47/549;;A61K47/543;;A61P1/16;;A61K47/542;;A61K47/547;;A61K47/545,A61K31/7115;;A61K47/54;;A61K47/55;;A61K47/60;;A61P1/16;;A61P31/14;;A61P31/20,,0,0,,,,PENDING
293,US,B2,US 8256330 B2,025-418-288-016-111,2012-09-04,2012,US 62025109 A,2009-11-17,US 62025109 A;;US 11647908 P,2008-11-20,Guarded surgical knife handle,"A guarded surgical knife handle includes a lower handle portion, an upper handle postion, and a button. The lower handle portion includes a blade holder, a proximal pair of lateral shelves, and a distal pair of lateral shelves. The upper handle portion includes a guard portion, a proximal post between the proximal pair of shelves with a first widened post portion wider than the lateral spacing between the shelves, and a distal post between the distal pair of shelves with a second widened post portion wider than the lateral spacing between the shelves. The button has a button waist narrower than the second lateral spacing and a widened button portion below the button waist wider than the second lateral spacing. A bias member connected to the button and at least one of the handle portions provides an upward force on the button.",AUCHTER GREGORY ALLEN;;BERARDI RANDAL LEE;;BLATT EDWIN WARREN;;LANDIS JEFFREY KIRK;;SCHIFF DAVID ROBERT;;GALEWYRICK SETH MCCUE;;ALCON RES LTD,AUCHTER GREGORY ALLEN;;BERARDI RANDAL LEE;;BLATT EDWIN WARREN;;LANDIS JEFFREY KIRK;;SCHIFF DAVID ROBERT;;GALEWYRICK SETH MCCUE,ALCON RESEARCH LTD (2010-01-18);;ALCON RESEARCH LLC (2019-02-28),https://lens.org/025-418-288-016-111,Granted Patent,yes,99,11,2,2,0,A61B17/3211;;A61B17/3211;;A61B2090/0801;;A61B2090/0801;;Y10T83/04;;Y10T83/04,A61B17/32;;B26B3/00,83/13;;30/2;;30/151;;30/329;;606/167,2,0,,,"International Searching Authority, PCT International Preliminary Examination Report, PCT/GB01/01561, May 13, 2002, 2 pages.;;International Searching Authority, PCT International Preliminary Examination Report, PCT/AU03/001187, Jan. 17, 2005, 8 pages.",ACTIVE
294,US,S,US D0588566 S,046-817-691-346-348,2009-03-17,2009,US 29694007 F,2007-10-31,US 29694007 F,2007-10-31,Communication device,,MOTOROLA INC,ZUFFO MARCELLO;;BLATT DAVID I;;BOSVELD PAUL A;;NILSEN RYAN M;;OOI BAN HIN;;PAGE MICHAEL J;;WOLF MONIKA R,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2007-11-01),https://lens.org/046-817-691-346-348,Design Right,no,0,0,1,1,0,,,1403;;D14138AA,0,0,,,,EXPIRED
295,EP,A1,EP 2827876 A1,165-498-912-315-887,2015-01-28,2015,EP 13765011 A,2013-03-12,US 201261614494 P;;US 201261613854 P;;US 2013/0030594 W,2012-03-22,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,,ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,"ALIOS BIOPHARMA, INC. (2015-07-08)",https://lens.org/165-498-912-315-887,Patent Application,yes,0,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/7076;;A61K31/7064;;A61K31/708;;A61P31/12;;A61P31/14,,0,0,,,,DISCONTINUED
296,US,A1,US 2013/0252920 A1,104-463-212-010-959,2013-09-26,2013,US 201313797511 A,2013-03-12,US 201313797511 A;;US 201261613854 P;;US 201261614494 P,2012-03-22,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.,ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,ALIOS BIOPHARMA INC (2013-03-19);;VERTEX PHARMACEUTICALS INC (2013-04-30),https://lens.org/104-463-212-010-959,Patent Application,yes,1,46,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/381;;A61K31/7072;;A61K31/4178;;A61K31/4709;;A61K31/497,514/51;;435/184;;435/375,0,0,,,,INACTIVE
297,HK,A1,HK 1203356 A1,172-755-161-826-683,2015-10-30,2015,HK 15103807 A,2015-04-20,US 2013/0030594 W;;US 201261614494 P;;US 201261613854 P,2012-03-22,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,,https://lens.org/172-755-161-826-683,Patent Application,no,0,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61P/;;A61K/,,0,0,,,,PENDING
298,TW,A,TW 201343170 A,038-539-012-765-034,2013-11-01,2013,TW 102110363 A,2013-03-22,US 201261614494 P;;US 201261613854 P;;US 201313797511 A,2012-03-22,Pharmaceutical combinations comprising a thionucleotide analog,Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.,ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,,https://lens.org/038-539-012-765-034,Patent of Addition,no,0,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/7072;;A61K31/381;;A61K38/07;;A61P31/14,,0,0,,,,PENDING
299,NZ,A,NZ 630805 A,062-891-812-447-352,2016-01-29,2016,NZ 63080513 A,2013-03-12,US 2013/0030594 W;;US 201261613854 P;;US 201261614494 P,2012-03-22,Pharmaceutical combinations comprising a thionucleotide analog,"Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents, Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.",ALIOS BIOPHARMA INC,BEIGELMAN LEONID;;BLATT LAWRENCE M;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,"ALIOS BIOPHARMA, INC., US (2015-06-04)",https://lens.org/062-891-812-447-352,Patent Application,no,0,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/7076;;A61K31/381;;A61K31/4178;;A61K31/4709;;A61K31/497;;A61K31/7064;;A61K31/7072;;A61K31/708;;A61K38/55;;A61P31/12;;A61P31/14,,0,0,,,,DISCONTINUED
300,US,B2,US 9012427 B2,081-803-885-486-447,2015-04-21,2015,US 201313797511 A,2013-03-12,US 201313797511 A;;US 201261613854 P;;US 201261614494 P,2012-03-22,Pharmaceutical combinations comprising a thionucleotide analog,Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.,ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,ALIOS BIOPHARMA INC (2013-03-19);;VERTEX PHARMACEUTICALS INC (2013-04-30),https://lens.org/081-803-885-486-447,Granted Patent,yes,100,36,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A01N43/04;;A61K31/381;;A61K31/4178;;A61K31/4709;;A61K31/497;;A61K31/70;;A61K31/7072;;A61K38/55,514/51;;514/42;;514/43;;514/49;;514/50,99,77,051-579-548-752-159;;110-319-106-372-068;;143-416-286-205-073;;140-578-027-417-744;;031-284-524-180-762;;057-962-693-734-715;;120-425-024-581-28X;;081-476-179-118-721;;049-588-361-219-816;;153-597-067-774-768;;058-595-712-322-746;;015-043-810-024-94X;;040-212-651-377-836;;005-330-622-018-787;;071-473-862-487-031;;086-844-534-180-393;;034-642-993-038-351;;168-654-602-206-563;;092-674-052-866-139;;013-890-637-720-275;;048-738-301-628-84X;;037-852-799-899-435;;059-012-552-396-509;;193-353-936-094-095;;017-550-767-331-926;;023-619-283-155-954;;034-128-501-002-247;;046-084-864-837-925;;009-984-098-577-205;;052-882-411-305-487;;167-774-228-174-644;;090-637-880-030-665;;018-872-439-043-894;;004-570-317-067-722;;126-786-864-208-674;;016-931-389-329-716;;056-294-812-481-793;;035-518-924-033-491;;025-487-308-080-356;;049-709-255-325-605;;130-445-704-730-403;;032-033-590-048-639;;150-189-772-110-201;;020-467-043-889-079;;121-608-552-414-352;;015-018-021-624-948;;012-332-237-050-273;;106-104-390-080-931;;001-760-979-603-588;;003-045-594-389-250;;027-960-586-184-300;;008-289-720-079-361;;098-315-733-729-934;;046-522-902-094-518;;059-178-573-558-079;;166-491-769-036-010;;077-632-731-699-521;;006-004-037-369-941;;042-572-859-668-132;;021-910-520-431-90X;;076-949-961-781-44X;;050-293-228-426-741;;061-850-235-846-996;;122-020-643-263-560;;002-104-329-193-856;;037-553-499-388-924;;071-402-811-994-641;;007-844-806-495-490;;044-716-722-819-684;;003-883-149-691-921;;123-599-642-831-10X;;119-910-506-700-812;;065-492-506-076-371;;099-157-950-995-011;;039-962-627-836-454;;029-288-229-274-113;;052-493-810-458-107,2443829;;10.1016/s0040-4039(01)91444-3;;10.1021/jo01359a027;;10.1021/jo01359a029;;10.1002/chin.198749335;;10.1016/0040-4039(95)01691-a;;10.1080/10426509608054709;;15600240;;10.1080/15257779508012498;;10.1002/0471142700.nc1300s16;;14700625;;10.1016/j.chembiol.2003.11.008;;pmc326506;;10.1093/nar/11.21.7611;;6316265;;7191265;;2833504;;10.1016/s0021-9258(18)60715-x;;10.1080/07328318908054328;;6253037;;10.1139/y80-110;;15134540;;10.2174/1389557043403936;;14216158;;12554735;;10.1074/jbc.m210914200;;4696411;;10.1016/0005-2736(73)90477-x;;1768293;;10.1016/s0040-4039(00)94171-6;;10.1039/c29710000190;;10.1039/p19820000385;;10.1002/recl.19871061106;;10.2174/138955706778742786;;17100638;;10.1128/aac.00186-07;;17502402;;pmc1932539;;10.1080/07328319808004215;;9708319;;pmc3459057;;10.1128/aac.00433-06;;pmc1693996;;17000745;;20175517;;pmc4363086;;10.1021/jm901621h;;10.1002/hlca.200490271;;10.1021/ci0255331;;12377009;;10.1111/j.1432-1033.1995.00480.x;;7705365;;10.1111/j.1432-1033.1995.0480n.x;;10479295;;10.1021/jm990158y;;10.1111/j.1432-1033.1974.tb03682.x;;4434988;;1183438;;10.1111/j.1432-1033.1975.tb02345.x;;619101;;10.1002/jps.2600670134;;pmc7094952;;20410884;;10.1038/nature08960;;14699133;;10.1074/jbc.m308286200;;10.1055/s-2003-40838;;10.1021/jm000073t;;11020285;;10.1016/j.bmc.2004.10.063;;15653328;;10.1021/ci050064z;;16045305;;6965728;;10.1021/jm00175a008;;490534;;10.1021/jm00194a028;;7568331;;11197336;;10.1016/s0968-0896(00)00221-2;;10.1021/jm00352a017;;7143354;;6286970;;10.1021/jm00349a008;;4676271;;10.1021/bi00775a016;;4738935;;10.1021/bi00741a027;;10.1002/ejoc.200600155;;17250831;;10.1016/j.febslet.2006.12.050;;10.1074/jbc.273.10.5557;;9488681;;3383195;;5732303;;5535743;;10.1139/o70-094;;1323681;;10.1021/jm00094a014;;10.1177/095632029600700308;;10.1021/bk-1975-0014.ch003;;10.1002/ddr.1167;;pmc2749248;;10.1021/jm900728u;;19678707;;10.1016/s0008-6215(00)82160-6;;15755661;;10.1016/j.bmc.2005.01.029;;10.1016/0008-6215(92)84160-t;;1797378;;10.1016/j.antiviral.2006.06.001;;16828888;;10.1016/j.bioorg.2008.02.006;;pmc2516375;;18394675;;10.1006/bioo.2001.1226;;11955000;;10.1074/jbc.m606558200;;16873361;;11863434;;10.1021/bi0119823;;1289806;;10.1016/0040-4039(91)80496-s;;10.1021/bi00755a039;;7752196;;pmc3445626;;10.1021/jm00010a017;;3950912;;10.1021/jm00153a003;;6292418;;10.1021/jm00352a016;;10.1016/s0008-6215(97)00007-4,"Aivazashvili et al., Use of 5'-C-methylnucleoside triphosphates in the synthesis of RNA catalyzed by RNA-polymerase of Escherichia coli, MOLBBJ, 1987, vol. 21, Issue 4, pp. 898-908.;;Aivasashvilli et al., Utilization of 5'-C-methylnucleoside triphosphates in RNA synthesis reaction catalyzed by Escherichia coli RNA-polymerase, Molekulyarnaya Biologiya (Moscow), 1987, vol. 21, Issue 4, pp. 1080-1091.;;Aspelund et al., 5-Isopropyl- and 5-propyl-1-methyl-3-phenyldialuric acids, Acta Acad. Aboensis, Math. & Phys., 1958, vol. 21, Issue 11, pp. 3-11.;;Bajwa et al., Thymidine nucleoside 3' ,5'-cyclic phosphoramidites and phosphites-configuration at phosphorus in trivalent and pentavalent cyclic nucleotides by phosphorus-31 and carbon-13 NMR, Tetrahedron Letters, 1978, vol. 5, pp. 421-424.;;Baker et al., Synthesis of potential anticancer agents. VI. Use of the O-benzoyl blocking group from synthesis of 6-chloropurine nucleosides, Journal of Organic Chemistry, 1957, vol. 22, pp. 954-959.;;Baker et al., Synthesis of potential anticancer agents. VII. Nucleosides derived from L-rhamnofuranose, Journal of Organic Chemistry, 1957, vol. 22, pp. 959-966.;;Baker et al., Synthesis of potential anticancer agents. VIII. Nucleosides derived from L-rhamnofuranose, Journal of Organic Chemistry, 1957, vol. 22, pp. 966-971.;;Baraniak et al., Ribonucleoside cyclic 3' ,5'-phosphoramidates: Synthesis, stereochemistry, and conversion into ribonucleoside cyclic 3' ,5'-phosphorothioates and -[180] phosphates, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry, 1987, vol. 8, pp. 1645-1656.;;Baraniak et al., Synthesis of adenosine cyclic 3' ,5'-phosphorofuoridate (cAMP-F), Tetrahedron Letters, 1995, vol. 36, Issue 44, Elsevier, pp. 8119-8122.;;Baraniak, Deoxyribonucleoside cyclic 3' ,5'-phosphorofluoridates phosphorus, Sulfur Silicon Relat. Elem., 1996, vol. 111, pp. 80.;;Beaulieu et al., Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections, Curr. Opin. Invest. Drugs, 2004, vol. 5, Issue 8, pp. 838-850.;;Beigelman et al., Synthesis of 5'-C-methyl-D-allo- & L-talo-ribonucleoside 3'-O-phosphoramidites & their incorporation into hammerhead ribozymes, Nucleosides & Nucleotides, 1995, vol. 14, Issue 5, pp. 901-905.;;Bergstrom, Nucleoside phosphorylation and related modifications, Current Protocols in Nucleic Acid Chemistry, Chapter 13, John Wiley & Sons, 2008, Suppl. 33, pp. 13.0.1-13.0.2.;;Bennett et al., Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system, Chemistry & Biology, 2003, vol. 10, Issue 12, pp. 1173-1181.;;Billich et al., Synthesis, conformation and enzymatic properties of 1- (62-D-allofuranosyl) uracil and some derivatives, Nucleic Acids Research, 1983, vol. 11, Issue 21, pp. 7611-7624.;;Bindal et al., The relationship of vasodilator activity of adenosine analogs with molecular connectivity and van der Waals volume, Arzneimittel-Forschung, 1980, vol. 30, Issue 6, pp. 924-928.;;Botelho et al., Inhibition of cAMP-dependent protein kinase by adenosine cyclic 3' ,5'-phosphorodithioate, a second cAMP antagonist, Journal of Biological Chemistry, 1988, vol. 263, Issue 11, pp. 5301-5305.;;Bottka et al., Evidence for the stereoelectronic control of the acid hydrolysis of adenosine cyclic 3', 5'-phosphoramidate diastereoisomers, Nucleosides & Nucleotides, 1989, vol. 8, Issue 7, pp. 1217-1229.;;Bruns, Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists, Canadian Journal of Physiology and Pharmacology, 1980, vol. 58, Issue 6, pp. 673-691.;;Bundgaard, ""Design of prodrugs"", Elsevier Science Publishers B.V. (1985), Table of Contents only.;;Cahard et al., Aryloxy phosphoramidate triesters as pro-tides, Mini-Reviews in Medicinal Chemistry, 2004, vol. 4, pp. 371-381.;;Cappuccino et al., Growth inhibition of clostridium feseri by carcinostatic purine and pyrimidine analogs. I. Effect of medium on growth inhibition, Cancer Research, 1964, vol. 24, pp. 1243-1248.;;Carroll et al., Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs, Journal of Biological Chemistry, 2003, vol. 278, Issue 14, pp. 11979-11984.;;Carey, Francis, Organic Chemistry, 2nd ed., McGraw Hill, Inc., New York (1992), pp. 328-331.;;CAS RN 486446-48-4, STNEasy, Entry Date Feb. 6, 2003, (https://stneasy.cas.org), retrieved on Nov. 17, 2011.;;CASS et al., Mediated transport of nucleosides by human erythrocytes. Specificity toward purine nucleosides as permeants, Biochemica et Biophysica Acta, Biomembranes, 1973, vol. 291, Issue 3, pp. 734-746.;;Chidgeavadze et al., Synthesis and substrate properties of C-methyl-2'-deoxynucleoside 5'-triphosphates in DNA synthesis reactions catalyzed by DNA polymerases, Bioorganicheskaya Khimiya, 1991, vol. 17, Issue 5, pp. 678-684.;;Chidgeavadze et al., 5'-C- and 3'-C-Methyl-2'-deoxynucleoside 5'-triphosphates and their substrate properties in DNA-polymerase-catalyzed DNA synthesis reactions, Soviet Journal of Bioorganic Chemistry (a translation of Bioorganicheskaya Khimiya), 1992, vol. 17, Issue 5, pp. 389-395.;;Cullis, The stereospecific conversion of p-chiral dialkyl phosphorothioates into 18O-phosphates, Tetrahedron Letters, 1983, vol. 24, Issue 50, pp. 5677-5680.;;Cusack et al., Simple syntheses of glycofuranosylamines derived from D-xylose, D-mannose, and L-rhamnose, intermediates in the preparation of some N-glycofuranosyl uracils, Chemical Communications, 1971, vol. 4, pp. 190-191.;;David et al., Synthesis of the two epimeric 5'-methylcytidines, their 5'-phosphates and [5-3H]-5'-pyrophosphates, and the two 5'-methyldeoxycytidines. A novel cytosine anhydronucleoside with two oxygen bridges between the base and the sugar, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry, 1982, vol. 1, pp. 385-393.;;De Vroom et al., Synthesis of ribonucleoside 3' ,5'-cyclic phosphorothioates using a modified hydroxybenzotriazole phosphotriester approach, Recueil des Travaux Chimiques des Pays-Bas, 1987, vol. 106, Issue 11, pp. 577-580.;;Del Vecchio et al., Small molecule and biologic inhibitors of hepatitis C virus: A symbiotic approach, Mini-Reviews in Medicinal Chemistry, Nov. 2006, vol. 6, Issue 11, pp. 1263-1268.;;Deval et al., Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase, Antimicrobial Agents and Chemotherapy, Aug. 2007, vol. 51, Issue 8, pp. 2920-2928.;;De Zwart et al., A functional screening of adenosine analogs at the adenosine A2B receptor: A search for potent agonists, Nucleosides & Nucleotides, 1998, vol. 17, Issue 6, pp. 969-985.;;Dutartre et al., General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues, Antimicro. Agts. Chemother., 2006, vol. 50, Issue 12, pp. 4161-4169.;;Dzhavadova et al., Molecular and crystal structures of 1-(6-desoxy-beta-D-allofuranosyl) cytosine and 1-(6-desoxy-alpha-L-talofuranosyl) cytosine, Sov. Phys. Crystallog., 1988, vol. 33, Issue 6, pp. 837-841.;;Dzhavadova et al., The molecular and crystal structures of 1-(6-deoxy-beta-D-allofuranosyl) cytosine and 1-(6-deoxy-alpha-L-talofuranosyl) cytosine, Kristallografiya, 1988, vol. 33, Issue 6, pp. 1408-1414.;;Dzhavadova et al., The molecular and crystal structure of 1-(2, 6-dideoxy-alpha-L-lyxo-hexofuranosyl) thymine, Bioorganicheskaya Khimiya, 1989, vol. 15, Issue 7, pp. 976-982.;;Eliahu, S. et al, A Novel Insulin Secretagogue Based on a Dinucleoside Polyphosphate Scaffold, Journal of Medicinal Chemistry, 2010, vol. 53, No. 6, pp. 2472-2481.;;Eppacher et al., Synthesis and incorporation of C(5')-ethynylated uracil-derived phosphoramidites into RNA, Helvetica Chimica Acta, 2004, vol. 87, pp. 3004-3020.;;Estrada et al., In silico studies toward the discovery of new anti-HIV nucleoside compounds with the use of TOPS-MODE and 2D/3D connectivity indices. 1. Pyrimidyl derivatives, Journal of Chemical Information and Computer Sciences, 2002, vol. 42, Issue 5, pp. 1194-1203.;;Feldwisch et al., Purification & characterization of a cAMP-binding protein of Volvox carteri f. nagariensis iyengar, European Journal of Biochemistry, 1995, vol. 228, Issue 2, pp. 480-489.;;Ferrini et al., Free amino acids in the egg of Ciona intestinalis during some development stages, Ricerca Scientifica, Parte 2: Rendiconti, Sezione B: Biologica, 1964, vol. 5, Issue 3, pp. 213-217.;;Fingl et al., The Pharmacological Basis of Therapeutics, 5th ed., MacMillan Publishing Co., Inc. (1975) Chapter 1, General Principles, pp. 1-46.;;Fischer, B. et al., 2-Thioether 5'-o-(1-Thiotriphosphate)adenosine Derivatives as New Insulin Secretagogues Acting through P2Y-Receptors, Journal of Medicinal Chemistry, 1999, vol. 42, No. 18, pp. 3636-3646.;;Follman et al., Novel nucleosides derived from 5'-C-methyl adenosine, Eur. Biophys. Congr., Proc., 1st, 1971, vol. 1, pp. 285-287.;;Follman et al., Adenine nucleosides in solution. Stabilization of the anti-conformation by C-5' substituents, European Journal of Biochemistry, 1974, vol. 47, Issue 1, pp. 187-197.;;Follman et al., Adenine nucleosides in solution: Circular dichroism studies and base conformation, European Journal of Biochemistry, 1975, vol. 58, Issue 1, pp. 31-41.;;Gangjee et al., Vasodilator activity of adenosine analogs, Journal of Pharmaceutical Sciences, 1978, vol. 67, Issue 1, pp. 121-123.;;Gao et al. ""Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect"" Nature (2010) vol. 465, pp. 96-100.;;Gardner et al. ""Comparative Kinetics of Nucleotide Analog Incorporation by Vent DNA Polymerase"" J. Bio. Chem. (2004) 279(12):11834-11842.;;Gimisis et al., Tuning the reactivity of O-tert-butyldimethylsilylimidazolyl aminals towards organolithium reagents, Synlett, 2003, vol. 10, pp. 1451-1454.;;Girardet et al., Synthesis and cytotoxicity of 4-amino-5-oxopyrido [2, 3-d] pyrimidine nucleosides, Journal of Medicinal Chemistry, 2000, vol. 43, Issue 20, pp. 3704-3713.;;Gonzalez et al., A radial distribution function approach to predict A2B agonist effect of adenosine analogues, Bioorganic & Medicinal Chemistry, 2005, vol. 13, Issue 3, pp. 601-608.;;Gopalakrishnan et al., A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models, Journal of Chemical Information and Modeling, 2005, vol. 45, pp. 1101-1108.;;Grant et al., Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides, Journal of Medicinal Chemistry, 1980, vol. 23, Issue 1, pp. 39-42.;;Grant et al., Hexofuranosyladenine nucleosides as substrates and inhibitors of calf intestinal adenosine deaminase, Journal of Medicinal Chemistry, 1979, vol. 22, Issue 8, pp. 1016-1018.;;Greene et al., Protective Groups in Organic Synthesis, 3. Ed., John Wiley & Sons, (1999) Cover & Contents pages.;;Greco et al., ""The search for synergy: a critical review from a response surface perspective"" Pharmacol. Rev. (1995) vol. 47, Issue 2, pp. 331-385.;;Gunic et al., Synthesis & cytotoxicity of 4'-C- and 5'-C-substituted toyocamycins, Bioorganic & Medicinal Chemistry, 2001, vol. 9, Issue 1, pp. 163-170.;;Gurskaya et al., X-ray crystallographic studies of nucleoside analogs. I. The crystal structure of 1-(6-deoxy-beta-D-allofuranosyl) cytosine, C10H15N3O5, Crystal Structure Communications, 1982, vol. 11, Issue 4, pp. 1245-1252.;;Hai et al., Species- or isozyme-specific enzyme inhibitors. 9. Selective effects in inhibitions of rat pyruvate kinase isozymes by adenosine 5'-diphosphate derivatives, Journal of Medicinal Chemistry, 1982, vol. 25, Issue 10, pp. 1184-1188.;;Hai et al., Species- or isozyme-specific enzyme inhibitors. 7. Selective effects in inhibitions of rat adenylate kinase isozymes by adenosine 5'-phosphate derivatives, Journal of Medicinal Chemistry, 1982, vol. 25, Issue 7, pp. 806-812.;;Hampton et al., Substrate properties of cycloadenosines with adenosine aminohydrolase as evidence for the conformation of enzyme-bound adenosine, Biochemistry, 1972, vol. 11, Issue 25, pp. 4736-4739.;;Hampton et al., Interactions of epimeric 5'-C-methyl and 5'-C-carbamyl derivatives of adenosine monophosphate with adenosine monophosphate utilizing enzymes, Biochemistry, 1973, vol. 12, Issue 17, pp. 3328-3332.;;Hayakawa et al., A strategy for the stereoselective preparation of thymidine phosphorothioates with the (R) or the (S) configuration at the stereogenic oligodeoxyribonucleotides with stereochemically pure phosphate/phosphorothioate chimeric backbones, European Journal of Organic Chemistry, 2006, vol. 17, pp. 3834-3844.;;Hayatshahi et al., QSARs and activity predicting models for competitive inhibitors of adenosine deaminase, FEBS Letters, 2007, vol. 581, Issue 3, pp. 506-514.;;Hebert et al., Structural features of the noncatalytic cGMP binding sites of frog photoreceptor phosphodiesterase using cGMP analogs, Journal of Biological Chemistry, 1998, vol. 273, Issue 10, pp. 5557-5565.;;Heinemann et al., Comparison of the cellular pharmacokinetics and toxicity of 2'.2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine, Cancer Research, 1988, vol. 48, pp. 4024-4031.;;Henderson et al., Inhibitors of adenine phosphoribosyltransferase, Cancer Chemotherapy Reports Supplement, 1968, vol. 1, Issue 2, pp. 363-373.;;Henderson et al., Mechanisms of inhibition of adenine phosphoribosyltransferase by adenine nucleosides and nucleotides, Canadian Journal of Biochemistry, 1970, vol. 48, Issue 5, pp. 573-579.;;Hiebl et al., Side-chain derivatives of biologically active nucleosides. Part 1. Side-chain analogs of 3'-azido-3'-deoxythymidine (AZT), Journal of Medicinal Chemistry, 1992, vol. 35, Issue 16, pp. 3016-3023.;;Hiebl et al., Side-chain derivatives of biologically active nucleosides. Part 2: Synthesis and anti-HIV activity of 5'-C-methyl derivatives of 3'-fluoro-3'-deoxythymidine, Antiviral Chemistry and Chemotherapy, 1996, vol. 7, Issue 3, pp. 173-77.;;Higuchi et al., ""Pro-drugs as novel drug delivery systems"", A.C.S. Symposium Series, American Chemical Society, 1975, vol. 14, pp. 154-183.;;Hillaire-Buys, D. et al., Pharmacological Evaluation and Chemical Stability of 2-benzylthieoether-5'-O-(1-thiotriphosphate)-Adenosine, A New Insulin Secretagogue Acting Through P2Y Receptors, Drug Development Research, 2001, vol. 53, No. 1, pp. 33-43.;;Hong, J. A. et al., Identification of Critical Ligand Binding Determinants in Mycrobacterium tuberculosis Adenosine-5'-phosphosulfate Reductase, Journal of Medicinal Chemistry, 2009, vol. 52, No. 17, pp. 5485-5495.;;Howgate et al., Conversion of 2',3'-O-isopropylideneadenosine into 9-(6-deoxy-beta-D-allofuranosyl)- and 9-(6-deoxy-alpha-L-talofuranosyl) adenines, Carbohydrate Research, 1972, vol. 2, pp. 309-315.;;Hrdlicka et al., Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd), Bioorganic & Medicinal Chemistry, 2005, vol. 13, vol. 7, pp. 2597-2621.;;Hrebabecky et al., Synthesis of 1-(3-azido-2,3-dideoxy-B-D-allofuranosyl)thymine, 1-(2,3-dideoxy-B-D-allofuranosyl)thymine, and 1-(2,3-dideoxy-B-D-erythro-hex-2-enofuranosyl)thymine*, Carbohydrate Research, 1991, vol. 216, pp. 179-186.;;Huang et al., Recent development of therapeutics for chronic HCV infection, Antiviral Research, 2006, vol. 71, Issue 2&3, pp. 351-362.;;Hung et al., A New Nonhydrolyzable Reactive cGMP Analogue, (Rp) -Guanosine-3' ,5'-cyclic-S-(4-bromo-2,3-dioxobutyl) monophosphorothioate Which Targets the cGMP Binding Site of Human Platelet PDE3A, Bioorganic Chemistry, 2008, vol. 36, Issue 3, Elsevier Inc., pp. 141-147.;;Hung et al., A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3' ,5'-cyclic-S-(4-bromo-2,3-dioxobutyl) monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase, Bioorganic Chemistry, 2002, vol. 30, vol. 1, pp. 16-31.;;Hung et al., New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: A role for the unique 44-amino acid insert, Journal of Biological Chemistry, 2006, vol. 281, Issue 39, pp. 29236-29244.;;Hung et al., A nonhydrolyzable reactive cAMP analogue, (Sp) -8-[4-bromo-2,3-dioxobutyl) thio]adenosine 3', 5'-cyclic S-(methyl) monophosphorothioate, irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase at micromolar concentrations, Biochemistry, 2002, vol. 41, Issue 9, pp. 2962-2969.;;Iimori et al., A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases, Nucleic Acids Symposium Series, 1992, vol. 27, pp. 169-170.;;Iimori et al., 2'-C-, 3'-C-, and 5'-C-Methylsangivamycins: Conformational lock with the methyl group, Tetrahedron Letters, 1991, vol. 32, Issue 49, pp. 7273-7276.;;IUPAC-IUB Commission on Biochemical Nomenclature, Biochemistry, 1972, vol. 11, pp. 942-944.;;Jacobson et al., Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors, Journal of Medicinal Chemistry, 1995, vol. 38, Issue 10, pp. 1720-1735.;;Kappler et al., Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues, Journal of Medicinal Chemistry, 1986, vol. 29, Issue 3, pp. 318-322.;;Kappler et al., Species- or isozyme-selective enzyme inhibitors. 8. Synthesis of disubstituted two-substrate condensation products as inhibitors of rat adenylate kinases, Journal of Medicinal Chemistry, 1982, vol. 25, Issue 10, pp. 1179-1184.;;Karpeiskii et al., Conformational analogs of nucleotides. V. Synthesis of 5'-C-methylnucleosides from 6-deoxy-D-allose, Bioorganicheskaya Khimiya, 1979, vol. 5, No. 6, pp. 895-905.;;Karpeiskii et al., Conformational analogs of nucleotides. V. Synthesis of 5'-C-methylnucleosides from 6-deoxy-D-allose, Soviet Journal of Bioorganic Chemistry (a translation of Bioorganicheskaya Khimiya), 1979, vol. 5, No. 1, pp. 672-680.;;Karpeiskii et al., Study of substrate specificity of nuclease S1 from Aspergillus oryzae in the hydrolysis of low molecular weight substrates, Bioorganicheskaya Khimiya, 1982, vol. 8, Issue 3, pp. 386-395.;;Karpeiskii et al., A study of substrate specificity of nuclease S1 from Aspergillus oryzae in the hydrolysis of low-molecular-weight substrates, Soviet Journal of Bioorganic Chemistry (a translation of Bioorganicheskaya Khimiya), 1983, vol. 8, Issue 3, pp. 196-204.;;Karpeiskii et al., Snthesis of 5'-C-methyluridines (D-allo and L-talo), 5'-mono-, di- and triphosphates, and dinucleoside phosphates on their basis, Nucleic Acids Symposium Series, 1981, Issue 9, pp. 157-160.;;Karpeiskii et al., Synthesis of 5'-mono-, di- and triphosphates of 5'-C-methyluridines, Bioorganicheskaya Khimiya, 1982, vol. 8, Issue 7, pp. 933-939.;;Karpeiskii et al., Synthesis of 5'-mono-, 5'-di- and 5'-triphosphates of 5'-C-methyluridines, Soviet Journal of Bioorganic Chemistry (a translation of Bioorganicheskaya Khimiya), 1983, vol. 8, Issue 7, pp. 498-504.;;Kett et al., Heterocyclic derivatives of sugars: An NMR study of the formation of 1-glycosyl-3, 5-dimethyl-1H-pyrazoles from hydrazones, Carbohydrate Research, 1997, vol. 299, Issue 3, pp. 129-141.",INACTIVE
301,WO,A1,WO 2013/142159 A1,049-557-117-708-915,2013-09-26,2013,US 2013/0030609 W,2013-03-12,US 201261614501 P;;US 201261613884 P,2012-03-21,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,"Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents, Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.",ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,,https://lens.org/049-557-117-708-915,Patent Application,yes,3,68,1,1,0,A61K31/4178;;A61K31/427;;A61K31/4965;;A61K31/4985;;A61K31/7064;;A61K31/7068;;A61K31/7076;;A61K31/708;;A61P31/12;;A61P31/14,A61K31/7076;;A61K31/381;;A61K31/4178;;A61K31/7064;;A61K31/708;;A61P31/12;;A61P31/14,,0,0,,,,PENDING
302,UY,A,UY 34698 A,145-329-937-684-133,2013-10-31,2013,UY 34698 A,2013-03-20,US 201313797511 A;;US 201261613854 P;;US 201261614494 P,2012-03-22,COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN ANÁLOGO DE TIONUCLEÓTIDOS,"Escanear fórmula (A), página 21/412",ALIOS BIOPHARMA INC;;VERTEX PHARMA,LEONID BEIGELMAN;;BLATT LAWRENCE M;;HUA TAN;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;MIN JIANG;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,,https://lens.org/145-329-937-684-133,Patent Application,no,0,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61P31/14;;A61K31/4178;;A61K31/427;;A61K31/4709;;A61K31/497;;A61K31/7072;;C07D401/14;;C07D403/14;;C07D417/14;;C07H19/073;;C07H19/10,,0,0,,,,PENDING
303,US,B1,US 6243092 B1,181-791-331-330-635,2001-06-05,2001,US 98293897 A,1997-12-02,US 98293897 A,1997-12-02,Transaction flow editing tool,"A system, method, and article of manufacture for editing visual primitives of a transaction flow used by a transaction processing system. A visual representation of a transaction flow containing visual primitives is accessed from a storage device by a digital computer. The visual primitives are then displayed on the visual display. The system then edits the visual primitives in a manner that provides for unrestricted placement of the visual primitives. A visual indicator is displayed if the transaction flow is incomplete. Alphanumeric text can be added to a visual primitive or placed elsewhere within the transaction flow. A connection is automatically established between a pair of visual primitives if the visual primitives overlap one another. Transaction flow templates can be selected and modified by the visual editing system.",ASPECT COMM,OKITA GLEN K;;AGARWAL SURESH K;;BODIE MARGARET K;;LIN FUNG-WAH;;CHAN YIU MAN;;MCCALMONT DAVID T;;BLATT ROBERT A,ASPECT TELECOMMUNICATIONS (1998-04-20);;ASPECT COMMUNICATIONS CORPORATION (1999-09-24);;WILMINGTON TRUST NATIONAL ASSOCIATION AS ADMINISTRATIVE AGENT (2014-11-07),https://lens.org/181-791-331-330-635,Granted Patent,yes,19,141,1,1,0,G06F8/34;;H04M3/51;;H04M3/5166;;H04M3/523;;G06F8/34;;H04M3/523;;H04M3/51;;H04M3/5166;;Y10S715/965;;Y10S715/966,G06F9/44;;H04M3/51;;H04M3/523,345/349;;345/348;;345/965;;345/966;;345/334;;700/83,0,0,,,,EXPIRED
304,WO,A1,WO 2013/142157 A1,108-795-124-641-669,2013-09-26,2013,US 2013/0030594 W,2013-03-12,US 201261613854 P;;US 201261614494 P,2012-03-22,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,"Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents, Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.",ALIOS BIOPHARMA INC;;VERTEX PHARMA,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,,https://lens.org/108-795-124-641-669,Patent Application,yes,2,28,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/7076;;A61K31/7064;;A61K31/708;;A61P31/12;;A61P31/14,,1,0,,,See also references of EP 2827876A4,PENDING
305,EP,A4,EP 2827876 A4,077-960-220-648-071,2015-10-28,2015,EP 13765011 A,2013-03-12,US 201261614494 P;;US 201261613854 P;;US 2013/0030594 W,2012-03-22,PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG,,ALIOS BIOPHARMA INC,BLATT LAWRENCE M;;BEIGELMAN LEONID;;TAN HUA;;SYMONS JULIAN ALEXANDER;;SMITH DAVID BERNARD;;JIANG MIN;;KIEFFER TARA LYNN;;RIJNBRAND CORNELIS ARIE,"ALIOS BIOPHARMA, INC. (2015-07-08)",https://lens.org/077-960-220-648-071,Search Report,no,4,0,10,10,0,A61K38/55;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61P31/12;;A61P31/14;;A61K31/7072;;A61K31/4709;;A61K31/4178;;A61K31/497;;A61K31/381;;A61K38/55,A61K31/7076;;A61K31/7064;;A61K31/708;;A61P31/12;;A61P31/14,,1,0,,,See also references of WO 2013142157A1,DISCONTINUED
306,US,S,US D0587667 S,077-783-598-461-829,2009-03-03,2009,US 28414807 F,2007-08-31,US 28414807 F,2007-08-31,Communication device,,MOTOROLA INC,BUTAN ALINA R;;FUJIMURA TOSHIHIRO;;NILSEN RYAN M;;ROBERTSON JR WILLIAM H;;WOLF MONIKA R;;BOSVELD PAUL;;SAWABINI NADIM M;;BLATT DAVID I,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2008-07-01),https://lens.org/077-783-598-461-829,Design Right,no,0,1,1,1,0,,,1403;;D14138AA;;D14/248,0,0,,,,EXPIRED
307,AR,A1,AR 106203 A1,155-650-962-893-803,2017-12-20,2017,AR P160102990 A,2016-09-29,US 201562234408 P,2015-09-29,TERAPIA COMBINADA Y RÉGIMEN DE TRATAMIENTO DEL HCV,"Composición que comprende el Compuesto de fórmula (1), el Compuesto de fórmula (2), y el Compuesto de fórmula (3) para el tratamiento de la hepatitis C y sus métodos de elaboración. Método de tratamiento. Usos. Formas de dosificación. Reivindicación 1: Una composición caracterizada porque comprende Compuesto de fórmula (1) (Simeprevir), Compuesto de fórmula (2) (Odalasvir), y Compuesto de fórmula (3) o su sal, hidrato o solvato.",ACHILLION PHARMACEUTICALS INC;;JANSSEN PHARMACEUTICALS INC,SIVI MAHADEVAN;;THOMAS NAOKI KAKUDA;;EUGENE JANS;;JAMES HUI;;JOHN M FRY;;MILIND DESHPANDE;;DAWEI CHEN;;SU CHANDA;;LAWRENCE M BLATT;;LIEVE BIJINENS;;MARIA GLORIA BEUMONT;;DAVID APELIAN,,https://lens.org/155-650-962-893-803,Patent Application,no,0,0,1,17,0,,A61K31/4709;;A61K31/4178;;A61K31/513;;A61P31/14,,0,0,,,,PENDING
308,US,B2,US 7048556 B2,128-034-500-282-508,2006-05-23,2006,US 72833603 A,2003-12-04,US 72833603 A,2003-12-04,Connector cover for communication device,"An apparatus for protecting an accessory connector ( 12 ) on a communication device ( 10 ). The communication device can include an opening ( 14 ) for providing access to the connector. The apparatus can be a cover ( 16 ) attached in a tethered relation to the communication device. A portion of the cover can be flexible so as to allow a user to selectively move the cover between a first position and a second position. In the first position, at the cover can substantially close the opening such that the connector is substantially protected from the infiltration of solid particles and the gross intrusion of liquids. In the second position, the cover can be held away from the connector such that substantially unimpeded access to the connector is permitted. The cover and communication device can have various associated features to ensure that the cover is retained in the first and second positions.",MOTOROLA INC,STANTON STEPHEN M;;ISBELL JAMES L;;MICHIELI MATTHEW R;;BOHLEN JOHN R;;ALLEN AARON R;;BLATT DAVID I;;HOSSEINI SAM V;;KARL DAV H;;NOGUEIRAS EDUARDO;;IEZZI PETER D,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2003-09-30),https://lens.org/128-034-500-282-508,Granted Patent,yes,10,35,2,2,0,H04M1/0274;;H04M1/0274;;H01R13/5213;;H01R13/5213,H01R13/44;;H01R13/52,439/135;;439/136,0,0,,,,EXPIRED
309,US,A1,US 2005/0124191 A1,186-359-456-545-188,2005-06-09,2005,US 72833603 A,2003-12-04,US 72833603 A,2003-12-04,Connector cover for communication device,"An apparatus for protecting an accessory connector ( 12 ) on a communication device ( 10 ). The communication device can include an opening ( 14 ) for providing access to the connector. The apparatus can be a cover ( 16 ) attached in a tethered relation to the communication device. A portion of the cover can be flexible so as to allow a user to selectively move the cover between a first position and a second position. In the first position, at the cover can substantially close the opening such that the connector is substantially protected from the infiltration of solid particles and the gross intrusion of liquids. In the second position, the cover can be held away from the connector such that substantially unimpeded access to the connector is permitted. The cover and communication device can have various associated features to ensure that the cover is retained in the first and second positions.",STANTON STEPHEN M.;;ISBELL JAMES L.;;MICHIELI MATTHEW R.;;BOHLEN JOHN R.;;ALLEN AARON R.;;BLATT DAVID I.;;HOSSEINI SAM V.;;KARL DAVE H.;;NOGUEIRAS EDUARDO;;IEZZI PETER D.,STANTON STEPHEN M;;ISBELL JAMES L;;MICHIELI MATTHEW R;;BOHLEN JOHN R;;ALLEN AARON R;;BLATT DAVID I;;HOSSEINI SAM V;;KARL DAVE H;;NOGUEIRAS EDUARDO;;IEZZI PETER D,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2003-09-30),https://lens.org/186-359-456-545-188,Patent Application,yes,9,34,2,2,0,H04M1/0274;;H04M1/0274;;H01R13/5213;;H01R13/5213,H01R13/52,439/135,0,0,,,,EXPIRED
310,CA,A1,CA 2403243 A1,019-692-937-078-334,2001-03-08,2001,CA 2403243 A,2000-08-30,US 15171399 P;;US 40664399 A;;US 15646799 P;;US 15623699 P;;US 43643099 A;;US 16910099 P;;US 17361299 P;;US 47443299 A;;US 47638799 A;;US 49882400 A;;US 53102500 A;;US 19776900 P;;US 57822300 A;;US 63638500 A;;US 0023998 W,1999-08-31,NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION,"Nucleic acid molecules (antisenses or ribozymes) useful as inhibitors of gen e expression, especially of HER2, BACE, TERT, PTP-1B, MetAP-2, HBV, phospholamban, presenilin-2 and PKC-alpha. The nucleic acid molecules can be modified in various ways on the sugar and/or base moieties and/or on the phosphate backbone. They are used in pharmaceutical formulations for the treatment of diseases involving increased expression of the target genes. Al so disclosed is a method for the synthesis of a modified pyrimidine nucleotide triphosphate and its incorporation into an oligonucleotide.",RIBOZYME PHARM INC,STINCHCOMB DAN;;KARPEISKY ALEXANDER;;BEAUDRY AMBER;;CHOWRIRA BHARAT;;BEIGELMAN LEONID;;MATULIC-ADAMIC JASENKA;;USMAN NASSIM;;DRAPER KENNETH;;BLATT LAWRENCE;;SWEEDLER DAVID;;MCSWIGGEN JAMES;;SPROAT BRIAN S;;LUGWIG JANOS;;BURGIN ALEX;;ZINNEN SHAWN,,https://lens.org/019-692-937-078-334,Patent Application,no,0,0,5,1181,31668,A61K38/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C12N15/113;;C07H19/10;;C07H19/20;;C07H21/00;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N2310/12;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/321;;C12N2310/322;;C12N2310/346;;C12P19/30;;C12P19/305;;C12Y207/07049;;C12Y301/03048,C12N15/09;;A61K31/7115;;A61K38/00;;A61K48/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C07H19/10;;C07H19/20;;C07H19/22;;C07H21/00;;C07H21/04;;C12N5/10;;C12N15/113;;C12P19/30,,0,0,,,,DISCONTINUED
311,WO,A2,WO 2001/016312 A2,038-342-344-735-967,2001-03-08,2001,US 0023998 W,2000-08-30,US 15171399 P;;US 40664399 A;;US 15646799 P;;US 15623699 P;;US 43643099 A;;US 16910099 P;;US 17361299 P;;US 47443299 A;;US 47638799 A;;US 49882400 A;;US 53102500 A;;US 19776900 P;;US 57822300 A;;US 63638500 A,1999-08-31,NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION,"Nucleic acid molecules (antisenses or ribozymes) useful as inhibitors of gene expression, especially of HER2, BACE, TERT, PTP-1B, MetAP-2, HBV, phospholamban, presenilin-2 and PKC-alpha. The nucleic acid molecules can be modified in various ways on the sugar and/or base moieties and/or on the phosphate backbone. They are used in pharmaceutical formulations for the treatment of diseases involving increased expression of the target genes. Also disclosed is a method for the synthesis of a modified pyrimidine nucleotide triphosphate and its incorporation into an oligonucleotide.",RIBOZYME PHARM INC;;MCSWIGGEN JAMES;;USMAN NASSIM;;BLATT LAWRENCE;;BEIGELMAN LEONID;;BURGIN ALEX;;KARPEISKY ALEXANDER;;MATULIC ADAMIC JASENKA;;SWEEDLER DAVID;;DRAPER KENNETH;;CHOWRIRA BHARAT;;STINCHCOMB DAN;;BEAUDRY AMBER;;ZINNEN SHAWN;;LUGWIG JANOS;;SPROAT BRIAN S,MCSWIGGEN JAMES;;USMAN NASSIM;;BLATT LAWRENCE;;BEIGELMAN LEONID;;BURGIN ALEX;;KARPEISKY ALEXANDER;;MATULIC-ADAMIC JASENKA;;SWEEDLER DAVID;;DRAPER KENNETH;;CHOWRIRA BHARAT;;STINCHCOMB DAN;;BEAUDRY AMBER;;ZINNEN SHAWN;;LUGWIG JANOS;;SPROAT BRIAN S,,https://lens.org/038-342-344-735-967,Patent Application,yes,0,85,5,1181,0,A61K38/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C12N15/113;;C07H19/10;;C07H19/20;;C07H21/00;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N2310/12;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/321;;C12N2310/322;;C12N2310/346;;C12P19/30;;C12P19/305;;C12Y207/07049;;C12Y301/03048,C12N15/09;;A61K31/7115;;A61K38/00;;A61K48/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C07H19/10;;C07H19/20;;C07H19/22;;C07H21/00;;C07H21/04;;C12N5/10;;C12N15/113;;C12P19/30,,0,0,,,,PENDING
312,EP,A2,EP 1212416 A2,043-999-485-696-401,2002-06-12,2002,EP 00963298 A,2000-08-30,US 0023998 W;;US 15171399 P;;US 40664399 A;;US 15646799 P;;US 15623699 P;;US 43643099 A;;US 16910099 P;;US 17361299 P;;US 47443299 A;;US 47638799 A;;US 49882400 A;;US 53102500 A;;US 19776900 P;;US 57822300 A;;US 63638500 A,1999-08-31,NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION,,RIBOZYME PHARM INC,MCSWIGGEN JAMES;;USMAN NASSIM;;BLATT LAWRENCE;;BEIGELMAN LEONID;;BURGIN ALEX;;KARPEISKY ALEXANDER;;MATULIC-ADAMIC JASENKA;;SWEEDLER DAVID;;DRAPER KENNETH;;CHOWRIRA BHARAT;;STINCHCOMB DAN;;BEAUDRY AMBER;;ZINNEN SHAWN;;LUGWIG JANOS;;SPROAT BRIAN S,,https://lens.org/043-999-485-696-401,Patent Application,yes,0,11,5,1181,0,A61K38/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C12N15/113;;C07H19/10;;C07H19/20;;C07H21/00;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N2310/12;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/321;;C12N2310/322;;C12N2310/346;;C12P19/30;;C12P19/305;;C12Y207/07049;;C12Y301/03048,C12N15/09;;A61K31/7115;;A61K38/00;;A61K48/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C07H19/10;;C07H19/20;;C07H19/22;;C07H21/00;;C07H21/04;;C12N5/10;;C12N15/113;;C12P19/30,,1,0,,,See references of WO 0116312A3,DISCONTINUED
313,WO,A3,WO 2001/016312 A3,117-003-496-000-529,2001-08-09,2001,US 0023998 W,2000-08-30,US 15171399 P;;US 40664399 A;;US 15646799 P;;US 15623699 P;;US 43643099 A;;US 16910099 P;;US 17361299 P;;US 47443299 A;;US 47638799 A;;US 49882400 A;;US 53102500 A;;US 19776900 P;;US 57822300 A;;US 63638500 A,1999-08-31,NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION,"Nucleic acid molecules (antisenses or ribozymes) useful as inhibitors of gene expression, especially of HER2, BACE, TERT, PTP-1B, MetAP-2, HBV, phospholamban, presenilin-2 and PKC-alpha. The nucleic acid molecules can be modified in various ways on the sugar and/or base moieties and/or on the phosphate backbone. They are used in pharmaceutical formulations for the treatment of diseases involving increased expression of the target genes. Also disclosed is a method for the synthesis of a modified pyrimidine nucleotide triphosphate and its incorporation into an oligonucleotide.",RIBOZYME PHARM INC;;MCSWIGGEN JAMES;;USMAN NASSIM;;BLATT LAWRENCE;;BEIGELMAN LEONID;;BURGIN ALEX;;KARPEISKY ALEXANDER;;MATULIC ADAMIC JASENKA;;SWEEDLER DAVID;;DRAPER KENNETH;;CHOWRIRA BHARAT;;STINCHCOMB DAN;;BEAUDRY AMBER;;ZINNEN SHAWN;;LUGWIG JANOS;;SPROAT BRIAN S,MCSWIGGEN JAMES;;USMAN NASSIM;;BLATT LAWRENCE;;BEIGELMAN LEONID;;BURGIN ALEX;;KARPEISKY ALEXANDER;;MATULIC-ADAMIC JASENKA;;SWEEDLER DAVID;;DRAPER KENNETH;;CHOWRIRA BHARAT;;STINCHCOMB DAN;;BEAUDRY AMBER;;ZINNEN SHAWN;;LUGWIG JANOS;;SPROAT BRIAN S,,https://lens.org/117-003-496-000-529,Search Report,yes,3,0,5,1181,0,A61K38/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C12N15/113;;C07H19/10;;C07H19/20;;C07H21/00;;C12N15/1131;;C12N15/1137;;C12N15/1138;;C12N2310/12;;C12N2310/18;;C12N2310/315;;C12N2310/317;;C12N2310/318;;C12N2310/321;;C12N2310/322;;C12N2310/346;;C12P19/30;;C12P19/305;;C12Y207/07049;;C12Y301/03048,C12N15/09;;A61K31/7115;;A61K38/00;;A61K48/00;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P25/28;;A61P35/00;;A61P43/00;;C07H19/10;;C07H19/20;;C07H19/22;;C07H21/00;;C07H21/04;;C12N5/10;;C12N15/113;;C12P19/30,,3,3,000-640-928-580-328;;131-978-112-574-37X;;090-610-999-707-565,8794164;;10.1016/s0959-440x(96)80119-9;;10.1016/s0040-4039(97)10784-5;;10801472;;10.1016/s1074-5521(00)00110-1,"USMAN N ET AL: ""HAMMERHEAD RIBOZYME ENGINEERING"", CURRENT OPINION IN STRUCTURAL BIOLOGY, no. 1, 1996, pages 527 - 533, XP000749676, ISSN: 0959-440X;;KARPEISKY A ET AL: ""Highly Efficient Synthesis Of 2'-O-Amino Nucleosides And Their Incorporation In Hammerhead Ribozymes"", TETRAHEDRON LETTERS, vol. 39, no. 10, 5 March 1998 (1998-03-05), pages 1131 - 1134, XP004109136, ISSN: 0040-4039;;BEAUDRY AMBER ET AL: ""In vitro selection of a novel nuclease-resistant RNA phosphodiesterase."", CHEMISTRY & BIOLOGY (LONDON), vol. 7, no. 5, May 2000 (2000-05-01), pages 323 - 334, XP002159942, ISSN: 1074-5521",PENDING
314,AU,A,AU 2000/074733 A,122-046-807-124-66X,2001-03-26,2001,AU 2000/074733 A,2000-08-31,US 53102500 A;;US 19776900 P;;US 57822300 A;;US 15171399 P;;US 40664399 A;;US 15646799 P;;US 15623699 P;;US 43643099 A;;US 16910099 P;;US 17361299 P;;US 47443299 A;;US 47638799 A;;US 49882400 A;;US 0023998 W,1999-08-31,Nucleic acid based modulators of gene expression,,RIBOZYME PHARM INC,JAMES MCSWIGGEN;;NASSIM USMAN;;LAWRENCE BLATT;;LEONID BEIGELMAN;;ALEX BURGIN;;ALEXANDER KARPEISKY;;JASENKA MATULIC-ADAMIC;;DAVID SWEEDLER;;KENNETH DRAPER;;BHARAT CHOWRIRA;;DAN STINCHCOMB;;AMBER BEAUDRY;;SHAWN ZINNEN;;JANOS LUGWIG;;BRIAN S SPROAT,,https://lens.org/122-046-807-124-66X,Patent Application,no,0,0,1,1181,0,,A61K31/7088;;A61P3/10;;A61P9/00;;A61P25/28;;A61P35/00;;C07H19/00;;C07H21/00;;C12N5/10;;C12N9/00;;C12N15/11;;C12P19/34,,0,0,,,,DISCONTINUED
315,MA,A,MA 43051 A,023-207-591-390-218,2018-08-08,2018,MA 43051 A,2016-09-29,US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P,2015-09-29,POLYTHÉRAPIE POUR LE TRAITEMENT D'UNE DU VHC,,ACHILLION PHARMACEUTICALS INC;;JANSSEN PHARMACEUTICALS INC,APELIAN DAVID;;BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;CHEN DAWEI;;DESHPANDE MILIND;;FRY JOHN;;HUI JAMES;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PHADKE AVINASH;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER,,https://lens.org/023-207-591-390-218,Unknown,no,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61K31/495;;A61K31/522;;A61P31/14,,0,0,,,,PENDING
316,BR,A2,BR 112018006206 A2,148-047-960-751-430,2018-10-09,2018,BR 112018006206 A,2016-09-29,US 2016/0054561 W;;US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P,2015-09-29,"composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa","uma composição, incluindo uma composição de dose fixa, compreendendo o composto (i), o composto (ii) e o composto (iii) para o tratamento de hepatite c, e métodos para fabricação da mesma.",ACHILLION PHARMACEUTICALS INC;;JANSSEN PHARMACEUTICALS INC,ALEX VAN DIJCK;;AVINASH PHADKE;;DAVID APELIAN;;DAWEI CHEN;;EUGENE JANS;;GASTON RAFAEL PICCHIO;;JAMES HUI;;JOHN FRY;;LAWRENCE M BLATT;;LIEVE BIJNENS;;MARIA GLORIA BEUMONT;;MILIND DESHPANDE;;PETER VAN REMOORTERE;;ROEL MERTENS;;SIVI MAHADEVAN;;SUSHMITA MUKHERJEE CHANDA;;THOMAS NAOKI KAKUDA,,https://lens.org/148-047-960-751-430,Patent Application,no,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61K31/495;;A61K31/522;;A61P31/14,,0,0,,,,DISCONTINUED
317,AU,A1,AU 2016/331073 A1,101-373-995-225-754,2018-05-10,2018,AU 2016/331073 A,2016-09-29,US 201662353708 P;;US 201662299338 P;;US 201662365541 P;;US 201562234408 P;;US 2016/0054561 W,2015-09-29,Combination therapy regimen for treatment of HCV,"A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.",ACHILLION PHARMACEUTICALS INC;;JANSSEN PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/101-373-995-225-754,Patent Application,no,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61P31/14;;A61K31/495;;A61K31/522,,0,0,,,,DISCONTINUED
318,WO,A1,WO 2017/059147 A1,063-404-425-067-54X,2017-04-06,2017,US 2016/0054561 W,2016-09-29,US 201662365541 P;;US 201562234408 P;;US 201662353708 P;;US 201662299338 P,2015-09-29,COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV,"A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/063-404-425-067-54X,Patent Application,yes,2,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61P31/14;;A61K31/495;;A61K31/522,,0,0,,,,PENDING
319,WO,A1,WO 2018/017994 A1,001-633-499-593-868,2018-01-25,2018,US 2017/0043352 W,2017-07-21,US 201662365541 P;;US 2016/0054561 W,2016-07-22,COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION,"A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/001-633-499-593-868,Patent Application,yes,4,0,2,17,0,A61K31/4184;;A61K9/16;;A61K9/1652;;A61K9/2054;;A61K31/4709;;A61K31/7072;;A61P31/14,A61P31/14;;A61K31/47,,3,0,,,"""Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection"", CLINICAL TRIALS.GOV, 26 May 2016 (2016-05-26), pages 1 - 3, Retrieved from the Internet <URL:https:/Iclinicaltrials.gov/archive/NCT02765490/2016_05_26>;;""Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL- 335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting"", HCV ADVOCATE, 7 November 2014 (2014-11-07), Retrieved from the Internet <URL:http://hepatitisc.hcvadvocate.org/2014/11/alios-biopharma-to-present-preclinical.html>;;WOLF ET AL.: ""Hepatitis C Organism-Specific Therapy"", MEDSCAPE, 22 November 2015 (2015-11-22), pages 1 - 2, Retrieved from the Internet <URL:http://emedicine.medscape.com/artide/2072024-overview#a1>",PENDING
320,US,A1,US 2017/0319572 A1,104-876-806-225-020,2017-11-09,2017,US 201715659464 A,2017-07-25,US 201715659464 A;;US 2016/0054561 W;;US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P,2015-09-29,COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION,"A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPHANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/104-876-806-225-020,Patent Application,yes,6,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61K31/4709;;A61K9/00;;A61K9/10;;A61K9/16;;A61K31/4184;;A61K31/7072,,0,0,,,,DISCONTINUED
321,US,A1,US 2018/0021360 A1,162-108-630-786-36X,2018-01-25,2018,US 201715656821 A,2017-07-21,US 201715656821 A;;US 201662365541 P;;US 201662495609 P,2016-07-22,Combination Therapy Regimen For Treatment Of Selected HCV Genotypes,"A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPHANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/162-108-630-786-36X,Patent Application,yes,0,1,2,17,0,A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1652;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K45/06;;A61K31/416;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/14;;A61K9/48;;A61K9/20;;A61K9/0053;;A61K45/06;;A61K9/2054;;A61K9/1652;;A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K31/416,A61K31/7072;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/48;;A61K31/4184;;A61K31/4709;;A61K45/06,,0,0,,,,DISCONTINUED
322,US,A1,US 2018/0021361 A1,065-921-721-246-751,2018-01-25,2018,US 201715656872 A,2017-07-21,US 201715656872 A;;US 201662365541 P;;US 201662495609 P,2016-07-22,COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION,"A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPHANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/065-921-721-246-751,Patent Application,yes,0,1,2,17,0,A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1652;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K45/06;;A61K31/416;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/14;;A61K9/48;;A61K9/20;;A61K9/0053;;A61K45/06;;A61K9/2054;;A61K9/1652;;A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K31/416,A61K31/7072;;A61K9/20;;A61K31/416;;A61K31/4709,,0,0,,,,DISCONTINUED
323,WO,A1,WO 2018/017989 A1,115-218-872-051-019,2018-01-25,2018,US 2017/0043346 W,2017-07-21,US 2016/0054561 W;;US 201662365541 P,2016-07-22,COMBINATION THERAPY REGIMEN FOR TREATMENT OF SELECTED HCV GENOTYPES,"A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/115-218-872-051-019,Patent Application,yes,4,0,2,17,0,A61K31/4184;;A61K9/16;;A61K9/1652;;A61K9/2054;;A61K31/4709;;A61K31/7072;;A61P31/14,A61K31/4184;;A61K9/00,,3,0,,,"""Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection"", CLINICALTRIALS.GOV, 26 May 2016 (2016-05-26), pages 1 - 3, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02765490/2016_05_26>;;""Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL- 335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting"", HCV ADVOCATE, 7 November 2014 (2014-11-07), Retrieved from the Internet <URL:http://hepatitisc.hcvadvocate.org/2014/11/alios-biopharma-to-present-preclinical.html>;;WOLF ET AL.: ""Hepatitis C Organism-Specific Thera py"", MEDSCAPE, 22 November 2015 (2015-11-22), pages 1 - 2, Retrieved from the Internet <URL:http://emedicine.medscape.com/artide/2072024-overview#a1>",PENDING
324,US,A1,US 2017/0087174 A1,180-424-146-606-600,2017-03-30,2017,US 201615281050 A,2016-09-29,US 201615281050 A;;US 201662365541 P;;US 201662353708 P;;US 201662299338 P;;US 201562234408 P,2015-09-29,COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV,"A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPHANDE MILIND;;HUI JAMES;;PHADKE AVINASH,JANSSEN PHARMACEUTICALS INC (2015-09-29);;JANSSEN-CILAG (2015-09-29);;ALIOS BIOPHARMA INC (2015-09-29);;JANSSEN RESEARCH & DEVELOPMENT LLC (2015-09-29);;JANSSEN PHARMACEUTICA NV (2016-09-29);;ACHILLION PHARMACEUTICALS INC (2015-09-29),https://lens.org/180-424-146-606-600,Patent Application,yes,0,1,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61K31/7072;;A61K9/00;;A61K9/10;;A61K31/4184;;A61K31/4709,,0,0,,,,PENDING
325,KR,A,KR 20180071276 A,102-177-152-650-857,2018-06-27,2018,KR 20187012074 A,2016-09-29,US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P;;US 2016/0054561 W,2015-09-29,HCV 치료를 위한 조합물 요법 투약법,"화합물 (I), 화합물 (II) 및 화합물 (III)을 포함하는 C형 간염 치료용 조성물, 예컨대 고정 용량 조성물, 및 그의 제조 방법이 기재된다.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/102-177-152-650-857,Patent Application,no,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61K31/4725;;A61K9/00;;A61K9/10;;A61K9/16;;A61K9/20;;A61K31/4184;;A61K31/7072;;A61P31/22,,0,0,,,,PENDING
326,EP,A1,EP 3355991 A1,118-855-663-295-579,2018-08-08,2018,EP 16852646 A,2016-09-29,US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P;;US 2016/0054561 W,2015-09-29,COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV,,JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/118-855-663-295-579,Patent Application,yes,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61P31/14;;A61K31/495;;A61K31/522,,0,0,,,,DISCONTINUED
327,CA,A1,CA 3000415 A1,050-537-215-566-559,2017-04-06,2017,CA 3000415 A,2016-09-29,US 201562234408 P;;US 201662299338 P;;US 201662353708 P;;US 201662365541 P;;US 2016/0054561 W,2015-09-29,COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV,"A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.",JANSSEN PHARMACEUTICALS INC;;ACHILLION PHARMACEUTICALS INC,BEUMONT MARIA GLORIA;;BIJNENS LIEVE;;BLATT LAWRENCE M;;CHANDA SUSHMITA MUKHERJEE;;FRY JOHN;;JANS EUGENE;;KAKUDA THOMAS NAOKI;;MAHADEVAN SIVI;;MERTENS ROEL;;PICCHIO GASTON RAFAEL;;VAN DIJCK ALEX;;VAN REMOORTERE PETER;;APELIAN DAVID;;CHEN DAWEI;;DESHPANDE MILIND;;HUI JAMES;;PHADKE AVINASH,,https://lens.org/050-537-215-566-559,Patent Application,no,0,0,12,17,0,A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K9/2054;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61P1/16;;A61P31/14;;A61P31/22;;A61P31/22;;A61K9/0053;;A61K9/10;;A61K9/1617;;A61K9/1652;;A61K9/2013;;A61K31/4184;;A61K31/4725;;A61K31/7072;;A61K2300/00;;A61K31/7072;;A61K31/4709;;A61K31/4184;;A61K9/0053;;A61K9/1617;;A61K9/1652;;A61K9/2054;;A61K9/2013;;A61K9/10;;A61K2300/00,A61P31/14,,0,0,,,,DISCONTINUED
